{"matching_results": 14918, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1026, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 828}, {"key": "negative", "matching_results": 195}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "freelancer.com.co", "matching_results": 838, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 770}, {"key": "negative", "matching_results": 66}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "tickerreport.com", "matching_results": 595, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 517}, {"key": "negative", "matching_results": 77}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 587, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 451}, {"key": "negative", "matching_results": 136}]}]}, {"key": "dailypolitical.com", "matching_results": 578, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 495}, {"key": "negative", "matching_results": 82}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 569, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 408}, {"key": "negative", "matching_results": 161}]}]}, {"key": "wkrb13.com", "matching_results": 554, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 438}, {"key": "negative", "matching_results": 116}]}]}, {"key": "theolympiareport.com", "matching_results": 501, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 368}, {"key": "negative", "matching_results": 132}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 379, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 289}, {"key": "negative", "matching_results": 89}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "reed.co.uk", "matching_results": 366, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 362}, {"key": "negative", "matching_results": 4}]}]}]}], "results": [{"id": "6LZWyHD6VhAUhvd_ZDJLzfr04vMhTCpvByAJIfCQr3pwNhs4EB6TEeNm5nrMpw8K", "result_metadata": {"score": 35.59884}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Piperazinyl Pyrrolidin-2-ones", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["City"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Ester", "relevance": 0.89355, "dbpedia_resource": "http://dbpedia.org/resource/Ester"}, {"text": "Carboxylic acid", "relevance": 0.86595, "dbpedia_resource": "http://dbpedia.org/resource/Carboxylic_acid"}, {"text": "Lipid", "relevance": 0.83835, "dbpedia_resource": "http://dbpedia.org/resource/Lipid"}, {"text": "Amide", "relevance": 0.835727, "dbpedia_resource": "http://dbpedia.org/resource/Amide"}, {"text": "Lithium aluminium hydride", "relevance": 0.813981, "dbpedia_resource": "http://dbpedia.org/resource/Lithium_aluminium_hydride"}, {"text": "Acetic acid", "relevance": 0.799412, "dbpedia_resource": "http://dbpedia.org/resource/Acetic_acid"}], "categories": [{"score": 0.834628, "label": "/health and fitness/disease/cholesterol"}, {"score": 0.66463, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998193, "count": 1}, {"text": "Study Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.913118, "count": 1}, {"text": "Design", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595089, "count": 1}, {"text": "Synthesis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590318, "count": 1}, {"text": "Evaluation of Piperazinyl Pyrrolidin-2-ones", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261331, "count": 1}, {"text": "Takeda Pharmaceutical Company Broaden Understanding of Carboxylic Ester Hydrolases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.157183, "count": 1}, {"text": "Novel Series of Reversible Monoacylglycerol Lipase Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.105677, "count": 1}]}, "crawl_date": "2018-11-24T20:18:38Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Study-Results-from-Takeda-Pharmaceutical-Company-Broaden-Understanding-of-Ca-27654543/", "host": "4-traders.com", "text": "Aida , Takeda Pharmaceut Co Ltd. , Res, Fujisawa, Kanagawa 2518555, Japan .", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.31285, "label": "negative"}, "text": "Journal of Medicinal Chemistry", "relevance": 0.834951, "type": "PrintMedia", "disambiguation": {"subtype": ["Journal"], "name": "Journal of Medicinal Chemistry", "dbpedia_resource": "http://dbpedia.org/resource/Journal_of_Medicinal_Chemistry"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Carboxylic Ester Hydrolases", "relevance": 0.775133, "type": "GeographicFeature"}, {"count": 2, "sentiment": {"score": -0.339716, "label": "negative"}, "text": "Piperazinyl Pyrrolidin-2-ones", "relevance": 0.567932, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fujisawa", "relevance": 0.559815, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.51531, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.482901, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "News Editor", "relevance": 0.455442, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NewsRx LLC", "relevance": 0.446565, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceut Co Ltd.", "relevance": 0.422754, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gene Therapy Weekly", "relevance": 0.402152, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amer Chemical Soc", "relevance": 0.398073, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Chemical Society", "relevance": 0.367176, "type": "Organization", "disambiguation": {"subtype": ["Company", "PeriodicalPublisher"], "name": "American Chemical Society", "dbpedia_resource": "http://dbpedia.org/resource/American_Chemical_Society"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Sugiyama", "relevance": 0.361553, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "T. Koike", "relevance": 0.359384, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "K. Aoyama", "relevance": 0.357709, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "S. Ikeda", "relevance": 0.353143, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "M. Sasaki", "relevance": 0.351779, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "M. Fushimi", "relevance": 0.343039, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "T. Kusumoto", "relevance": 0.341734, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J. Aida", "relevance": 0.340121, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "N. Arimura", "relevance": 0.339125, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "S. Sogabe", "relevance": 0.335211, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kanagawa", "relevance": 0.331522, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Kanagawa-ku, Yokohama", "dbpedia_resource": "http://dbpedia.org/resource/Kanagawa-ku,_Yokohama"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USA", "relevance": 0.326678, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Washington", "relevance": 0.318325, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": 0.663539, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by NewsRx journalists", "keywords": [{"text": "NewsRx journalists"}]}, "sentence": " According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "object": {"text": "news reporting", "keywords": [{"text": "news reporting"}]}, "action": {"verb": {"text": "originate", "tense": "present"}, "text": "originating", "normalized": "originate"}}, {"subject": {"text": "research stated, \"Monoacylglycerol lipase (MAGL)", "keywords": [{"text": "Monoacylglycerol lipase"}, {"text": "research"}, {"text": "MAGL"}]}, "sentence": " According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "object": {"text": "a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain", "keywords": [{"text": "major serine hydrolase"}, {"text": "arachidonic acid"}, {"text": "glycerol"}, {"text": "AA"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a major serine hydrolase", "keywords": [{"text": "major serine hydrolase"}]}, "sentence": " According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "object": {"text": "2-arachidonoylglycerol", "keywords": [{"text": "2-arachidonoylglycerol"}]}, "action": {"verb": {"text": "hydrolyze", "tense": "present"}, "text": "hydrolyzes", "normalized": "hydrolyze"}}, {"subject": {"text": "2-AG and AA"}, "sentence": " Because 2-AG and AA are endogenous biologically active ligands in the brain, inhibition of MAGL is an attractive therapeutic target for CNS disorders, particularly neurodegenerative diseases.\"", "object": {"text": "endogenous biologically active ligands in the brain", "keywords": [{"text": "biologically active ligands"}, {"text": "brain"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "inhibition of MAGL", "keywords": [{"text": "inhibition"}, {"text": "MAGL"}]}, "sentence": " Because 2-AG and AA are endogenous biologically active ligands in the brain, inhibition of MAGL is an attractive therapeutic target for CNS disorders, particularly neurodegenerative diseases.\"", "object": {"text": "an attractive therapeutic target for CNS disorders, particularly neurodegenerative diseases", "keywords": [{"text": "attractive therapeutic target"}, {"text": "CNS disorders"}, {"text": "neurodegenerative diseases"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The news reporters", "keywords": [{"text": "news reporters"}]}, "sentence": " The news reporters obtained a Quote: from the research from Takeda Pharmaceutical Company , \"In this study, we report the structure-based drug design of novel piperazinyl pyrrolidin-2-ones starting from our hit compounds 2a and 2b.", "object": {"text": "a Quote", "keywords": [{"text": "Quote"}]}, "action": {"verb": {"text": "obtain", "tense": "past"}, "text": "obtained", "normalized": "obtain"}}, {"subject": {"text": "we"}, "sentence": " The news reporters obtained a Quote: from the research from Takeda Pharmaceutical Company , \"In this study, we report the structure-based drug design of novel piperazinyl pyrrolidin-2-ones starting from our hit compounds 2a and 2b.", "object": {"text": "the structure-based drug design of novel piperazinyl pyrrolidin-2-ones starting from our hit compounds 2a and 2b", "keywords": [{"text": "structure-based drug design"}, {"text": "novel piperazinyl pyrrolidin-2-ones"}, {"text": "hit"}], "entities": [{"type": "Location", "text": "Piperazinyl Pyrrolidin-2-ones", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "report", "tense": "present"}, "text": "report", "normalized": "report"}}, {"subject": {"text": "the interaction of the piperazinyl pyrrolidin-2-one core and its substituents", "keywords": [{"text": "piperazinyl pyrrolidin-2-one core"}, {"text": "interaction"}]}, "sentence": " By enhancing the interaction of the piperazinyl pyrrolidin-2-one core and its substituents with the MAGL enzyme via design modifications, we identified a potent and reversible MAGL inhibitor, compound \u00ae-3t.\"", "object": {"text": "with the MAGL enzyme", "keywords": [{"text": "MAGL enzyme"}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhancing", "normalized": "enhance"}}, {"subject": {"text": "we"}, "sentence": " By enhancing the interaction of the piperazinyl pyrrolidin-2-one core and its substituents with the MAGL enzyme via design modifications, we identified a potent and reversible MAGL inhibitor, compound \u00ae-3t.\"", "object": {"text": "a potent and reversible MAGL inhibitor, compound \u00ae-3t", "keywords": [{"text": "reversible MAGL inhibitor"}, {"text": "compound \u00ae-3t"}]}, "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "the research", "keywords": [{"text": "research"}]}, "sentence": " According to the news reporters, the research concluded: \"Oral administration of compound \u00ae-3t to mice decreased AA levels and elevated 2-AG levels in the brain.\"", "object": {"text": "Oral administration of compound \u00ae-3t to mice decreased AA levels and elevated 2-AG levels in the brain", "keywords": [{"text": "elevated 2-AG levels"}, {"text": "Oral administration"}, {"text": "AA levels"}, {"text": "mice"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "more information on this research", "keywords": [{"text": "information"}, {"text": "research"}]}, "sentence": " For more information on this research see: Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors.", "object": {"text": "Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors", "keywords": [{"text": "Reversible Monoacylglycerol Lipase"}, {"text": "Piperazinyl Pyrrolidin-2-ones"}, {"text": "Novel Series"}, {"text": "Inhibitors"}], "entities": [{"type": "Location", "text": "Piperazinyl Pyrrolidin-2-ones", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "Journal of Medicinal Chemistry", "keywords": [{"text": "Medicinal Chemistry"}, {"text": "Journal"}], "entities": [{"type": "PrintMedia", "text": "Journal of Medicinal Chemistry", "disambiguation": {"subtype": ["Journal"], "name": "Journal of Medicinal Chemistry", "dbpedia_resource": "http://dbpedia.org/resource/Journal_of_Medicinal_Chemistry"}}]}, "sentence": " Journal of Medicinal Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA . ( American Chemical Society - www.acs.org; Journal of Medicinal Chemistry - www.pubs.acs.org/journal/jmcmar)", "object": {"text": "Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA", "keywords": [{"text": "Amer Chemical Soc"}, {"text": "16TH St"}, {"text": "NW"}, {"text": "Washington"}], "entities": [{"type": "Organization", "text": "Amer Chemical Soc"}, {"type": "Location", "text": "Washington", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Location", "text": "USA", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "can be contacted", "normalized": "can be contact"}}, {"subject": {"text": "additional information", "keywords": [{"text": "additional information"}]}, "sentence": " Our news correspondents report that additional information may be obtained by contacting J. Aida", "object": {"text": "obtained by contacting J. Aida", "keywords": [{"text": "J. Aida"}], "entities": [{"type": "Person", "text": "J. Aida"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by contacting J. Aida", "keywords": [{"text": "J. Aida"}], "entities": [{"type": "Person", "text": "J. Aida"}]}, "sentence": " Our news correspondents report that additional information may be obtained by contacting J. Aida", "object": {"text": "additional information", "keywords": [{"text": "additional information"}]}, "action": {"verb": {"text": "obtain", "tense": "future"}, "text": "may be obtained", "normalized": "may be obtain"}}, {"subject": {"text": "Our news correspondents report", "keywords": [{"text": "news correspondents"}, {"text": "report"}], "entities": []}, "sentence": " Our news correspondents report that additional information may be obtained by contacting J. Aida", "object": {"text": "J. Aida", "keywords": [{"text": "J. Aida"}], "entities": [{"type": "Person", "text": "J. Aida"}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "contacting", "normalized": "contact"}}, {"subject": {"text": "M. Fushimi", "keywords": [{"text": "M. Fushimi"}], "entities": [{"type": "Person", "text": "M. Fushimi"}]}, "sentence": " Additional authors for this research include M. Fushimi", "object": {"text": "Additional authors for this research", "keywords": [{"text": "Additional authors"}, {"text": "research"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "This DOI", "keywords": [{"text": "DOI"}]}, "sentence": " This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.", "object": {"text": "a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation", "keywords": [{"text": "online electronic document"}, {"text": "direct source"}, {"text": "journal article"}, {"text": "citation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Our reports", "keywords": [{"text": "reports"}]}, "sentence": " (Our reports deliver fact-based news of research and discoveries from around the world.)", "object": {"text": "fact-based news of research and discoveries", "keywords": [{"text": "fact-based news"}, {"text": "discoveries"}, {"text": "research"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "deliver", "normalized": "deliver"}}], "concepts": [{"text": "Enzyme", "relevance": 0.973614, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme"}, {"text": "Enzymes", "relevance": 0.964558, "dbpedia_resource": "http://dbpedia.org/resource/Enzymes"}, {"text": "Enzyme inhibitor", "relevance": 0.900627, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Chemistry", "relevance": 0.861527, "dbpedia_resource": "http://dbpedia.org/resource/Chemistry"}, {"text": "American Chemical Society", "relevance": 0.801922, "dbpedia_resource": "http://dbpedia.org/resource/American_Chemical_Society"}, {"text": "Anandamide", "relevance": 0.780005, "dbpedia_resource": "http://dbpedia.org/resource/Anandamide"}, {"text": "Pharmacology", "relevance": 0.719881, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.709655, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Monoacylglycerol lipase", "relevance": 0.707283, "dbpedia_resource": "http://dbpedia.org/resource/Monoacylglycerol_lipase"}, {"text": "Neurodegeneration", "relevance": 0.705827, "dbpedia_resource": "http://dbpedia.org/resource/Neurodegeneration"}, {"text": "NEWS", "relevance": 0.693333, "dbpedia_resource": "http://dbpedia.org/resource/NEWS"}, {"text": "Inhibitor", "relevance": 0.689546, "dbpedia_resource": "http://dbpedia.org/resource/Inhibitor"}, {"text": "Ester", "relevance": 0.675608, "dbpedia_resource": "http://dbpedia.org/resource/Ester"}, {"text": "Drug design", "relevance": 0.665434, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Carboxylic acid", "relevance": 0.665085, "dbpedia_resource": "http://dbpedia.org/resource/Carboxylic_acid"}, {"text": "Fatty acid", "relevance": 0.648872, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_acid"}, {"text": "JZL184", "relevance": 0.643443, "dbpedia_resource": "http://dbpedia.org/resource/JZL184"}, {"text": "Neurodegenerative disorders", "relevance": 0.641987, "dbpedia_resource": "http://dbpedia.org/resource/Neurodegenerative_disorders"}, {"text": "Lipid", "relevance": 0.633254, "dbpedia_resource": "http://dbpedia.org/resource/Lipid"}, {"text": "Neurology", "relevance": 0.630128, "dbpedia_resource": "http://dbpedia.org/resource/Neurology"}, {"text": "Medicine", "relevance": 0.627072, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Chemical compound", "relevance": 0.613701, "dbpedia_resource": "http://dbpedia.org/resource/Chemical_compound"}, {"text": "URB754", "relevance": 0.595342, "dbpedia_resource": "http://dbpedia.org/resource/URB754"}, {"text": "Neurodegenerative diseases", "relevance": 0.591533, "dbpedia_resource": "http://dbpedia.org/resource/Neurodegenerative_diseases"}, {"text": "Brain", "relevance": 0.571828, "dbpedia_resource": "http://dbpedia.org/resource/Brain"}, {"text": "Hydrolase", "relevance": 0.561241, "dbpedia_resource": "http://dbpedia.org/resource/Hydrolase"}], "categories": [{"score": 0.825868, "label": "/health and fitness/disease/cholesterol"}, {"score": 0.771555, "label": "/science/chemistry/organic chemistry"}, {"score": 0.625651, "label": "/health and fitness/disorders"}], "relations": [{"type": "employedBy", "sentence": "By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Enzymes and Coenzymes - Carboxylic Ester Hydrolases.", "score": 0.459223, "arguments": [{"text": "Editor", "location": [30, 36], "entities": [{"type": "Person", "text": "Reporter"}]}, {"text": "Staff News", "location": [19, 29], "entities": [{"type": "Organization", "text": "Staff News"}]}]}, {"type": "locatedAt", "sentence": "\" According to the news reporters, the research concluded: \"Oral administration of compound \u00ae-3t to mice decreased AA levels and elevated 2-AG levels in the brain.", "score": 0.439672, "arguments": [{"text": "administration", "location": [1107, 1121], "entities": [{"type": "GeopoliticalEntity", "text": "administration", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "compound", "location": [1125, 1133], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "hasAttribute", "sentence": "Journal of Medicinal Chemistry , 2018;61(20):9205-9217.", "score": 0.788999, "arguments": [{"text": "Journal of Medicinal Chemistry", "location": [1385, 1415], "entities": [{"type": "Organization", "text": "American Chemical Society - www.acs.org; Journal of Medicinal Chemistry"}]}, {"text": "9205-9217", "location": [1430, 1439], "entities": [{"type": "Phone", "text": "9205-9217"}]}]}, {"type": "locatedAt", "sentence": "Journal of Medicinal Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA .", "score": 0.972593, "arguments": [{"text": "NW", "location": [1526, 1528], "entities": [{"type": "GeopoliticalEntity", "text": "NW"}]}, {"text": "Washington", "location": [1531, 1541], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}]}, {"type": "locatedAt", "sentence": "Journal of Medicinal Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA .", "score": 0.552263, "arguments": [{"text": "NW", "location": [1526, 1528], "entities": [{"type": "GeopoliticalEntity", "text": "NW"}]}, {"text": "DC", "location": [1543, 1545], "entities": [{"type": "GeopoliticalEntity", "text": "DC"}]}]}, {"type": "populationOf", "sentence": "Journal of Medicinal Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA .", "score": 0.544966, "arguments": [{"text": "20036", "location": [1546, 1551], "entities": [{"type": "Cardinal", "text": "20036"}]}, {"text": "DC", "location": [1543, 1545], "entities": [{"type": "GeopoliticalEntity", "text": "DC"}]}]}, {"type": "locatedAt", "sentence": "Journal of Medicinal Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW , Washington, DC 20036, USA .", "score": 0.701729, "arguments": [{"text": "DC", "location": [1543, 1545], "entities": [{"type": "GeopoliticalEntity", "text": "DC"}]}, {"text": "USA", "location": [1553, 1556], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "( American Chemical Society - www.acs.org; Journal of Medicinal Chemistry - www.pubs.acs.org/journal/jmcmar) Our news correspondents report that additional information may be obtained by contacting J. Aida , Takeda Pharmaceut Co Ltd. , Res, Fujisawa, Kanagawa 2518555, Japan .", "score": 0.501587, "arguments": [{"text": "Res", "location": [1795, 1798], "entities": [{"type": "Person", "text": "Res"}]}, {"text": "Japan", "location": [1828, 1833], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Enzymes and Coenzymes - Carboxylic Ester Hydrolases.", "score": 0.613003, "arguments": [{"text": "Editor", "location": [30, 36], "entities": [{"type": "Person", "text": "Reporter"}]}, {"text": "Gene Therapy Weekly", "location": [40, 59], "entities": [{"type": "Organization", "text": "Gene Therapy Weekly"}]}]}, {"type": "locatedAt", "sentence": "According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "score": 0.98944, "arguments": [{"text": "Fujisawa", "location": [195, 203], "entities": [{"type": "GeopoliticalEntity", "text": "Fujisawa"}]}, {"text": "Japan", "location": [205, 210], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "score": 0.821756, "arguments": [{"text": "journalists", "location": [223, 234], "entities": [{"type": "Person", "text": "journalists"}]}, {"text": "NewsRx", "location": [216, 222], "entities": [{"type": "Organization", "text": "NewsRx LLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "According to news reporting originating in Fujisawa, Japan , by NewsRx journalists, research stated, \"Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain.", "score": 0.40949, "arguments": [{"text": "Monoacylglycerol lipase", "location": [254, 277], "entities": [{"type": "Person", "text": "Monoacylglycerol lipase"}]}, {"text": "MAGL", "location": [279, 283], "entities": [{"type": "Organization", "text": "MAGL inhibitor"}]}]}, {"type": "locatedAt", "sentence": "\" The news reporters obtained a Quote: from the research from Takeda Pharmaceutical Company , \"In this study, we report the structure-based drug design of novel piperazinyl pyrrolidin-2-ones starting from our hit compounds 2a and 2b.", "score": 0.159142, "arguments": [{"text": "2a", "location": [825, 827], "entities": [{"type": "Person", "text": "2a"}]}, {"text": "compounds", "location": [815, 824], "entities": [{"type": "Location", "text": "compounds"}]}]}, {"type": "locatedAt", "sentence": "By enhancing the interaction of the piperazinyl pyrrolidin-2-one core and its substituents with the MAGL enzyme via design modifications, we identified a potent and reversible MAGL inhibitor, compound \u00ae-3t.", "score": 0.430543, "arguments": [{"text": "we", "location": [974, 976], "entities": [{"type": "Person", "text": "our"}]}, {"text": "compound", "location": [1028, 1036], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "partOfMany", "sentence": "By enhancing the interaction of the piperazinyl pyrrolidin-2-one core and its substituents with the MAGL enzyme via design modifications, we identified a potent and reversible MAGL inhibitor, compound \u00ae-3t.", "score": 0.529356, "arguments": [{"text": "\u00ae", "location": [1037, 1038], "entities": [{"type": "Person", "text": "\u00ae"}]}, {"text": "we", "location": [974, 976], "entities": [{"type": "Person", "text": "our"}]}]}, {"type": "locatedAt", "sentence": "By enhancing the interaction of the piperazinyl pyrrolidin-2-one core and its substituents with the MAGL enzyme via design modifications, we identified a potent and reversible MAGL inhibitor, compound \u00ae-3t.", "score": 0.273661, "arguments": [{"text": "MAGL inhibitor", "location": [1012, 1026], "entities": [{"type": "Organization", "text": "MAGL inhibitor"}]}, {"text": "compound", "location": [1028, 1036], "entities": [{"type": "Facility", "text": "compound"}]}]}], "keywords": [{"text": "new report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.753181, "count": 1}, {"text": "news", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.66855, "count": 1}, {"text": "news reporters", "sentiment": {"score": 0.550648, "label": "positive"}, "relevance": 0.661842, "count": 2}, {"text": "reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65579, "count": 1}, {"text": "additional information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.648937, "count": 2}, {"text": "direct object identifier", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643674, "count": 1}, {"text": "American Chemical Society", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598634, "count": 1}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0.550648, "label": "positive"}, "relevance": 0.588833, "count": 1}, {"text": "online electronic document", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.583606, "count": 1}, {"text": "research", "sentiment": {"score": 0.550648, "label": "positive"}, "relevance": 0.579968, "count": 4}, {"text": "news correspondents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567757, "count": 1}, {"text": "information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56213, "count": 1}, {"text": "News Reporter-Staff News Editor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559536, "count": 1}, {"text": "Gene Therapy Weekly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556085, "count": 1}, {"text": "Journal of Medicinal Chemistry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55551, "count": 3}, {"text": "fact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540493, "count": 1}, {"text": "direct source", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.537182, "count": 1}, {"text": "news of research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535675, "count": 1}, {"text": "link", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.535675, "count": 1}, {"text": "arachidonic acid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533377, "count": 1}, {"text": "study", "sentiment": {"score": 0.550648, "label": "positive"}, "relevance": 0.529705, "count": 1}, {"text": "Additional authors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529672, "count": 1}, {"text": "Investigators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528234, "count": 1}, {"text": "purchase", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.527364, "count": 1}, {"text": "major serine hydrolase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525546, "count": 1}, {"text": "Design", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525339, "count": 1}, {"text": "2-AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524955, "count": 2}, {"text": "Fujisawa", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524767, "count": 2}, {"text": "Enzymes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523074, "count": 2}, {"text": "DOI", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.520867, "count": 2}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520252, "count": 2}, {"text": "compound", "sentiment": {"score": 0.855746, "label": "positive"}, "relevance": 0.520225, "count": 1}, {"text": "structure", "sentiment": {"score": 0.550648, "label": "positive"}, "relevance": 0.519435, "count": 1}, {"text": "journal article", "sentiment": {"score": 0.483091, "label": "positive"}, "relevance": 0.519262, "count": 1}, {"text": "journal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518584, "count": 1}, {"text": "Monoacylglycerol lipase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516483, "count": 1}, {"text": "brain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516371, "count": 3}, {"text": "Copyright", "sentiment": {"score": 0.685977, "label": "positive"}, "relevance": 0.516065, "count": 1}, {"text": "Synthesis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516061, "count": 1}, {"text": "neurodegenerative diseases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515878, "count": 1}, {"text": "NewsRx journalists", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515859, "count": 1}, {"text": "substituents", "sentiment": {"score": 0.855746, "label": "positive"}, "relevance": 0.5157, "count": 1}, {"text": "org", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515691, "count": 1}, {"text": "mice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515604, "count": 1}, {"text": "Res", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514918, "count": 1}, {"text": "inhibition of MAGL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511811, "count": 1}, {"text": "Takeda Pharmaceut Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508796, "count": 1}, {"text": "pubs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50876, "count": 1}, {"text": "Kanagawa", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507513, "count": 1}, {"text": "Washington", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507428, "count": 1}]}, "extracted_metadata": {"sha1": "256d39aa2c2525432dadb20ad026310d33e254b2", "filename": "1543090718646.zip-8050e479f559d004c59b0ab98e545d7f.xml", "file_type": "json"}, "external_links": ["https://doi.org/10.1021/acs.jmedchem.8b00824."], "title": "Takeda Pharmaceutical : Study Results from Takeda Pharmaceutical Company Broaden Understanding of Carboxylic Ester Hydrolases (Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors)", "forum_title": "Markets : News, Sectors, Healthcare - Marketscreener.com"}, {"id": "BuBzrypnUadWLqbe4e3g6GmvPRME96Cmz5hcEqyU-lkh6wgWaukrOfiGUlHEs_VC", "result_metadata": {"score": 27.039717}, "author": "tanuj", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cipla", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Cipla", "dbpedia_resource": "http://dbpedia.org/resource/Cipla"}}, {"count": 1, "sentiment": {"score": -0.426668, "label": "negative"}, "text": "Cosmo Pharmaceuticals", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Budesonide", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.811763, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.670419, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Budesonide Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999461, "count": 1}, {"text": "Sandoz", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.716479, "count": 1}, {"text": "Cosmo Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399811, "count": 1}, {"text": "Cipla", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.092203, "count": 1}]}, "crawl_date": "2018-11-24T20:11:50Z", "url": "https://www.findmarketresearch.org/2018/11/budesonide-market-key-players-pfizer-sandoz-cipla-cosmo-pharmaceuticals-takeda-2/", "host": "findmarketresearch.org", "text": "//www.persistencemarketresearch.com/samples/13456 Global Budesonide Market: Key Players Few market players in global budesonide are Pfizer, Sandoz, Cipla, Cosmo Pharmaceuticals, Takeda, Manus Aktteva Biopharma LLP, Abbott, Lunan Better Pharmaceutical, Novartis, Mylan, Novartis, Skyepharma, AstraZeneca AB, Wellcome Australia Ltd, AstraZeneca plc, AstraZeneca Australia, Chiesi Farmaceutici S.p.A, Orion", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T10:28:00+05:00", "enriched_text": {"entities": [{"count": 32, "sentiment": {"score": -0.414846, "label": "negative"}, "text": "Budesonide", "relevance": 0.890278, "type": "Drug"}, {"count": 7, "sentiment": {"score": -0.527384, "label": "negative"}, "text": "asthma", "relevance": 0.18917, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca plc", "relevance": 0.0974479, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": -0.487716, "label": "negative"}, "text": "COPD", "relevance": 0.0918745, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}, {"count": 2, "sentiment": {"score": -0.250111, "label": "negative"}, "text": "FDA", "relevance": 0.0880607, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 2, "sentiment": {"score": -0.858392, "label": "negative"}, "text": "Middle East", "relevance": 0.085866, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.0833182, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.444421, "label": "positive"}, "text": "North America", "relevance": 0.0818181, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": -0.858392, "label": "negative"}, "text": "Latin America", "relevance": 0.0768563, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": -0.444227, "label": "negative"}, "text": "glucocorticoid", "relevance": 0.0765256, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0.444421, "label": "positive"}, "text": "Europe", "relevance": 0.0760978, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.250111, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.0722487, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": -0.257569, "label": "negative"}, "text": "pulmicort respules", "relevance": 0.0704684, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.558433, "label": "negative"}, "text": "chest tightness", "relevance": 0.069644, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.0681732, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": -0.858392, "label": "negative"}, "text": "Africa", "relevance": 0.0680254, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.0677616, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Australia", "relevance": 0.0676396, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Manus Aktteva Biopharma LLP", "relevance": 0.0673031, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.250111, "label": "negative"}, "text": "uceris", "relevance": 0.0671055, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chiesi Farmaceutici", "relevance": 0.0645903, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.735758, "label": "negative"}, "text": "skin disorder", "relevance": 0.0643474, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Cutaneous condition", "dbpedia_resource": "http://dbpedia.org/resource/Cutaneous_condition"}}, {"count": 1, "sentiment": {"score": -0.778835, "label": "negative"}, "text": "allergic rhinitis", "relevance": 0.0641884, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Allergic rhinitis", "dbpedia_resource": "http://dbpedia.org/resource/Allergic_rhinitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orion Corporation", "relevance": 0.0641845, "type": "Company", "disambiguation": {"subtype": [], "name": "Orion Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Orion_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Synmosa Biopharma Corporation", "relevance": 0.0640033, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.490775, "label": "negative"}, "text": "China", "relevance": 0.0624293, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.0620974, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regional Overview", "relevance": 0.0615826, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lunan Better Pharmaceutical", "relevance": 0.0610688, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.0591095, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wellcome Australia Ltd", "relevance": 0.058829, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cipla", "relevance": 0.0582113, "type": "Company", "disambiguation": {"subtype": [], "name": "Cipla", "dbpedia_resource": "http://dbpedia.org/resource/Cipla"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan", "relevance": 0.0558608, "type": "Company", "disambiguation": {"subtype": [], "name": "Mylan", "dbpedia_resource": "http://dbpedia.org/resource/Mylan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0554733, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Skyepharma", "relevance": 0.052751, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.405267, "label": "negative"}, "text": "Cosmo Pharmaceuticals", "relevance": 0.0525217, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.0509106, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.0506311, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12 months", "relevance": 0.0506311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6 years", "relevance": 0.0506311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8 years", "relevance": 0.0506311, "type": "Quantity"}], "sentiment": {"document": {"score": -0.561776, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "seasonal asthma", "keywords": [{"text": "seasonal asthma"}]}, "sentence": " With the change in climate and environment, seasonal asthma has become main cause of respiratory ailments.", "object": {"text": "main cause of respiratory ailments", "keywords": [{"text": "respiratory ailments"}, {"text": "main cause"}]}, "action": {"verb": {"text": "become", "tense": "past"}, "text": "has become", "normalized": "have become"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is used to control and prevent symptoms such as wheezing and shortness of breath caused by asthma.", "object": {"text": "to control"}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is used to control and prevent symptoms such as wheezing and shortness of breath caused by asthma.", "object": {"text": "symptoms", "keywords": [{"text": "symptoms"}]}, "action": {"verb": {"text": "prevent", "tense": "present"}, "text": "prevent", "normalized": "prevent"}}, {"subject": {"text": "by asthma", "keywords": [{"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "sentence": " Budesonide is used to control and prevent symptoms such as wheezing and shortness of breath caused by asthma.", "object": {"text": "symptoms such as wheezing and shortness of breath", "keywords": [{"text": "shortness"}, {"text": "breath"}, {"text": "symptoms"}], "entities": []}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide belongs to a class of drugs named as corticosteroids.", "object": {"text": "to a class of drugs named as corticosteroids", "keywords": [{"text": "corticosteroids"}, {"text": "drugs"}, {"text": "class"}]}, "action": {"verb": {"text": "belong", "tense": "present"}, "text": "belongs", "normalized": "belong"}}, {"subject": {"text": "It"}, "sentence": " It works directly to the lungs to make breathing easier by reducing the irritation and swelling of the airways.", "object": {"text": "to the lungs", "keywords": [{"text": "lungs"}]}, "action": {"verb": {"text": "work", "tense": "present"}, "text": "works", "normalized": "work"}}, {"subject": {"text": "breathing", "keywords": [{"text": "breathing"}]}, "sentence": " It works directly to the lungs to make breathing easier by reducing the irritation and swelling of the airways.", "object": {"text": "easier"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "to make", "normalized": "to make"}}, {"subject": {"text": "It"}, "sentence": " It works directly to the lungs to make breathing easier by reducing the irritation and swelling of the airways.", "object": {"text": "the irritation", "keywords": [{"text": "irritation"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reducing", "normalized": "reduce"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide sold under the brand name pulmicort among others, is a steroid medication.", "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "Budesonide sold under the brand name pulmicort among others,", "keywords": [{"text": "Budesonide"}, {"text": "brand name pulmicort"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide sold under the brand name pulmicort among others, is a steroid medication.", "object": {"text": "a steroid medication", "keywords": [{"text": "steroid medication"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is available as an inhaler, pill, nasal spray, and rectal.", "object": {"text": "available as an inhaler", "keywords": [{"text": "inhaler"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The inhaled form", "keywords": [{"text": "inhaled form"}]}, "sentence": " The inhaled form is used in long-term management of asthma and chronic obstructive pulmonary disease (COPD).", "object": {"text": "in long-term management of asthma and chronic obstructive pulmonary disease (COPD)", "keywords": [{"text": "obstructive pulmonary disease"}, {"text": "long-term management"}, {"text": "COPD"}, {"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}, {"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "is used", "normalized": "be use"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is used to avert difficulty while breathing, chest tightness, wheezing and coughing caused by asthma.", "object": {"text": "difficulty", "keywords": [{"text": "difficulty"}]}, "action": {"verb": {"text": "avert", "tense": "future"}, "text": "to avert", "normalized": "to avert"}}, {"subject": {"text": "by asthma", "keywords": [{"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "sentence": " Budesonide is used to avert difficulty while breathing, chest tightness, wheezing and coughing caused by asthma.", "object": {"text": "wheezing and coughing"}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "Budesonide powder for oral inhalation", "keywords": [{"text": "Budesonide powder"}, {"text": "oral inhalation"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide powder for oral inhalation is used in adults and children; 6 years of age and older.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "is used", "normalized": "be use"}}, {"subject": {"text": "Budesonide suspension for oral inhalation", "keywords": [{"text": "Budesonide suspension"}, {"text": "oral inhalation"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide suspension for oral inhalation is also used in children 12 months to 8 years of age.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "is also used", "normalized": "be also use"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide helps to prevent asthma attacks and shortness of breath.", "object": {"text": "to prevent asthma attacks", "keywords": [{"text": "asthma attacks"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide helps to prevent asthma attacks and shortness of breath.", "object": {"text": "asthma attacks", "keywords": [{"text": "asthma attacks"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "prevent", "tense": "future"}, "text": "helps to prevent", "normalized": "help to prevent"}}, {"subject": {"text": "Each budesonide inhaler", "keywords": [{"text": "budesonide inhaler"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Each budesonide inhaler is designed to provide 60 to 120 inhalations, depending on its size.", "object": {"text": "60"}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "is designed to provide", "normalized": "be design to provide"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is a glucocorticoid used in management of asthma, the treatment of various skin disorder, and allergic rhinitis.", "object": {"text": "a glucocorticoid", "keywords": [{"text": "glucocorticoid"}], "entities": [{"type": "Drug", "text": "glucocorticoid"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a glucocorticoid", "keywords": [{"text": "glucocorticoid"}], "entities": [{"type": "Drug", "text": "glucocorticoid"}]}, "sentence": " Budesonide is a glucocorticoid used in management of asthma, the treatment of various skin disorder, and allergic rhinitis.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is provided as a mixture of two epimers (22R and 22S).", "object": {"text": "as a mixture of two epimers (22R and 22S)", "keywords": [{"text": "mixture"}, {"text": "epimers"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "The extended release oral tablet", "keywords": [{"text": "release oral tablet"}]}, "sentence": " The extended release oral tablet, marketed as uceris got approved by FDA for the management of ulcerative colitis.", "object": {"text": "as uceris", "keywords": [{"text": "uceris"}], "entities": [{"type": "Company", "text": "uceris"}]}, "action": {"verb": {"text": "market", "tense": "past"}, "text": "marketed", "normalized": "market"}}, {"subject": {"text": "by FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The extended release oral tablet, marketed as uceris got approved by FDA for the management of ulcerative colitis.", "object": {"text": "uceris", "keywords": [{"text": "uceris"}], "entities": [{"type": "Company", "text": "uceris"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "got approved", "normalized": "get approve"}}, {"subject": {"text": "The global demand for budesonide", "keywords": [{"text": "global demand"}, {"text": "budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " The global demand for budesonide is expected substantial growth over the forecast period.", "object": {"text": "substantial growth", "keywords": [{"text": "substantial growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected", "normalized": "be expect"}}, {"subject": {"text": "Global Budesonide", "keywords": [{"text": "Global Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Global Budesonide is appropriate to the course of medication called corticosteroids.", "object": {"text": "appropriate to the course of medication called corticosteroids", "keywords": [{"text": "corticosteroids"}, {"text": "medication"}, {"text": "course"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Budesonide, an adrenocortical hormone,", "keywords": [{"text": "adrenocortical hormone"}, {"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide, an adrenocortical hormone, was developed by AstraZeneca in the 1990s.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was developed", "normalized": "be develop"}}, {"subject": {"text": "by AstraZeneca", "keywords": [{"text": "AstraZeneca"}], "entities": [{"type": "Company", "text": "AstraZeneca plc", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}]}, "sentence": " Budesonide, an adrenocortical hormone, was developed by AstraZeneca in the 1990s.", "object": {"text": "Budesonide, an adrenocortical hormone,", "keywords": [{"text": "adrenocortical hormone"}, {"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "was developed", "normalized": "be develop"}}, {"subject": {"text": "It"}, "sentence": " It is mainly used for the treatment of non-budesonide glucocorticoid-dependent or glucocorticoid.", "object": {"text": "mainly used for the treatment of non-budesonide glucocorticoid-dependent or glucocorticoid", "keywords": [{"text": "treatment"}], "entities": [{"type": "Drug", "text": "glucocorticoid"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is mainly used for the treatment of non-budesonide glucocorticoid-dependent or glucocorticoid.", "object": {"text": "for the treatment of non-budesonide glucocorticoid-dependent or glucocorticoid", "keywords": [{"text": "treatment"}], "entities": [{"type": "Drug", "text": "glucocorticoid"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "is mainly used", "normalized": "be mainly use"}}, {"subject": {"text": "by FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In June 1997, budesonide aerosol got approved by FDA.", "object": {"text": "budesonide aerosol", "keywords": [{"text": "budesonide aerosol"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "got approved", "normalized": "get approve"}}, {"subject": {"text": "the increasing rate of air pollution", "keywords": [{"text": "air pollution"}, {"text": "rate"}]}, "sentence": " In recent years, the increasing rate of air pollution will increase asthma and other breathing problem.", "object": {"text": "asthma and other breathing problem", "keywords": [{"text": "breathing problem"}, {"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "will increase", "normalized": "will increase"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is used to treat mild to moderate crohn\u2019s disease.", "object": {"text": "to treat mild to moderate crohn\u2019s disease", "keywords": [{"text": "crohn"}, {"text": "disease"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is generic name of a prescription drug sold under the brand names entocortec, uceris, pulmicort, pulmicort flexhaler, pulmicort respules, and rhinocort.", "object": {"text": "generic name of a prescription drug sold under the brand names entocortec", "keywords": [{"text": "prescription drug"}, {"text": "brand names"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It\u2019s also one of the drugs found in the inhaler symbicort, used to treat COPD and asthma.", "object": {"text": "one of the drugs", "keywords": [{"text": "drugs"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the drugs", "keywords": [{"text": "drugs"}]}, "sentence": " It\u2019s also one of the drugs found in the inhaler symbicort, used to treat COPD and asthma.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "found", "normalized": "find"}}, {"subject": {"text": "Budesonide", "keywords": [{"text": "Budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " Budesonide is expected to grow at significant CAGR in near future.", "object": {"text": "at significant CAGR in near future", "keywords": [{"text": "significant CAGR"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "product type budesonide market", "keywords": [{"text": "product type budesonide"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " On the basis of product type budesonide market can be segmented as aerosol, sprays, inhalants, and suspension, pill&rectal forms.", "object": {"text": "as aerosol, sprays, inhalants, and suspension, pill&rectal forms", "keywords": [{"text": "inhalants"}, {"text": "sprays"}, {"text": "aerosol"}, {"text": "pill&rectal forms"}]}, "action": {"verb": {"text": "segment", "tense": "future"}, "text": "can be segmented", "normalized": "can be segment"}}, {"subject": {"text": "budesonide market", "keywords": [{"text": "budesonide market"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "sentence": " On the basis of region, budesonide market is segmented into North America, Latin America, Europe, Asia Pacific and Middle East and Africa.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Asia pacific", "keywords": [{"text": "Asia pacific"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Asia pacific have significant high market share in budesonide market as compared to others owing to increasing population as well as increasing pollution issue in this region especially in the countries such as India and China.", "object": {"text": "significant high market share in budesonide market as compared to others owing to increasing population as well as increasing pollution issue in this region especially in the countries such as India and China", "keywords": [{"text": "budesonide market"}, {"text": "pollution issue"}, {"text": "market share"}, {"text": "population"}], "entities": [{"type": "Drug", "text": "Budesonide"}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "China", "keywords": [{"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " China is expected to dominate budesonide market in the near future.", "object": {"text": "budesonide market", "keywords": [{"text": "budesonide market"}], "entities": [{"type": "Drug", "text": "Budesonide"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "is expected to dominate", "normalized": "be expect to dominate"}}, {"subject": {"text": "The market size of budesonide in Asia Pacific", "keywords": [{"text": "budesonide"}, {"text": "market size"}, {"text": "Asia Pacific"}], "entities": [{"type": "Drug", "text": "Budesonide"}, {"type": "Company", "text": "Asia Pacific"}]}, "sentence": " The market size of budesonide in Asia Pacific is expected to keep growing in next few years.", "action": {"verb": {"text": "grow", "tense": "present"}, "text": "is expected to keep growing", "normalized": "be expect to keep grow"}}, {"subject": {"text": "The North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The North America is expected to Experience significant growth in coming years following Europe.", "object": {"text": "significant growth", "keywords": [{"text": "significant growth"}]}, "action": {"verb": {"text": "Experience", "tense": "future"}, "text": "is expected to Experience", "normalized": "be expect to Experience"}}, {"subject": {"text": "years"}, "sentence": " The North America is expected to Experience significant growth in coming years following Europe.", "action": {"verb": {"text": "come", "tense": "present"}, "text": "coming", "normalized": "come"}}, {"subject": {"text": "Latin America and Middle East & Africa", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " Latin America and Middle East & Africa is projected to experience stagnant growth rate during the forecast period.", "object": {"text": "projected to experience stagnant growth rate", "keywords": [{"text": "stagnant growth rate"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Latin America and Middle East & Africa", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " Latin America and Middle East & Africa is projected to experience stagnant growth rate during the forecast period.", "object": {"text": "stagnant growth rate", "keywords": [{"text": "stagnant growth rate"}]}, "action": {"verb": {"text": "experience", "tense": "future"}, "text": "is projected to experience", "normalized": "be project to experience"}}], "concepts": [{"text": "Asthma", "relevance": 0.953896, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Budesonide", "relevance": 0.735226, "dbpedia_resource": "http://dbpedia.org/resource/Budesonide"}, {"text": "Chronic obstructive pulmonary disease", "relevance": 0.603873, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}, {"text": "AstraZeneca", "relevance": 0.566297, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Glucocorticoid", "relevance": 0.44995, "dbpedia_resource": "http://dbpedia.org/resource/Glucocorticoid"}, {"text": "Formoterol", "relevance": 0.436332, "dbpedia_resource": "http://dbpedia.org/resource/Formoterol"}, {"text": "Nebulizer", "relevance": 0.379649, "dbpedia_resource": "http://dbpedia.org/resource/Nebulizer"}, {"text": "Budesonide/formoterol", "relevance": 0.345588, "dbpedia_resource": "http://dbpedia.org/resource/Budesonide/formoterol"}, {"text": "Rhinitis", "relevance": 0.340051, "dbpedia_resource": "http://dbpedia.org/resource/Rhinitis"}, {"text": "Corticosteroid", "relevance": 0.32347, "dbpedia_resource": "http://dbpedia.org/resource/Corticosteroid"}, {"text": "Inhaler", "relevance": 0.299414, "dbpedia_resource": "http://dbpedia.org/resource/Inhaler"}, {"text": "Bambuterol", "relevance": 0.289836, "dbpedia_resource": "http://dbpedia.org/resource/Bambuterol"}, {"text": "Inhalation", "relevance": 0.263283, "dbpedia_resource": "http://dbpedia.org/resource/Inhalation"}], "categories": [{"score": 0.999702, "label": "/health and fitness/disease/asthma"}], "relations": [{"type": "locatedAt", "sentence": "On the basis of region, budesonide market is segmented into North America, Latin America, Europe, Asia Pacific and Middle East and Africa.", "score": 0.558259, "arguments": [{"text": "Pacific", "location": [3189, 3196], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [3184, 3188], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Budesonide Market: Regional Overview Asia pacific have significant high market share in budesonide market as compared to others owing to increasing population as well as increasing pollution issue in this region especially in the countries such as India and China.", "score": 0.379164, "arguments": [{"text": "region", "location": [3437, 3443], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "countries", "location": [3462, 3471], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Global Budesonide Market: Regional Overview Asia pacific have significant high market share in budesonide market as compared to others owing to increasing population as well as increasing pollution issue in this region especially in the countries such as India and China.", "score": 0.577843, "arguments": [{"text": "India", "location": [3480, 3485], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3462, 3471], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Global Budesonide Market: Regional Overview Asia pacific have significant high market share in budesonide market as compared to others owing to increasing population as well as increasing pollution issue in this region especially in the countries such as India and China.", "score": 0.73751, "arguments": [{"text": "China", "location": [3490, 3495], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3462, 3471], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The market size of budesonide in Asia Pacific is expected to keep growing in next few years.", "score": 0.804017, "arguments": [{"text": "Asia", "location": [3598, 3602], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3603, 3610], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "ownerOf", "sentence": "//www.persistencemarketresearch.com/samples/13456 Global Budesonide Market: Key Players Few market players in global budesonide are Pfizer, Sandoz, Cipla, Cosmo Pharmaceuticals, Takeda, Manus Aktteva Biopharma LLP, Abbott, Lunan Better Pharmaceutical, Novartis, Mylan, Novartis, Skyepharma, AstraZeneca AB, Wellcome Australia Ltd, AstraZeneca plc, AstraZeneca Australia, Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus, Synmosa Biopharma Corporation.", "score": 0.695163, "arguments": [{"text": "Key Players\nFew", "location": [3947, 3962], "entities": [{"type": "Organization", "text": "Key Players\nFew", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "market", "location": [3963, 3969], "entities": [{"type": "Facility", "text": "market"}]}]}], "keywords": [{"text": "Global Budesonide Market", "sentiment": {"score": 0.38693, "mixed": "1", "label": "positive"}, "relevance": 0.961544, "count": 5}, {"text": "Budesonide", "sentiment": {"score": -0.780825, "label": "negative"}, "relevance": 0.758783, "count": 11}, {"text": "global demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.747706, "count": 1}, {"text": "basis of product type", "sentiment": {"score": -0.539492, "label": "negative"}, "relevance": 0.665527, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0.855991, "label": "positive"}, "relevance": 0.62446, "count": 2}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624274, "count": 2}, {"text": "Market Overview", "sentiment": {"score": -0.928173, "label": "negative"}, "relevance": 0.616911, "count": 1}, {"text": "region basis", "sentiment": {"score": -0.666927, "label": "negative"}, "relevance": 0.583575, "count": 1}, {"text": "demand", "sentiment": {"score": 0.627707, "label": "positive"}, "relevance": 0.582719, "count": 1}, {"text": "Budesonide powder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576818, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.868188, "label": "negative"}, "relevance": 0.576495, "count": 2}, {"text": "Global Budesonide", "sentiment": {"score": 0.416715, "label": "positive"}, "relevance": 0.575172, "count": 1}, {"text": "global demand of global budesonide", "sentiment": {"score": -0.539492, "label": "negative"}, "relevance": 0.571302, "count": 1}, {"text": "substantial growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57083, "count": 1}, {"text": "basis of product type budesonide market", "sentiment": {"score": -0.666927, "label": "negative"}, "relevance": 0.567571, "count": 1}, {"text": "Key Players", "sentiment": {"score": 0.873006, "label": "positive"}, "relevance": 0.565994, "count": 1}, {"text": "Budesonide suspension", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562896, "count": 1}, {"text": "steady growth", "sentiment": {"score": 0.627707, "label": "positive"}, "relevance": 0.561379, "count": 1}, {"text": "seasonal asthma", "sentiment": {"score": -0.928173, "label": "negative"}, "relevance": 0.541157, "count": 1}, {"text": "asthma", "sentiment": {"score": -0.600462, "mixed": "1", "label": "negative"}, "relevance": 0.540538, "count": 5}, {"text": "basis application budesonide market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539335, "count": 1}, {"text": "brand name pulmicort", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536448, "count": 1}, {"text": "budesonide inhaler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535316, "count": 1}, {"text": "inhaler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535236, "count": 2}, {"text": "Middle East", "sentiment": {"score": -0.342986, "mixed": "1", "label": "negative"}, "relevance": 0.534022, "count": 2}, {"text": "application", "sentiment": {"score": -0.605269, "label": "negative"}, "relevance": 0.531886, "count": 1}, {"text": "significant growth", "sentiment": {"score": -0.868188, "label": "negative"}, "relevance": 0.531851, "count": 1}, {"text": "significant high market share", "sentiment": {"score": 0.855991, "label": "positive"}, "relevance": 0.53089, "count": 1}, {"text": "region", "sentiment": {"score": 0.855991, "label": "positive"}, "relevance": 0.529811, "count": 1}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527808, "count": 1}, {"text": "size", "sentiment": {"score": -0.76824, "label": "negative"}, "relevance": 0.525381, "count": 1}, {"text": "China", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525184, "count": 2}, {"text": "class of drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524645, "count": 1}, {"text": "significant CAGR", "sentiment": {"score": -0.539492, "label": "negative"}, "relevance": 0.524142, "count": 1}, {"text": "powder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52307, "count": 1}, {"text": "suspension", "sentiment": {"score": -0.666927, "label": "negative"}, "relevance": 0.523062, "count": 2}, {"text": "recent years", "sentiment": {"score": -0.871696, "label": "negative"}, "relevance": 0.522403, "count": 1}, {"text": "inhalation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521895, "count": 1}, {"text": "drugs", "sentiment": {"score": -0.904579, "label": "negative"}, "relevance": 0.521119, "count": 1}, {"text": "nasal spray", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520502, "count": 1}, {"text": "Novartis", "sentiment": {"score": 0.873006, "label": "positive"}, "relevance": 0.51984, "count": 2}, {"text": "mouth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518736, "count": 2}, {"text": "change", "sentiment": {"score": -0.928173, "label": "negative"}, "relevance": 0.518675, "count": 1}, {"text": "treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518304, "count": 1}, {"text": "chronic obstructive pulmonary disease", "sentiment": {"score": -0.689543, "label": "negative"}, "relevance": 0.517903, "count": 1}, {"text": "market players", "sentiment": {"score": 0.873006, "label": "positive"}, "relevance": 0.516325, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.868188, "label": "negative"}, "relevance": 0.515965, "count": 2}, {"text": "basis of region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51579, "count": 1}, {"text": "generic name of a prescription drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515319, "count": 1}, {"text": "others", "sentiment": {"score": 0.855991, "label": "positive"}, "relevance": 0.515046, "count": 3}]}, "extracted_metadata": {"sha1": "2498bf25c4d4b192fac656b86ca763ab1eaef5ef", "filename": "1543090310734.zip-8ea76f0acf85edc091290f1136348510.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/13456", "https://www.persistencemarketresearch.com/market-research/budesonide-market.asp"], "title": "Budesonide Pfizer, Sandoz, Cipla, Cosmo Pharmaceuticals, Takeda", "forum_title": "Research Insights | Find Market Research - Part 177"}, {"id": "9BZZb_4JrhA_ARnkn-DUkqoqtVgTvcGchCZGL85EI3-phvrukKNQOCCTfk2JsCnF", "result_metadata": {"score": 26.74037}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Clearance", "keywords": [{"text": "Clearance"}]}, "sentence": "Takeda Pharmaceutical : Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc", "object": {"text": "from the European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "Receives", "tense": "present"}, "text": "Receives", "normalized": "Receives"}}], "concepts": [{"text": "European Commission", "relevance": 0.971008, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "European Union", "relevance": 0.937672, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Parliament", "relevance": 0.858258, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "European Council", "relevance": 0.852116, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}], "categories": [{"score": 0.934212, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.864158, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.992691, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.973735, "count": 1}, {"text": "Clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.815512, "count": 1}, {"text": "Acquisition of Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.149964, "count": 1}]}, "crawl_date": "2018-11-25T13:09:50Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Receives-Clearance-from-the-European-Commission-for-the-Proposed-Acquisition-27658248/", "host": "4-traders.com", "text": "About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-25T00:00:00+01:00", "enriched_text": {"entities": [{"count": 15, "sentiment": {"score": 0.204531, "label": "positive"}, "text": "Takeda", "relevance": 0.859516, "type": "Person"}, {"count": 13, "sentiment": {"score": -0.0176461, "label": "negative"}, "text": "Takeda", "relevance": 0.822906, "type": "Company"}, {"count": 16, "sentiment": {"score": -0.541151, "label": "negative"}, "text": "Vedolizumab", "relevance": 0.580907, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "relevance": 0.542852, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.47025, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Takeda", "relevance": 0.44817, "type": "JobTitle"}, {"count": 9, "sentiment": {"score": -0.0716983, "label": "negative"}, "text": "Shire", "relevance": 0.43868, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.643548, "label": "negative"}, "text": "bowel disease", "relevance": 0.398964, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": -0.781712, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.342951, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EGM", "relevance": 0.304526, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.300654, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.29491, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.285886, "type": "Crime"}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.284433, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.283531, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 2, "sentiment": {"score": -0.386126, "label": "negative"}, "text": "Vedolizumab", "relevance": 0.276797, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.724411, "label": "negative"}, "text": "Crohn\u2019s disease", "relevance": 0.273931, "type": "HealthCondition"}, {"count": 3, "sentiment": {"score": 0.664935, "label": "positive"}, "text": "European Commission", "relevance": 0.27151, "type": "Organization"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.267564, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AETOS Wire", "relevance": 0.263571, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.485501, "label": "positive"}, "text": "Tokyo", "relevance": 0.258502, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazilian Administrative Council for Economic Defense", "relevance": 0.252209, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "progressive multifocal leukoencephalopathy", "relevance": 0.251989, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Entyvio", "relevance": 0.247271, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.416862, "label": "negative"}, "text": "Entyvio", "relevance": 0.244082, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.437544, "label": "negative"}, "text": "IBD", "relevance": 0.243937, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.242996, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.242819, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.242345, "type": "Organization", "disambiguation": {"subtype": ["BuildingFunction"], "name": "University", "dbpedia_resource": "http://dbpedia.org/resource/University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "INTEX Osaka", "relevance": 0.242285, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.242069, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 2, "sentiment": {"score": -0.464166, "label": "negative"}, "text": "epinephrine", "relevance": 0.239159, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.213998, "label": "negative"}, "text": "celiac disease", "relevance": 0.238193, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.236241, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.24941, "label": "negative"}, "text": "UC", "relevance": 0.235041, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan Fair Trade Commission", "relevance": 0.233031, "type": "Organization", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States Federal Trade Commission", "relevance": 0.232503, "type": "Organization", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"count": 2, "sentiment": {"score": -0.737746, "label": "negative"}, "text": "tuberculosis", "relevance": 0.232183, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.232174, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.336475, "label": "negative"}, "text": "paracetamol", "relevance": 0.231606, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "mechanism of action", "relevance": 0.229894, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "natalizumab", "relevance": 0.22643, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shyjan", "relevance": 0.225026, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J Pathol.", "relevance": 0.221588, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jersey court", "relevance": 0.221528, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SyndiGate Media Inc.", "relevance": 0.21838, "type": "Company"}], "sentiment": {"document": {"score": -0.341457, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d)", "keywords": [{"text": "Takeda"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) announces that it has received clearance from the European Commission (the \u201cEC\u201d) for the proposed acquisition of Shire plc (\u201cShire\u201d) announced on May 8, 2018 (the \u201cAcquisition\u201d).", "object": {"text": "that it has received clearance from the European Commission (the \u201cEC\u201d) for the proposed acquisition of Shire plc (\u201cShire\u201d) announced on May 8, 2018 (the \u201cAcquisition\u201d)", "keywords": [{"text": "Shire plc"}, {"text": "proposed acquisition"}, {"text": "European Commission"}, {"text": "EC"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "The EC\u2019s approval", "keywords": [{"text": "EC\u2019s approval"}]}, "sentence": " The EC\u2019s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "conditional on Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "commitments", "keywords": [{"text": "commitments"}]}, "sentence": " The EC\u2019s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "to the EC", "keywords": [{"text": "EC"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "given", "normalized": "give"}}, {"subject": {"text": "bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647 , Takeda and Shire", "keywords": [{"text": "pipeline compound SHP647"}, {"text": "Takeda"}, {"text": "bowel diseases"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Entyvio"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "committed to divest the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647 , Takeda and Shire", "keywords": [{"text": "inflammatory bowel diseases"}, {"text": "pipeline compound SHP647"}, {"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}, {"type": "Company", "text": "Entyvio"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "have committed to divest", "normalized": "have commit to divest"}}, {"subject": {"text": "rights", "keywords": [{"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The divestment of SHP647 and certain associated rights", "keywords": [{"text": "divestment"}, {"text": "SHP647"}, {"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "not a condition to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}, {"text": "condition"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "an exciting pipeline compound", "keywords": [{"text": "exciting pipeline compound"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an exciting pipeline compound and Takeda", "keywords": [{"text": "exciting pipeline compound"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "the asset to attract interest from a number of potential buyers", "keywords": [{"text": "potential buyers"}, {"text": "asset"}, {"text": "number"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "been granted marketing authorization in more than 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "granted marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "authorization", "keywords": [{"text": "authorization"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "has been granted marketing", "normalized": "have be grant market"}}, {"subject": {"text": "Christophe Weber", "keywords": [{"text": "Christophe Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " \u201cWe are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire,\u201d said Christophe Weber", "object": {"text": "We are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "object": {"text": "another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}, {"text": "step"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "object": {"text": "a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "creating", "normalized": "create"}}, {"subject": {"text": "we"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "object": {"text": "optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities", "keywords": [{"text": "significant long-term value"}, {"text": "Brazilian Administrative Council"}, {"text": "Japan Fair Trade"}, {"text": "United States Federal"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Organization", "text": "United States Federal Trade Commission", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"type": "Organization", "text": "Japan Fair Trade Commission", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"type": "Organization", "text": "State Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Organization", "text": "Brazilian Administrative Council for Economic Defense"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "object": {"text": "this powerful combination.", "keywords": [{"text": "powerful combination"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "object": {"text": "clearances", "keywords": [{"text": "clearances"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Shareholders"}, {"text": "notice"}, {"text": "decision"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "a circular"}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "has published", "normalized": "have publish"}}, {"subject": {"text": "a circular"}, "sentence": " As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "necessary matters"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "containing", "normalized": "contain"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "an Extraordinary General Meeting of Shareholders (the \u201cEGM\u201d)", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "to hold", "normalized": "to hold"}}, {"subject": {"text": "The EGM", "keywords": [{"text": "EGM"}], "entities": [{"type": "Company", "text": "EGM"}]}, "sentence": " The EGM is to be convened at 10:00 a.m. ( Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "object": {"text": "convened"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "object": {"text": "its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "previously announced expectation"}, {"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "confirm", "tense": "present"}, "text": "confirms", "normalized": "confirm"}}, {"subject": {"text": "its"}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "object": {"text": "expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "expectation"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "by the Jersey court", "keywords": [{"text": "Jersey court"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "object": {"text": "the necessary shareholder approvals and sanction of the scheme of arrangement", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "sanction"}, {"text": "arrangement"}, {"text": "scheme"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "made as appropriate"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "as appropriate"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "About Entyvio\u00ae (vedolizumab) Vedolizumab", "keywords": [{"text": "Entyvio\u00ae"}, {"text": "vedolizumab"}, {"text": ") Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "object": {"text": "a gut-selective biologic", "keywords": [{"text": "gut-selective biologic"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "About Entyvio\u00ae (vedolizumab) Vedolizumab", "keywords": [{"text": "Entyvio\u00ae"}, {"text": "vedolizumab"}, {"text": ") Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an intravenous (IV) formulation.1 It"}, "sentence": " About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "object": {"text": "a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin", "keywords": [{"text": "humanized monoclonal antibody"}, {"text": "alpha4beta7 integrin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a humanized monoclonal antibody", "keywords": [{"text": "humanized monoclonal antibody"}]}, "sentence": " About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "object": {"text": "the binding of alpha4beta7 integrin", "keywords": [{"text": "integrin"}, {"text": "binding"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1", "keywords": [{"text": "cell adhesion molecule"}]}, "sentence": " About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "action": {"verb": {"text": "express", "tense": "past"}, "text": "expressed", "normalized": "express"}}, {"subject": {"text": "These cells", "keywords": [{"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD).4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "shown to play a role in mediating the inflammatory process", "keywords": [{"text": "inflammatory process"}, {"text": "role"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "These cells", "keywords": [{"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD).4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "a role", "keywords": [{"text": "role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "to play", "normalized": "to play"}}, {"subject": {"text": "vedolizumab", "keywords": [{"text": "vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD).4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "alpha4beta7 integrin", "keywords": [{"text": "integrin"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "certain white blood cells", "keywords": [{"text": "certain white blood"}, {"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD).4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "gut tissues", "keywords": [{"text": "gut tissues"}]}, "action": {"verb": {"text": "infiltrate", "tense": "future"}, "text": "to infiltrate", "normalized": "to infiltrate"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "severely active UC"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "active UC and CD", "keywords": [{"text": "active UC"}, {"text": "CD"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union , with over 200,000 patient years of exposure to date.", "object": {"text": "been granted marketing authorization in over 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union , with over 200,000 patient years of exposure to date.", "object": {"text": "granted marketing authorization in over 60 countries, including the United States and European Union ,", "keywords": [{"text": "marketing authorization"}, {"text": "United States"}, {"text": "European Union"}, {"text": "countries"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the United States and European Union", "keywords": [{"text": "United States"}, {"text": "European Union"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union , with over 200,000 patient years of exposure to date.", "object": {"text": "60 countries", "keywords": [{"text": "countries"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Ulcerative colitis Vedolizumab", "keywords": [{"text": "Ulcerative colitis Vedolizumab"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "indicated for the treatment of adult patients", "keywords": [{"text": "adult patients"}, {"text": "treatment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "active ulcerative colitis"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "Ulcerative colitis Vedolizumab", "keywords": [{"text": "Ulcerative colitis Vedolizumab"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "indicate", "tense": "past"}, "text": "is indicated", "normalized": "be indicate"}}, {"subject": {"text": "active ulcerative colitis", "keywords": [{"text": "colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}, {"subject": {"text": "Crohn", "keywords": [{"text": "Crohn"}]}, "sentence": " Crohn\u2019s disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "disease Vedolizumab", "keywords": [{"text": "disease Vedolizumab"}], "entities": [{"type": "Company", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Crohn\u2019s disease Vedolizumab", "keywords": [{"text": "Crohn"}, {"text": "disease Vedolizumab"}], "entities": [{"type": "Company", "text": "Vedolizumab"}]}, "sentence": " Crohn\u2019s disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "indicated for the treatment of adult patients with moderately to severely active Crohn\u2019s disease who have had an inadequate response with", "keywords": [{"text": "severely active Crohn"}, {"text": "inadequate response"}, {"text": "adult patients"}, {"text": "treatment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.953811, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammatory bowel disease", "relevance": 0.732936, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Crohn's disease", "relevance": 0.596567, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.580869, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Inflammation", "relevance": 0.572196, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Immune system", "relevance": 0.476526, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.44055, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Opportunistic infection", "relevance": 0.383882, "dbpedia_resource": "http://dbpedia.org/resource/Opportunistic_infection"}], "categories": [{"score": 0.98253, "label": "/health and fitness/disease"}, {"score": 0.897489, "label": "/health and fitness/therapy"}, {"score": 0.756855, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "(AETOS Wire) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\"Takeda\") announces that it has received clearance from the European Commission (the \"EC\") for the proposed acquisition of Shire plc (\"Shire\") announced on May 8, 2018 (the \"Acquisition\").", "score": 0.517688, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [213, 250], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [262, 271], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.806393, "arguments": [{"text": "SHP647", "location": [977, 983], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [1008, 1016], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "affectedBy", "sentence": "Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "score": 0.630817, "arguments": [{"text": "Takeda", "location": [1101, 1107], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "granted", "location": [1153, 1160], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber , President and Chief Executive Officer of Takeda .", "score": 0.535509, "arguments": [{"text": "European Commission", "location": [1348, 1367], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "acquisition", "location": [1429, 1440], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber , President and Chief Executive Officer of Takeda .", "score": 0.501149, "arguments": [{"text": "our", "location": [1425, 1428], "entities": [{"type": "Person", "text": "our"}]}, {"text": "acquisition", "location": [1429, 1440], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber , President and Chief Executive Officer of Takeda .", "score": 0.818686, "arguments": [{"text": "Christophe Weber", "location": [1457, 1473], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1452, 1456], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "managerOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission , the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber , President and Chief Executive Officer of Takeda .", "score": 0.638112, "arguments": [{"text": "Chief Executive Officer", "location": [1490, 1513], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Takeda", "location": [1517, 1523], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.975389, "arguments": [{"text": "Federal Trade Commission", "location": [1903, 1927], "entities": [{"type": "Organization", "text": "Federal Trade Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "United States", "location": [1889, 1902], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.66467, "arguments": [{"text": "Trade Commission", "location": [1945, 1961], "entities": [{"type": "Organization", "text": "Trade Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Japan Fair", "location": [1934, 1944], "entities": [{"type": "Organization", "text": "Japan Fair", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "locatedAt", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.766631, "arguments": [{"text": "State Administration", "location": [1968, 1988], "entities": [{"type": "Organization", "text": "State Administration"}]}, {"text": "Market Regulation", "location": [1993, 2010], "entities": [{"type": "Facility", "text": "Market Regulation"}]}]}, {"type": "locatedAt", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.57791, "arguments": [{"text": "Market Regulation", "location": [1993, 2010], "entities": [{"type": "Facility", "text": "Market Regulation"}]}, {"text": "China", "location": [2014, 2019], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "(AETOS Wire) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\"Takeda\") announces that it has received clearance from the European Commission (the \"EC\") for the proposed acquisition of Shire plc (\"Shire\") announced on May 8, 2018 (the \"Acquisition\").", "score": 0.693864, "arguments": [{"text": "Shire plc", "location": [375, 384], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [360, 371], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.916422, "arguments": [{"text": "Administrative Council", "location": [2038, 2060], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Brazilian", "location": [2028, 2037], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" The Acquisition has now received clearances from the European Commission , the United States Federal Trade Commission , the Japan Fair Trade Commission , the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense , among other regulatory authorities.", "score": 0.606065, "arguments": [{"text": "Administrative Council", "location": [2038, 2060], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Economic Defense", "location": [2065, 2081], "entities": [{"type": "Organization", "text": "Economic Defense"}]}]}, {"type": "timeOf", "sentence": "As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \"EGM\") to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.989633, "arguments": [{"text": "November 12, 2018", "location": [2136, 2153], "entities": [{"type": "Date", "text": "November 12, 2018"}]}, {"text": "announced", "location": [2123, 2132], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "As announced on November 12, 2018 , Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \"EGM\") to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.920704, "arguments": [{"text": "Takeda", "location": [2156, 2162], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announced", "location": [2123, 2132], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "score": 0.752213, "arguments": [{"text": "Takeda", "location": [2468, 2474], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "confirms", "location": [2480, 2488], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda aspires to advance how patients manage their disease.", "score": 0.996234, "arguments": [{"text": "Takeda", "location": [10030, 10036], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "aspires", "location": [10037, 10044], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. ( Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.688963, "arguments": [{"text": "INTEX Osaka", "location": [2441, 2452], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}, {"text": "Tokyo", "location": [2406, 2411], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. ( Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.549389, "arguments": [{"text": "Hall 6B Zone", "location": [2454, 2466], "entities": [{"type": "Person", "text": "Hall 6B Zone"}]}, {"text": "INTEX Osaka", "location": [2441, 2452], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "score": 0.762879, "arguments": [{"text": "its", "location": [2489, 2492], "entities": [{"type": "Organization", "text": "State Administration"}]}, {"text": "announced", "location": [2504, 2513], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "basedIn", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019 .", "score": 0.864715, "arguments": [{"text": "court", "location": [2645, 2650], "entities": [{"type": "Organization", "text": "court", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Jersey", "location": [2638, 2644], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "timeOf", "sentence": "About Entyvio\u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.", "score": 0.860079, "arguments": [{"text": "MAdCAM-1", "location": [3161, 3169], "entities": [{"type": "Date", "text": "MAdCAM-1"}]}, {"text": "expressed", "location": [3188, 3197], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.856623, "arguments": [{"text": "patients", "location": [4158, 4166], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4202, 4220], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.376044, "arguments": [{"text": "who", "location": [4221, 4224], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4202, 4220], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "timeOf", "sentence": "(AETOS Wire) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\"Takeda\") announces that it has received clearance from the European Commission (the \"EC\") for the proposed acquisition of Shire plc (\"Shire\") announced on May 8, 2018 (the \"Acquisition\").", "score": 0.621075, "arguments": [{"text": "May 8, 2018", "location": [408, 419], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "acquisition", "location": [360, 371], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "Crohn's disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.602843, "arguments": [{"text": "Crohn", "location": [4495, 4500], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "who", "location": [4511, 4514], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "Infections Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity.", "score": 0.917841, "arguments": [{"text": "Vedolizumab", "location": [6044, 6055], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "Infections", "location": [6033, 6043], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.719148, "arguments": [{"text": "Vedolizumab", "location": [6294, 6305], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "infections", "location": [6371, 6381], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.55785, "arguments": [{"text": "Vedolizumab", "location": [6294, 6305], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "tuberculosis", "location": [6390, 6402], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.493412, "arguments": [{"text": "Vedolizumab", "location": [6294, 6305], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "sepsis", "location": [6404, 6410], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.613335, "arguments": [{"text": "patients", "location": [6342, 6350], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6371, 6381], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Patients should be monitored closely for infections before, during and after treatment.", "score": 0.950673, "arguments": [{"text": "Patients", "location": [6817, 6825], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6858, 6868], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.605086, "arguments": [{"text": "patients", "location": [6342, 6350], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "tuberculosis", "location": [6390, 6402], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.540018, "arguments": [{"text": "patients", "location": [6342, 6350], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "sepsis", "location": [6404, 6410], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.628185, "arguments": [{"text": "who", "location": [6573, 6576], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6594, 6603], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections.", "score": 0.593938, "arguments": [{"text": "patients", "location": [6720, 6728], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6762, 6771], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus.", "score": 0.88926, "arguments": [{"text": "John Cunningham", "location": [7238, 7253], "entities": [{"type": "Person", "text": "John Cunningham"}]}, {"text": "infection", "location": [7214, 7223], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known.", "score": 0.844701, "arguments": [{"text": "patients", "location": [7521, 7529], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "inflammatory bowel disease", "location": [7535, 7561], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "timeOf", "sentence": "(AETOS Wire) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\"Takeda\") announces that it has received clearance from the European Commission (the \"EC\") for the proposed acquisition of Shire plc (\"Shire\") announced on May 8, 2018 (the \"Acquisition\").", "score": 0.950114, "arguments": [{"text": "May 8, 2018", "location": [408, 419], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "announced", "location": [395, 404], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur.", "score": 0.789071, "arguments": [{"text": "patients", "location": [7617, 7625], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological signs", "location": [7675, 7693], "entities": [{"type": "HealthCondition", "text": "neurological signs"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.590675, "arguments": [{"text": "patients", "location": [8314, 8322], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [8328, 8346], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.475228, "arguments": [{"text": "patients", "location": [8314, 8322], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "disease", "location": [8359, 8366], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.791504, "arguments": [{"text": "Crohn", "location": [8351, 8356], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [8359, 8366], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "managerOf", "sentence": "Please consult with your local regulatory agency for approved labeling in your country.", "score": 0.421848, "arguments": [{"text": "your", "location": [9422, 9426], "entities": [{"type": "Person", "text": "your"}]}, {"text": "regulatory agency", "location": [9433, 9450], "entities": [{"type": "Organization", "text": "regulatory agency"}]}]}, {"type": "employedBy", "sentence": "For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO\u00ae.7 For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO\u00ae.", "score": 0.943169, "arguments": [{"text": "audiences", "location": [9499, 9508], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "U.S.", "location": [9494, 9498], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO\u00ae.7 For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO\u00ae.", "score": 0.617295, "arguments": [{"text": "audiences", "location": [9603, 9612], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "EU", "location": [9600, 9602], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.996669, "arguments": [{"text": "Takeda", "location": [9685, 9691], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Commitment", "location": [9694, 9704], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "affectedBy", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.394161, "arguments": [{"text": "Gastroenterology Gastrointestinal", "location": [9708, 9741], "entities": [{"type": "Organization", "text": "Gastroenterology Gastrointestinal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Commitment", "location": [9694, 9704], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "hasAttribute", "sentence": "Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders.", "score": 0.468927, "arguments": [{"text": "Takeda", "location": [10105, 10111], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "inflammatory bowel disease", "location": [10193, 10219], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.931421, "arguments": [{"text": "team", "location": [10297, 10301], "entities": [{"type": "Person", "text": "team"}]}, {"text": "celiac disease", "location": [10333, 10347], "entities": [{"type": "HealthCondition", "text": "celiac disease"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.78444, "arguments": [{"text": "Takeda", "location": [676, 682], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "diseases", "location": [659, 667], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "hasAttribute", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.58672, "arguments": [{"text": "Takeda", "location": [9685, 9691], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "diseases", "location": [9747, 9755], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.761418, "arguments": [{"text": "team", "location": [10297, 10301], "entities": [{"type": "Person", "text": "team"}]}, {"text": "liver diseases", "location": [10352, 10366], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [11108, 11114], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "employees", "location": [11115, 11124], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.361207, "arguments": [{"text": "Takeda", "location": [11195, 11201], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "partners", "location": [11204, 11212], "entities": [{"type": "Person", "text": "partners"}]}]}, {"type": "hasAttribute", "sentence": "For more information, visit https://www.takeda.com/newsroom/. Additional Information This Announcement is provided for information purposes only.", "score": 0.063535, "arguments": [{"text": "Additional Information", "location": [11317, 11339], "entities": [{"type": "Organization", "text": "Additional Information", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.takeda.com/newsroom/.", "location": [11283, 11316], "entities": [{"type": "Web", "text": "https://www.takeda.com/newsroom/."}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.880516, "arguments": [{"text": "you", "location": [14360, 14363], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [14378, 14387], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.545758, "arguments": [{"text": "date", "location": [14479, 14483], "entities": [{"type": "Date", "text": "date"}]}, {"text": "Announcement", "location": [14492, 14504], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.959491, "arguments": [{"text": "Shire", "location": [14578, 14583], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [14605, 14611], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.865986, "arguments": [{"text": "10-K", "location": [14620, 14624], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [14605, 14611], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [14632, 14637], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [14661, 14668], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [14810, 14844], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "www.Shire.com", "location": [14867, 14880], "entities": [{"type": "Web", "text": "www.Shire.com"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.464603, "arguments": [{"text": "Shire", "location": [728, 733], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "diseases", "location": [659, 667], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.413159, "arguments": [{"text": "they", "location": [14968, 14972], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Announcement", "location": [14992, 15004], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [15142, 15148], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [15092, 15104], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [15197, 15203], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [15288, 15293], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [15207, 15212], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [15288, 15293], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [15220, 15226], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [15288, 15293], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [15333, 15340], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [15345, 15354], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon ( London time) on November 21, 2018 .", "score": 0.576713, "arguments": [{"text": "Rule", "location": [16688, 16692], "entities": [{"type": "Organization", "text": "Code Under Rule"}]}, {"text": "Code", "location": [16705, 16709], "entities": [{"type": "Organization", "text": "Code"}]}]}, {"type": "agentOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon ( London time) on November 21, 2018 .", "score": 0.485232, "arguments": [{"text": "Code", "location": [16705, 16709], "entities": [{"type": "Organization", "text": "Code"}]}, {"text": "Announcement", "location": [16726, 16738], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [19588, 19592], "entities": [{"type": "Organization", "text": "Code Under Rule"}]}, {"text": "8.3", "location": [19593, 19596], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [19779, 19786], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [19797, 19804], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.535642, "arguments": [{"text": "Shire", "location": [728, 733], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "pipeline", "location": [736, 744], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.457452, "arguments": [{"text": "Panel", "location": [20258, 20263], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [20266, 20290], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "timeOf", "sentence": "Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.", "score": 0.862359, "arguments": [{"text": "molecule-1", "location": [20812, 20822], "entities": [{"type": "Date", "text": "molecule-1"}]}, {"text": "expressed", "location": [20841, 20850], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "basedIn", "sentence": "(c) 2018 CNPHUB - All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers", "score": 0.648188, "arguments": [{"text": "Newspapers", "location": [21435, 21445], "entities": [{"type": "Organization", "text": "Newspapers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Middle East", "location": [21407, 21418], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "(c) 2018 CNPHUB - All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers", "score": 0.890458, "arguments": [{"text": "Newspapers", "location": [21435, 21445], "entities": [{"type": "Organization", "text": "Newspapers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "North African", "location": [21421, 21434], "entities": [{"type": "GeopoliticalEntity", "text": "North African", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.581049, "arguments": [{"text": "pipeline", "location": [736, 744], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [745, 753], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.458079, "arguments": [{"text": "pipeline", "location": [809, 817], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [818, 826], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.650891, "arguments": [{"text": "pipeline", "location": [999, 1007], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [1008, 1016], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.385469, "arguments": [{"text": "SHP647", "location": [754, 760], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [745, 753], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647 , Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.351216, "arguments": [{"text": "SHP647", "location": [827, 833], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [818, 826], "entities": [{"type": "Facility", "text": "compound"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.370694, "mixed": "1", "label": "negative"}, "relevance": 0.586852, "count": 22}, {"text": "acquisition of Shire plc", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.572817, "count": 1}, {"text": "treatment of adult patients", "sentiment": {"score": -0.736053, "label": "negative"}, "relevance": 0.57085, "count": 3}, {"text": "Special warnings", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.56817, "count": 1}, {"text": "Disclosure requirements of the Code", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.549627, "count": 1}, {"text": "possible combination", "sentiment": {"score": -0.631802, "label": "negative"}, "relevance": 0.543004, "count": 5}, {"text": "alpha4beta7 integrin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542024, "count": 3}, {"text": "Further announcements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541009, "count": 1}, {"text": "Shire", "sentiment": {"score": -0.521803, "mixed": "1", "label": "negative"}, "relevance": 0.540384, "count": 12}, {"text": "vedolizumab", "sentiment": {"score": -0.591744, "mixed": "1", "label": "negative"}, "relevance": 0.539996, "count": 14}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0.619727, "label": "positive"}, "relevance": 0.538764, "count": 5}, {"text": "such patients", "sentiment": {"score": 0.853863, "label": "positive"}, "relevance": 0.535206, "count": 1}, {"text": "securities exchange offeror", "sentiment": {"score": 0.548479, "mixed": "1", "label": "positive"}, "relevance": 0.535004, "count": 9}, {"text": "Statements", "sentiment": {"score": 0.707653, "label": "positive"}, "relevance": 0.53449, "count": 1}, {"text": "statements", "sentiment": {"score": -0.315474, "mixed": "1", "label": "negative"}, "relevance": 0.53449, "count": 14}, {"text": "hypersensitivity reactions", "sentiment": {"score": -0.573836, "label": "negative"}, "relevance": 0.533963, "count": 2}, {"text": "Infections Vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533681, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0.383672, "mixed": "1", "label": "positive"}, "relevance": 0.532675, "count": 3}, {"text": "securities", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.532644, "count": 1}, {"text": "ordinary shares", "sentiment": {"score": -0.631802, "label": "negative"}, "relevance": 0.530559, "count": 1}, {"text": "Shire\u2019s pipeline compound SHP647", "sentiment": {"score": -0.716209, "label": "negative"}, "relevance": 0.529777, "count": 1}, {"text": "VIOLATION OF THE RELEVANT LAWS", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.528062, "count": 1}, {"text": "area of inflammatory bowel diseases", "sentiment": {"score": -0.716209, "label": "negative"}, "relevance": 0.527671, "count": 1}, {"text": "tumor necrosis factor-alpha", "sentiment": {"score": -0.69031, "label": "negative"}, "relevance": 0.527612, "count": 3}, {"text": "product Entyvio", "sentiment": {"score": -0.716209, "label": "negative"}, "relevance": 0.525952, "count": 1}, {"text": "Announcement", "sentiment": {"score": 0.408075, "mixed": "1", "label": "positive"}, "relevance": 0.525597, "count": 10}, {"text": "special precautions", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.525523, "count": 1}, {"text": "patient years of exposure", "sentiment": {"score": -0.77705, "label": "negative"}, "relevance": 0.525273, "count": 1}, {"text": "Infusion-related reactions", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.525215, "count": 1}, {"text": "transfer of securities of Shire", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.524392, "count": 1}, {"text": "person", "sentiment": {"score": 0.569774, "label": "positive"}, "relevance": 0.52437, "count": 5}, {"text": "Vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523138, "count": 1}, {"text": "Securities", "sentiment": {"score": -0.755071, "label": "negative"}, "relevance": 0.52178, "count": 1}, {"text": "pharmaceutical company", "sentiment": {"score": 0.947101, "label": "positive"}, "relevance": 0.521424, "count": 1}, {"text": "risk of opportunistic infections", "sentiment": {"score": -0.776276, "label": "negative"}, "relevance": 0.521022, "count": 1}, {"text": "binding of alpha4beta7 integrin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520818, "count": 1}, {"text": "Market Regulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520097, "count": 1}, {"text": "use Vedolizumab", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.519898, "count": 1}, {"text": "Dealing Disclosure", "sentiment": {"score": 0.527581, "label": "positive"}, "relevance": 0.518853, "count": 5}, {"text": "Development team", "sentiment": {"score": 0.985792, "label": "positive"}, "relevance": 0.518775, "count": 1}, {"text": "ulcerative colitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518719, "count": 2}, {"text": "severe IRR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518591, "count": 1}, {"text": "clinical studies", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.518366, "count": 1}, {"text": "exchange", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.518335, "count": 2}, {"text": "risks", "sentiment": {"score": -0.896114, "label": "negative"}, "relevance": 0.517986, "count": 3}, {"text": "progressive multifocal leukoencephalopathy", "sentiment": {"score": -0.706252, "label": "negative"}, "relevance": 0.517153, "count": 1}, {"text": "Appropriate monitoring", "sentiment": {"score": 0.778665, "label": "positive"}, "relevance": 0.516724, "count": 1}, {"text": "appropriate treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51554, "count": 2}, {"text": "companies", "sentiment": {"score": -0.631802, "label": "negative"}, "relevance": 0.515393, "count": 1}, {"text": "markets", "sentiment": {"score": 0.85793, "label": "positive"}, "relevance": 0.515057, "count": 1}]}, "extracted_metadata": {"sha1": "ec8324d4f5e7874707fdd7e473fa00f00d455b3d", "filename": "1543151390559.zip-ca03efefc3945c9421720582198487fe.xml", "file_type": "json"}, "external_links": ["https://www.takeda.com/newsroom/."], "title": "Takeda Pharmaceutical : Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc", "forum_title": "Markets : News, Latest News - Marketscreener.com"}, {"id": "lYWGeYfe1R-8u1F-7Xuq5OdGIFGX0y9e_oob4Qmu9399v5fnqYf1gRS33H_Qh4UW", "result_metadata": {"score": 25.985308}, "author": "info@me-newswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "European Commission", "relevance": 0.971008, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "European Union", "relevance": 0.937672, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Parliament", "relevance": 0.858258, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "European Council", "relevance": 0.852116, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}], "categories": [{"score": 0.988516, "label": "/business and industrial/company/merger and acquisition"}], "relations": [], "keywords": [{"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.985621, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.985252, "count": 1}, {"text": "Clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.862858, "count": 1}, {"text": "Acquisition of Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384325, "count": 1}]}, "crawl_date": "2018-11-25T12:17:21Z", "url": "https://www.aetoswire.com/news/takeda-receives-clearance-from-the-european-commission-for-the-proposed-acquisition-of-shire-plc/en", "host": "aetoswire.com", "text": "About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-25T10:07:00Z", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": -0.0176461, "label": "negative"}, "text": "Takeda", "relevance": 0.862639, "type": "Company"}, {"count": 15, "sentiment": {"score": 0.204531, "label": "positive"}, "text": "Takeda", "relevance": 0.862225, "type": "Person"}, {"count": 16, "sentiment": {"score": -0.541151, "label": "negative"}, "text": "Vedolizumab", "relevance": 0.582364, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "relevance": 0.542877, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.336952, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.449979, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Takeda", "relevance": 0.410648, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.643548, "label": "negative"}, "text": "bowel disease", "relevance": 0.40431, "type": "HealthCondition"}, {"count": 9, "sentiment": {"score": -0.0716983, "label": "negative"}, "text": "Shire", "relevance": 0.389045, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.777473, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.342876, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.328661, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.29857, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.290496, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.285298, "type": "Crime"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.282904, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 2, "sentiment": {"score": -0.330482, "label": "negative"}, "text": "Vedolizumab", "relevance": 0.27916, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.718759, "label": "negative"}, "text": "Crohn\u2019s disease", "relevance": 0.273684, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "OSAKA", "relevance": 0.270978, "type": "Location", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"count": 3, "sentiment": {"score": 0.657112, "label": "positive"}, "text": "European Commission", "relevance": 0.269595, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EGM", "relevance": 0.263267, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.485501, "label": "positive"}, "text": "Tokyo", "relevance": 0.258674, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.257317, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Entyvio", "relevance": 0.255464, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazilian Administrative Council for Economic Defense", "relevance": 0.252499, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.416862, "label": "negative"}, "text": "Entyvio", "relevance": 0.252226, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "progressive multifocal leukoencephalopathy", "relevance": 0.251863, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "INTEX Osaka", "relevance": 0.245288, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.437544, "label": "negative"}, "text": "IBD", "relevance": 0.24354, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "gastrointestinal tract", "relevance": 0.243527, "type": "Anatomy"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.24217, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jersey court", "relevance": 0.241749, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.241713, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 2, "sentiment": {"score": -0.464166, "label": "negative"}, "text": "epinephrine", "relevance": 0.239198, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.238985, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.213998, "label": "negative"}, "text": "celiac disease", "relevance": 0.237847, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}, {"count": 1, "sentiment": {"score": -0.24648, "label": "negative"}, "text": "UC", "relevance": 0.234724, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan Fair Trade Commission", "relevance": 0.234427, "type": "Organization", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States Federal Trade Commission", "relevance": 0.232753, "type": "Organization", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.232378, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": -0.737746, "label": "negative"}, "text": "tuberculosis", "relevance": 0.232089, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.336475, "label": "negative"}, "text": "paracetamol", "relevance": 0.231585, "type": "Drug"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.226176, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "natalizumab", "relevance": 0.226124, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shyjan", "relevance": 0.224679, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.223966, "type": "Organization", "disambiguation": {"subtype": ["BuildingFunction"], "name": "University", "dbpedia_resource": "http://dbpedia.org/resource/University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wyant T", "relevance": 0.222289, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J Pathol.", "relevance": 0.221205, "type": "Person"}], "sentiment": {"document": {"score": -0.348831, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d)", "keywords": [{"text": "Takeda"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announces that it has received clearance from the European Commission (the \u201c EC \u201d) for the proposed acquisition of Shire plc (\u201c Shire \u201d) announced on May 8, 2018 (the \u201c Acquisition \u201d).", "object": {"text": "that it has received clearance from the European Commission (the \u201c EC \u201d) for the proposed acquisition of Shire plc (\u201c Shire \u201d) announced on May 8, 2018 (the \u201c Acquisition \u201d)", "keywords": [{"text": "Shire plc"}, {"text": "proposed acquisition"}, {"text": "European Commission"}, {"text": "EC"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "The EC\u2019s approval", "keywords": [{"text": "EC\u2019s approval"}]}, "sentence": " The EC\u2019s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "conditional on Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "commitments", "keywords": [{"text": "commitments"}]}, "sentence": " The EC\u2019s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "to the EC", "keywords": [{"text": "EC"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "given", "normalized": "give"}}, {"subject": {"text": "bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647, Takeda and Shire", "keywords": [{"text": "pipeline compound SHP647"}, {"text": "Takeda"}, {"text": "bowel diseases"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Entyvio"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "committed to divest the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647, Takeda and Shire", "keywords": [{"text": "inflammatory bowel diseases"}, {"text": "pipeline compound SHP647"}, {"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}, {"type": "Company", "text": "Entyvio"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda\u2019s marketed product Entyvio (vedolizumab) and Shire\u2019s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "have committed to divest", "normalized": "have commit to divest"}}, {"subject": {"text": "rights", "keywords": [{"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The divestment of SHP647 and certain associated rights", "keywords": [{"text": "divestment"}, {"text": "SHP647"}, {"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "not a condition to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}, {"text": "condition"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "an exciting pipeline compound", "keywords": [{"text": "exciting pipeline compound"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an exciting pipeline compound and Takeda", "keywords": [{"text": "exciting pipeline compound"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "the asset to attract interest from a number of potential buyers", "keywords": [{"text": "potential buyers"}, {"text": "asset"}, {"text": "number"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "been granted marketing authorization in more than 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "granted marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda\u2019s diverse specialty gastrointestinal portfolio.", "object": {"text": "authorization", "keywords": [{"text": "authorization"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "has been granted marketing", "normalized": "have be grant market"}}, {"subject": {"text": "Christophe Weber, President and Chief Executive Officer of Takeda", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Christophe Weber"}, {"text": "Takeda"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Christophe Weber"}, {"type": "JobTitle", "text": "President and Chief Executive Officer of Takeda"}]}, "sentence": " \u201cWe are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\u201d said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}, {"text": "step"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "creating", "normalized": "create"}}, {"subject": {"text": "we"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities", "keywords": [{"text": "significant long-term value"}, {"text": "Brazilian Administrative Council"}, {"text": "Japan Fair Trade"}, {"text": "United States Federal"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Organization", "text": "United States Federal Trade Commission", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"type": "Organization", "text": "Japan Fair Trade Commission", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"type": "Organization", "text": "State Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Organization", "text": "Brazilian Administrative Council for Economic Defense"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "this powerful combination.", "keywords": [{"text": "powerful combination"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "clearances", "keywords": [{"text": "clearances"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Shareholders"}, {"text": "notice"}, {"text": "decision"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "a circular"}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "has published", "normalized": "have publish"}}, {"subject": {"text": "a circular"}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "necessary matters"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "containing", "normalized": "contain"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d) to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "an Extraordinary General Meeting of Shareholders (the \u201c EGM \u201d)", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "to hold", "normalized": "to hold"}}, {"subject": {"text": "The EGM", "keywords": [{"text": "EGM"}], "entities": [{"type": "Company", "text": "EGM"}]}, "sentence": " The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "object": {"text": "convened"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "previously announced expectation"}, {"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "confirm", "tense": "present"}, "text": "confirms", "normalized": "confirm"}}, {"subject": {"text": "its"}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "expectation"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "by the Jersey court", "keywords": [{"text": "Jersey court"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "the necessary shareholder approvals and sanction of the scheme of arrangement", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "sanction"}, {"text": "arrangement"}, {"text": "scheme"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "made as appropriate"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "as appropriate"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "About Entyvio \u00ae (vedolizumab) Vedolizumab", "keywords": [{"text": "Entyvio"}, {"text": "vedolizumab"}, {"text": ") Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "a gut-selective biologic", "keywords": [{"text": "gut-selective biologic"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "About Entyvio \u00ae (vedolizumab) Vedolizumab", "keywords": [{"text": "Entyvio"}, {"text": "vedolizumab"}, {"text": ") Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "About Entyvio \u00ae (vedolizumab) Vedolizumab", "keywords": [{"text": "Entyvio"}, {"text": "vedolizumab"}, {"text": ") Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "as an intravenous (IV) formulation", "keywords": [{"text": "formulation"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "1 It"}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "object": {"text": "a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin", "keywords": [{"text": "humanized monoclonal antibody"}, {"text": "alpha4beta7 integrin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a humanized monoclonal antibody", "keywords": [{"text": "humanized monoclonal antibody"}]}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "object": {"text": "the binding of alpha4beta7 integrin", "keywords": [{"text": "integrin"}, {"text": "binding"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1", "keywords": [{"text": "cell adhesion molecule"}]}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "action": {"verb": {"text": "express", "tense": "past"}, "text": "expressed", "normalized": "express"}}, {"subject": {"text": "These cells", "keywords": [{"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "shown to play a role in mediating the inflammatory process", "keywords": [{"text": "inflammatory process"}, {"text": "role"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "These cells", "keywords": [{"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "a role", "keywords": [{"text": "role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "to play", "normalized": "to play"}}, {"subject": {"text": "the inflammatory process", "keywords": [{"text": "inflammatory process"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "in ulcerative colitis (UC) and Crohn\u2019s disease (CD)", "keywords": [{"text": "ulcerative colitis"}, {"text": "Crohn\u2019s disease"}, {"text": "UC"}, {"text": "CD"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "UC", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "action": {"verb": {"text": "mediate", "tense": "present"}, "text": "mediating", "normalized": "mediate"}}, {"subject": {"text": "certain white blood cells", "keywords": [{"text": "certain white blood"}, {"text": "cells"}]}, "sentence": " These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn\u2019s disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "gut tissues", "keywords": [{"text": "gut tissues"}]}, "action": {"verb": {"text": "infiltrate", "tense": "future"}, "text": "to infiltrate", "normalized": "to infiltrate"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "severely active UC"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "active UC and CD", "keywords": [{"text": "active UC"}, {"text": "CD"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "been granted marketing authorization in over 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "granted marketing authorization in over 60 countries, including the United States and European Union,", "keywords": [{"text": "marketing authorization"}, {"text": "United States"}, {"text": "European Union"}, {"text": "countries"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the United States and European Union", "keywords": [{"text": "United States"}, {"text": "European Union"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "60 countries", "keywords": [{"text": "countries"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "6 Therapeutic Indications Ulcerative colitis Vedolizumab", "keywords": [{"text": "Indications Ulcerative colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " 6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "indicated for the treatment of adult patients", "keywords": [{"text": "adult patients"}, {"text": "treatment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "active ulcerative colitis"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " 6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "Ulcerative colitis Vedolizumab", "keywords": [{"text": "Ulcerative colitis Vedolizumab"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "indicate", "tense": "past"}, "text": "is indicated", "normalized": "be indicate"}}, {"subject": {"text": "active ulcerative colitis", "keywords": [{"text": "colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " 6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}, {"subject": {"text": "Crohn", "keywords": [{"text": "Crohn"}]}, "sentence": " Crohn\u2019s disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "disease Vedolizumab", "keywords": [{"text": "disease Vedolizumab"}], "entities": [{"type": "Company", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.954916, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammatory bowel disease", "relevance": 0.733759, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Crohn's disease", "relevance": 0.598161, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.581747, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Inflammation", "relevance": 0.573734, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Immune system", "relevance": 0.477804, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.44055, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Opportunistic infection", "relevance": 0.384501, "dbpedia_resource": "http://dbpedia.org/resource/Opportunistic_infection"}], "categories": [{"score": 0.982872, "label": "/health and fitness/disease"}, {"score": 0.893399, "label": "/health and fitness/therapy"}, {"score": 0.759478, "label": "/health and fitness/disorders"}], "relations": [{"type": "locatedAt", "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\" Takeda \") announces that it has received clearance from the European Commission (the \" EC \") for the proposed acquisition of Shire plc (\" Shire \") announced on May 8, 2018 (the \" Acquisition \").", "score": 0.95076, "arguments": [{"text": "OSAKA", "location": [6, 11], "entities": [{"type": "GeopoliticalEntity", "text": "OSAKA"}]}, {"text": "Japan", "location": [13, 18], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.385469, "arguments": [{"text": "SHP647", "location": [787, 793], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [778, 786], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.351216, "arguments": [{"text": "SHP647", "location": [859, 865], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [850, 858], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "locatedAt", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.806393, "arguments": [{"text": "SHP647", "location": [1009, 1015], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [1040, 1048], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "affectedBy", "sentence": "Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "score": 0.630817, "arguments": [{"text": "Takeda", "location": [1133, 1139], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "granted", "location": [1185, 1192], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.535509, "arguments": [{"text": "European Commission", "location": [1380, 1399], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "acquisition", "location": [1460, 1471], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.501149, "arguments": [{"text": "our", "location": [1456, 1459], "entities": [{"type": "Person", "text": "our"}]}, {"text": "acquisition", "location": [1460, 1471], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.818686, "arguments": [{"text": "Christophe Weber", "location": [1488, 1504], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1483, 1487], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "managerOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.638112, "arguments": [{"text": "Chief Executive Officer", "location": [1520, 1543], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Takeda", "location": [1547, 1553], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.97896, "arguments": [{"text": "Federal Trade Commission", "location": [1931, 1955], "entities": [{"type": "Organization", "text": "Federal Trade Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "United States", "location": [1917, 1930], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.905291, "arguments": [{"text": "Fair Trade Commission", "location": [1967, 1988], "entities": [{"type": "Organization", "text": "Fair Trade Commission"}]}, {"text": "Japan", "location": [1961, 1966], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.743705, "arguments": [{"text": "State Administration", "location": [1994, 2014], "entities": [{"type": "Organization", "text": "State Administration"}]}, {"text": "Market Regulation", "location": [2019, 2036], "entities": [{"type": "Facility", "text": "Market Regulation"}]}]}, {"type": "agentOf", "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\" Takeda \") announces that it has received clearance from the European Commission (the \" EC \") for the proposed acquisition of Shire plc (\" Shire \") announced on May 8, 2018 (the \" Acquisition \").", "score": 0.569337, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [238, 275], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [289, 298], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.578736, "arguments": [{"text": "Market Regulation", "location": [2019, 2036], "entities": [{"type": "Facility", "text": "Market Regulation"}]}, {"text": "China", "location": [2040, 2045], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.905601, "arguments": [{"text": "Administrative Council", "location": [2064, 2086], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Brazilian", "location": [2054, 2063], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.582756, "arguments": [{"text": "Administrative Council", "location": [2064, 2086], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Economic Defense", "location": [2091, 2107], "entities": [{"type": "Organization", "text": "Economic Defense"}]}]}, {"type": "timeOf", "sentence": "As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \" EGM \") to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.989633, "arguments": [{"text": "November 12, 2018", "location": [2161, 2178], "entities": [{"type": "Date", "text": "November 12, 2018"}]}, {"text": "announced", "location": [2148, 2157], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the \" EGM \") to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.920704, "arguments": [{"text": "Takeda", "location": [2180, 2186], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announced", "location": [2148, 2157], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.962786, "arguments": [{"text": "Takeda", "location": [2493, 2499], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "confirms", "location": [2505, 2513], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.585287, "arguments": [{"text": "Takeda", "location": [2493, 2499], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announced", "location": [2529, 2538], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda aspires to advance how patients manage their disease.", "score": 0.996234, "arguments": [{"text": "Takeda", "location": [10046, 10052], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "aspires", "location": [10053, 10060], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.688963, "arguments": [{"text": "INTEX Osaka", "location": [2466, 2477], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}, {"text": "Tokyo", "location": [2431, 2436], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.549389, "arguments": [{"text": "Hall 6B Zone", "location": [2479, 2491], "entities": [{"type": "Person", "text": "Hall 6B Zone"}]}, {"text": "INTEX Osaka", "location": [2466, 2477], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.487964, "arguments": [{"text": "its", "location": [2514, 2517], "entities": [{"type": "Organization", "text": "Fair Trade Commission"}]}, {"text": "announced", "location": [2529, 2538], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "basedIn", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.864715, "arguments": [{"text": "court", "location": [2670, 2675], "entities": [{"type": "Organization", "text": "court", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Jersey", "location": [2663, 2669], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "timeOf", "sentence": "2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "score": 0.905683, "arguments": [{"text": "MAdCAM-1", "location": [3188, 3196], "entities": [{"type": "Date", "text": "MAdCAM-1"}]}, {"text": "expressed", "location": [3215, 3224], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "affectedBy", "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\" Takeda \") announces that it has received clearance from the European Commission (the \" EC \") for the proposed acquisition of Shire plc (\" Shire \") announced on May 8, 2018 (the \" Acquisition \").", "score": 0.671758, "arguments": [{"text": "Shire plc", "location": [404, 413], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [389, 400], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.856623, "arguments": [{"text": "patients", "location": [4186, 4194], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4230, 4248], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.376044, "arguments": [{"text": "who", "location": [4249, 4252], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4230, 4248], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "partOfMany", "sentence": "Crohn's disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.602843, "arguments": [{"text": "Crohn", "location": [4523, 4528], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "who", "location": [4539, 4542], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "Infections Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity.", "score": 0.917841, "arguments": [{"text": "Vedolizumab", "location": [6054, 6065], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "Infections", "location": [6043, 6053], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.719148, "arguments": [{"text": "Vedolizumab", "location": [6304, 6315], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "infections", "location": [6381, 6391], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.55785, "arguments": [{"text": "Vedolizumab", "location": [6304, 6315], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "tuberculosis", "location": [6400, 6412], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.493412, "arguments": [{"text": "Vedolizumab", "location": [6304, 6315], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "sepsis", "location": [6414, 6420], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.613335, "arguments": [{"text": "patients", "location": [6352, 6360], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6381, 6391], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Patients should be monitored closely for infections before, during and after treatment.", "score": 0.950673, "arguments": [{"text": "Patients", "location": [6827, 6835], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6868, 6878], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.605086, "arguments": [{"text": "patients", "location": [6352, 6360], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "tuberculosis", "location": [6400, 6412], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.540018, "arguments": [{"text": "patients", "location": [6352, 6360], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "sepsis", "location": [6414, 6420], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.628185, "arguments": [{"text": "who", "location": [6583, 6586], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6604, 6613], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections.", "score": 0.593938, "arguments": [{"text": "patients", "location": [6730, 6738], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6772, 6781], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus.", "score": 0.88926, "arguments": [{"text": "John Cunningham", "location": [7248, 7263], "entities": [{"type": "Person", "text": "John Cunningham"}]}, {"text": "infection", "location": [7224, 7233], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "timeOf", "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\" Takeda \") announces that it has received clearance from the European Commission (the \" EC \") for the proposed acquisition of Shire plc (\" Shire \") announced on May 8, 2018 (the \" Acquisition \").", "score": 0.584188, "arguments": [{"text": "May 8, 2018", "location": [439, 450], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "acquisition", "location": [389, 400], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known.", "score": 0.844701, "arguments": [{"text": "patients", "location": [7531, 7539], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "inflammatory bowel disease", "location": [7545, 7571], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur.", "score": 0.789071, "arguments": [{"text": "patients", "location": [7627, 7635], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological signs", "location": [7685, 7703], "entities": [{"type": "HealthCondition", "text": "neurological signs"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.590675, "arguments": [{"text": "patients", "location": [8324, 8332], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [8338, 8356], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.475228, "arguments": [{"text": "patients", "location": [8324, 8332], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "disease", "location": [8369, 8376], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.791504, "arguments": [{"text": "Crohn", "location": [8361, 8366], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [8369, 8376], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "managerOf", "sentence": "Please consult with your local regulatory agency for approved labeling in your country .", "score": 0.421848, "arguments": [{"text": "your", "location": [9432, 9436], "entities": [{"type": "Person", "text": "your"}]}, {"text": "regulatory agency", "location": [9443, 9460], "entities": [{"type": "Organization", "text": "regulatory agency"}]}]}, {"type": "employedBy", "sentence": "For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO \u00ae .", "score": 0.961621, "arguments": [{"text": "audiences", "location": [9510, 9519], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "U.S.", "location": [9505, 9509], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "7 For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO \u00ae .", "score": 0.646657, "arguments": [{"text": "audiences", "location": [9617, 9626], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "EU", "location": [9614, 9616], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.996669, "arguments": [{"text": "Takeda", "location": [9701, 9707], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Commitment", "location": [9710, 9720], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "affectedBy", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.394161, "arguments": [{"text": "Gastroenterology Gastrointestinal", "location": [9724, 9757], "entities": [{"type": "Organization", "text": "Gastroenterology Gastrointestinal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Commitment", "location": [9710, 9720], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "hasAttribute", "sentence": "Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders.", "score": 0.468927, "arguments": [{"text": "Takeda", "location": [10121, 10127], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "inflammatory bowel disease", "location": [10209, 10235], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "timeOf", "sentence": "Print OSAKA, Japan- ( BUSINESS WIRE ) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (\" Takeda \") announces that it has received clearance from the European Commission (the \" EC \") for the proposed acquisition of Shire plc (\" Shire \") announced on May 8, 2018 (the \" Acquisition \").", "score": 0.944074, "arguments": [{"text": "May 8, 2018", "location": [439, 450], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "announced", "location": [426, 435], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.931421, "arguments": [{"text": "team", "location": [10313, 10317], "entities": [{"type": "Person", "text": "team"}]}, {"text": "celiac disease", "location": [10349, 10363], "entities": [{"type": "HealthCondition", "text": "celiac disease"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.761418, "arguments": [{"text": "team", "location": [10313, 10317], "entities": [{"type": "Person", "text": "team"}]}, {"text": "liver diseases", "location": [10368, 10382], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [11125, 11131], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "employees", "location": [11132, 11141], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.361207, "arguments": [{"text": "Takeda", "location": [11212, 11218], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "partners", "location": [11221, 11229], "entities": [{"type": "Person", "text": "partners"}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.880516, "arguments": [{"text": "you", "location": [14377, 14380], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [14395, 14404], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.545758, "arguments": [{"text": "date", "location": [14496, 14500], "entities": [{"type": "Date", "text": "date"}]}, {"text": "Announcement", "location": [14509, 14521], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov ), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.959491, "arguments": [{"text": "Shire", "location": [14595, 14600], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [14622, 14628], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov ), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.865986, "arguments": [{"text": "10-K", "location": [14637, 14641], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [14622, 14628], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov ), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [14649, 14654], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [14678, 14685], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov ), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [14827, 14861], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "www.Shire.com", "location": [14884, 14897], "entities": [{"type": "Web", "text": "www.Shire.com"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.78444, "arguments": [{"text": "Takeda", "location": [709, 715], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "diseases", "location": [692, 700], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "hasAttribute", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.58672, "arguments": [{"text": "Takeda", "location": [9701, 9707], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "diseases", "location": [9763, 9771], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov ), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.413159, "arguments": [{"text": "they", "location": [14986, 14990], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Announcement", "location": [15010, 15022], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [15160, 15166], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [15110, 15122], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [15215, 15221], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [15306, 15311], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [15225, 15230], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [15306, 15311], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [15238, 15244], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [15306, 15311], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [15351, 15358], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [15363, 15372], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 21, 2018.", "score": 0.576713, "arguments": [{"text": "Rule", "location": [16704, 16708], "entities": [{"type": "Organization", "text": "Code Under Rule"}]}, {"text": "Code", "location": [16721, 16725], "entities": [{"type": "Organization", "text": "Code"}]}]}, {"type": "agentOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 21, 2018.", "score": 0.485232, "arguments": [{"text": "Code", "location": [16721, 16725], "entities": [{"type": "Organization", "text": "Code"}]}, {"text": "Announcement", "location": [16742, 16754], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [19599, 19603], "entities": [{"type": "Organization", "text": "Code Under Rule"}]}, {"text": "8.3", "location": [19604, 19607], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [19790, 19797], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [19808, 19815], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.464603, "arguments": [{"text": "Shire", "location": [761, 766], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "diseases", "location": [692, 700], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.457452, "arguments": [{"text": "Panel", "location": [20270, 20275], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [20278, 20302], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "employedBy", "sentence": "1 Entyvio \u00ae Summary of Product Characteristics.", "score": 0.606684, "arguments": [{"text": "\u00ae Summary", "location": [20455, 20464], "entities": [{"type": "Person", "text": "\u00ae Summary"}]}, {"text": "Product Characteristics", "location": [20468, 20491], "entities": [{"type": "Organization", "text": "Summary of Product Characteristics"}]}]}, {"type": "timeOf", "sentence": "Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.", "score": 0.862359, "arguments": [{"text": "molecule-1", "location": [20823, 20833], "entities": [{"type": "Date", "text": "molecule-1"}]}, {"text": "expressed", "location": [20852, 20861], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.535642, "arguments": [{"text": "Shire", "location": [761, 766], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "pipeline", "location": [769, 777], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.581049, "arguments": [{"text": "pipeline", "location": [769, 777], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [778, 786], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.458079, "arguments": [{"text": "pipeline", "location": [841, 849], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [850, 858], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.650891, "arguments": [{"text": "pipeline", "location": [1031, 1039], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [1040, 1048], "entities": [{"type": "Facility", "text": "compound"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.389076, "mixed": "1", "label": "negative"}, "relevance": 0.585198, "count": 22}, {"text": "acquisition of Shire plc", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.578231, "count": 1}, {"text": "treatment of adult patients", "sentiment": {"score": -0.736053, "label": "negative"}, "relevance": 0.566966, "count": 3}, {"text": "Special warnings", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.566087, "count": 1}, {"text": "Disclosure requirements of the Code", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.550449, "count": 1}, {"text": "alpha4beta7 integrin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550049, "count": 3}, {"text": "possible combination", "sentiment": {"score": -0.631802, "label": "negative"}, "relevance": 0.542753, "count": 5}, {"text": "Shire", "sentiment": {"score": -0.534831, "mixed": "1", "label": "negative"}, "relevance": 0.542696, "count": 12}, {"text": "Further announcements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541178, "count": 1}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0.619727, "label": "positive"}, "relevance": 0.539102, "count": 5}, {"text": "vedolizumab", "sentiment": {"score": -0.607669, "mixed": "1", "label": "negative"}, "relevance": 0.538035, "count": 14}, {"text": "European Commission", "sentiment": {"score": 0.383672, "mixed": "1", "label": "positive"}, "relevance": 0.53585, "count": 3}, {"text": "securities exchange offeror", "sentiment": {"score": 0.548479, "mixed": "1", "label": "positive"}, "relevance": 0.535497, "count": 9}, {"text": "Statements", "sentiment": {"score": 0.707653, "label": "positive"}, "relevance": 0.534738, "count": 1}, {"text": "statements", "sentiment": {"score": -0.315474, "mixed": "1", "label": "negative"}, "relevance": 0.534738, "count": 14}, {"text": "Infections Vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533222, "count": 1}, {"text": "securities", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.533133, "count": 1}, {"text": "hypersensitivity reactions", "sentiment": {"score": -0.573836, "label": "negative"}, "relevance": 0.531534, "count": 2}, {"text": "tumor necrosis factor-alpha", "sentiment": {"score": -0.734843, "label": "negative"}, "relevance": 0.530852, "count": 3}, {"text": "ordinary shares", "sentiment": {"score": -0.631802, "label": "negative"}, "relevance": 0.530818, "count": 1}, {"text": "Shire\u2019s pipeline compound SHP647", "sentiment": {"score": -0.799267, "label": "negative"}, "relevance": 0.529216, "count": 1}, {"text": "Announcement", "sentiment": {"score": 0.408075, "mixed": "1", "label": "positive"}, "relevance": 0.525661, "count": 10}, {"text": "product Entyvio", "sentiment": {"score": -0.799267, "label": "negative"}, "relevance": 0.525348, "count": 1}, {"text": "binding of alpha4beta7 integrin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52526, "count": 1}, {"text": "transfer of securities of Shire", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.525119, "count": 1}, {"text": "Infusion-related reactions", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.524997, "count": 1}, {"text": "special precautions", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.524563, "count": 1}, {"text": "person", "sentiment": {"score": 0.569774, "label": "positive"}, "relevance": 0.524523, "count": 5}, {"text": "patient years of exposure", "sentiment": {"score": -0.77705, "label": "negative"}, "relevance": 0.523872, "count": 1}, {"text": "area of inflammatory bowel diseases", "sentiment": {"score": -0.799267, "label": "negative"}, "relevance": 0.523824, "count": 1}, {"text": "Securities", "sentiment": {"score": -0.755071, "label": "negative"}, "relevance": 0.522106, "count": 1}, {"text": "Vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521839, "count": 1}, {"text": "risk of opportunistic infections", "sentiment": {"score": -0.776276, "label": "negative"}, "relevance": 0.520558, "count": 1}, {"text": "Market Regulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520228, "count": 1}, {"text": "Dealing Disclosure", "sentiment": {"score": 0.527581, "label": "positive"}, "relevance": 0.519148, "count": 5}, {"text": "Development team", "sentiment": {"score": 0.985792, "label": "positive"}, "relevance": 0.518761, "count": 1}, {"text": "use Vedolizumab", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.518639, "count": 1}, {"text": "exchange", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.518585, "count": 2}, {"text": "severe IRR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518271, "count": 1}, {"text": "United States Federal Trade Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518049, "count": 1}, {"text": "clinical studies", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.517929, "count": 1}, {"text": "monoclonal antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51758, "count": 1}, {"text": "risks", "sentiment": {"score": -0.896114, "label": "negative"}, "relevance": 0.517522, "count": 3}, {"text": "progressive multifocal leukoencephalopathy", "sentiment": {"score": -0.706252, "label": "negative"}, "relevance": 0.517096, "count": 1}, {"text": "Appropriate monitoring", "sentiment": {"score": 0.778665, "label": "positive"}, "relevance": 0.516997, "count": 1}, {"text": "ulcerative colitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516726, "count": 2}, {"text": "pharmaceutical company", "sentiment": {"score": 0.947101, "label": "positive"}, "relevance": 0.516254, "count": 1}, {"text": "EC\u2019s approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515885, "count": 1}, {"text": "appropriate treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515277, "count": 2}, {"text": "markets", "sentiment": {"score": 0.85793, "label": "positive"}, "relevance": 0.515098, "count": 1}]}, "extracted_metadata": {"sha1": "b778f3137121c5e08b500df1f9eec0713a3a0231", "filename": "1543148241718.zip-9e2d73f1f1191105bc8c6abfd1862f5b.xml", "file_type": "json"}, "external_links": ["https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=TSE%3A+4502&index=4&md5=ce1a32fa064166e2e752006fe8a42459", "https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Fnewsroom%2F&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=https%3A%2F%2Fwww.takeda.com%2Fnewsroom%2F&index=5&md5=ccfd4adf39d9b0bc1a5faab4bad4ed06", "https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fgeneral.takedapharm.com%2FENTYVIOMG&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=Medication+Guide&index=2&md5=14774650f6ca42b6540c4e57094fa478", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FEPAR_-_Product_Information%2Fhuman%2F002782%2FWC500168528.pdf&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=Summary+of+Product+Characteristics+%28SmPC%29&index=3&md5=f35c0825aadb9b684cf84c13e23a3fae", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=www.sec.gov&index=7&md5=f34142a4182ff388651024c43f9f99c7", "https://www.takeda.com/newsroom/", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.Shire.com%2F&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=www.Shire.com&index=6&md5=eea006e64de952c220e0769a4291712e", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk%2F&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=9&md5=a4b532e6b3474543ef486d252d113ea2", "https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fgeneral.takedapharm.com%2FENTYVIOPI&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=Prescribing+Information&index=1&md5=3d9b9c6047c4ef0b999eedc065d6dd9d", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com%2Finvestors%2Foffer-for-shire&esheet=51902693&newsitemid=20181120005443&lan=en-US&anchor=www.takeda.com%2Finvestors%2Foffer-for-shire&index=8&md5=07509e28eeec8a6b1a46a2d4f3a0a288"], "title": "Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc", "forum_title": "AETOS Wire"}, {"id": "eaOFaQMZVDZOly_PxhqCPsBj7GpnMqwoiFlEM4fFyWeObJZaef-F7adtCzD1UITl", "result_metadata": {"score": 25.597065}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.999993, "label": "/news/national news"}, {"score": 0.999987, "label": "/business and industrial/business news"}, {"score": 0.952853, "label": "/news/international news"}], "relations": [], "keywords": [{"text": "Wire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999596, "count": 1}, {"text": "News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.950907, "count": 1}, {"text": "myScience", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315024, "count": 1}]}, "crawl_date": "2018-11-25T10:30:36Z", "url": "https://www.myscience.org.uk/news/wire/why_lobbying_is_not_always_an_obscure_activity-2018-uantwerpen", "host": "myscience.org.uk", "text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Life Sciences", "relevance": 0.836245, "type": "Organization", "disambiguation": {"subtype": [], "name": "Life sciences", "dbpedia_resource": "http://dbpedia.org/resource/Life_sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Earth Sciences - Life Sciences", "relevance": 0.675389, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.615765, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.494541, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cardiff University", "relevance": 0.479784, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Nottingham", "relevance": 0.360988, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Universities of Bristol", "relevance": 0.339358, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Research Council", "relevance": 0.32913, "type": "Organization", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James River", "relevance": 0.313604, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0.665961, "label": "positive"}, "text": "Scottish government", "relevance": 0.304567, "type": "Organization", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Virginia", "relevance": 0.298225, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRC", "relevance": 0.294256, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.288952, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tennessee", "relevance": 0.286911, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": 0.284597, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "located evidence for the site of America's first English Thanksgiving on the James River in Virginia", "keywords": [{"text": "James River"}, {"text": "Thanksgiving"}, {"text": "evidence"}, {"text": "site"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "GeographicFeature", "text": "James River"}, {"type": "Location", "text": "Virginia", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "evidence", "keywords": [{"text": "evidence"}]}, "action": {"verb": {"text": "locate", "tense": "past"}, "text": "have located", "normalized": "have locate"}}, {"subject": {"text": "by the University of Nottingham", "keywords": [{"text": "Nottingham"}, {"text": "University"}], "entities": [{"type": "Organization", "text": "University of Nottingham", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "19.11.2018 A research team", "keywords": [{"text": "research team"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "by the the Medical Research Council (MRC)", "keywords": [{"text": "MRC"}, {"text": "Medical Research Council"}], "entities": [{"type": "Organization", "text": "Medical Research Council", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"type": "Organization", "text": "MRC"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "a grant", "keywords": [{"text": "grant"}]}, "action": {"verb": {"text": "award", "tense": "past"}, "text": "has been awarded", "normalized": "have be award"}}, {"subject": {"text": "the clinical translation of renal imaging and transform the way kidney disease", "keywords": [{"text": "way kidney disease"}, {"text": "renal imaging"}, {"text": "clinical translation"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "diagnosed"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}, {"text": "New approaches"}, {"text": "Earth Sciences"}, {"text": "Life Sciences"}], "entities": [{"type": "Organization", "text": "Earth Sciences - Life Sciences"}, {"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "form", "tense": "past"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "19.11.2018 With lowest cost green energy", "keywords": [{"text": "lowest cost green"}, {"text": "energy"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the future", "keywords": [{"text": "future"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "Computer Science / Telecom", "keywords": [{"text": "Telecom"}, {"text": "Science"}], "entities": []}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future", "keywords": [{"text": "onshore wind farms"}, {"text": "affordable wind power"}, {"text": "industry desire"}, {"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understanding", "normalized": "understand"}}, {"subject": {"text": "understanding how to \u2018repower' existing onshore wind farms", "keywords": [{"text": "onshore wind farms"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the Scottish government", "keywords": [{"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "supports", "normalized": "support"}}, {"subject": {"text": "the Scottish government and industry", "keywords": [{"text": "Scottish government"}, {"text": "industry"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "affordable wind power", "keywords": [{"text": "affordable wind"}, {"text": "power"}], "entities": []}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "to generate", "normalized": "to generate"}}], "concepts": [{"text": "Genetics", "relevance": 0.96581, "dbpedia_resource": "http://dbpedia.org/resource/Genetics"}, {"text": "Pharmacology", "relevance": 0.956142, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Nutrition", "relevance": 0.878096, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Psychiatry", "relevance": 0.822709, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatry"}, {"text": "Medicine", "relevance": 0.809112, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.792414, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Wind farm", "relevance": 0.772576, "dbpedia_resource": "http://dbpedia.org/resource/Wind_farm"}, {"text": "Mental disorder", "relevance": 0.75695, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.745731, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Clinical trial", "relevance": 0.714706, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Wind power", "relevance": 0.709195, "dbpedia_resource": "http://dbpedia.org/resource/Wind_power"}, {"text": "Science", "relevance": 0.681694, "dbpedia_resource": "http://dbpedia.org/resource/Science"}, {"text": "Drug development", "relevance": 0.654584, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Drug discovery", "relevance": 0.651247, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Gene", "relevance": 0.644384, "dbpedia_resource": "http://dbpedia.org/resource/Gene"}, {"text": "Wind", "relevance": 0.641573, "dbpedia_resource": "http://dbpedia.org/resource/Wind"}], "categories": [{"score": 0.912367, "label": "/science/medicine/medical research"}, {"score": 0.886062, "label": "/business and industrial/energy/renewable energy/wind energy"}, {"score": 0.847148, "label": "/health and fitness/disorders"}], "relations": [{"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.865818, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "America", "location": [100, 107], "entities": [{"type": "GeopoliticalEntity", "text": "America", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.736589, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "partOfMany", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.820195, "arguments": [{"text": "Thanksgiving", "location": [124, 136], "entities": [{"type": "Person", "text": "Thanksgiving"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "residesIn", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.732729, "arguments": [{"text": "James River", "location": [144, 155], "entities": [{"type": "Person", "text": "James River"}]}, {"text": "Virginia", "location": [159, 167], "entities": [{"type": "GeopoliticalEntity", "text": "Virginia"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "score": 0.614282, "arguments": [{"text": "Medical Research Council", "location": [293, 317], "entities": [{"type": "Organization", "text": "Medical Research Council"}]}, {"text": "awarded", "location": [266, 273], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Agronomy / Food Science - 19.11.2018 There is an urgent need for new dietary approaches and treatments to tackle the global health crisis of obesity in children and adults say experts.", "score": 0.69565, "arguments": [{"text": "adults", "location": [1144, 1150], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "say", "location": [1151, 1154], "entities": [{"type": "EventCommunication", "text": "say"}]}]}], "keywords": [{"text": "Life Sciences", "sentiment": {"score": -0.656557, "label": "negative"}, "relevance": 0.949396, "count": 4}, {"text": "Earth Sciences", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.840453, "count": 1}, {"text": "Universities of Bristol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672122, "count": 1}, {"text": "Food Science", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.648895, "count": 1}, {"text": "research team", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.64359, "count": 1}, {"text": "drug discovery collaboration", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.634426, "count": 1}, {"text": "Medical Research Council", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.601073, "count": 1}, {"text": "psychiatric disorders Cardiff University", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.596053, "count": 1}, {"text": "collaboration", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.590331, "count": 1}, {"text": "lowest cost", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.585581, "count": 1}, {"text": "green energy", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.581693, "count": 1}, {"text": "psychiatric disorders", "sentiment": {"score": -0.37013, "mixed": "1", "label": "negative"}, "relevance": 0.576386, "count": 1}, {"text": "New approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.5751, "count": 1}, {"text": "urgent need", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.574867, "count": 1}, {"text": "Scottish government", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.570715, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.564555, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.562587, "count": 1}, {"text": "Computer Science", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.559528, "count": 1}, {"text": "University of Nottingham", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.555807, "count": 1}, {"text": "Agronomy", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.553495, "count": 1}, {"text": "Archaeologists", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542134, "count": 1}, {"text": "Music", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.541937, "count": 1}, {"text": "Telecom", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.534746, "count": 1}, {"text": "grant", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.532393, "count": 1}, {"text": "genomics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.528277, "count": 1}, {"text": "neuroscience", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.52763, "count": 1}, {"text": "James River", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527316, "count": 1}, {"text": "MRC", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.525936, "count": 1}, {"text": "Tennessee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525603, "count": 1}, {"text": "treatments", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.524143, "count": 1}, {"text": "evidence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522629, "count": 1}, {"text": "University's large scale", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.521522, "count": 1}, {"text": "schizophrenia", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.51951, "count": 1}, {"text": "children", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.512786, "count": 1}, {"text": "onshore wind farms", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.510958, "count": 1}, {"text": "adults", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.510546, "count": 1}, {"text": "world-class expertise", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.50856, "count": 1}, {"text": "Virginia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507174, "count": 1}, {"text": "experts", "sentiment": {"score": 0.537436, "mixed": "1", "label": "positive"}, "relevance": 0.507174, "count": 1}, {"text": "clinical translation of renal imaging", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.504165, "count": 1}, {"text": "Takeda's extensive drug discovery", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.500584, "count": 1}, {"text": "genomic data", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.494596, "count": 1}, {"text": "new approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.489763, "count": 1}, {"text": "new dietary approaches", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.481157, "count": 1}, {"text": "global health crisis of obesity", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.477114, "count": 1}, {"text": "psychiatric genetics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.475852, "count": 1}, {"text": "industry desire", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.466367, "count": 1}, {"text": "site of America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460584, "count": 1}, {"text": "way kidney disease", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.460217, "count": 1}, {"text": "first English Thanksgiving", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456967, "count": 1}]}, "extracted_metadata": {"sha1": "08224ee936cb9e1136f06180bbb7fc5e8409039c", "filename": "1543141836727.zip-87e553e03bd37a4ed44f9ad3006f7a6c.xml", "file_type": "json"}, "title": "Wire | myScience / News"}, {"id": "ZgTveka7CSdkSojsvFm7fabS0wbobTrGBebD7iKvEXjoJnjt-RbPrwq_yh-Dca9-", "result_metadata": {"score": 22.837742}, "author": "shweeta", "enriched_title": {"entities": [{"count": 2, "sentiment": {"score": -0.677917, "label": "negative"}, "text": "Bowel Disease", "relevance": 0.33, "type": "HealthCondition"}], "sentiment": {"document": {"score": -0.944477, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Inflammatory Bowel Disease (IBD) Treatment Market", "keywords": [{"text": "Inflammatory Bowel Disease"}, {"text": ") Treatment Market"}], "entities": [{"type": "HealthCondition", "text": "Bowel Disease"}, {"type": "HealthCondition", "text": "Bowel Disease"}]}, "sentence": "Inflammatory Bowel Disease (IBD) Treatment Market to Witness a Pronounce Growth During 2017 to 2025", "object": {"text": "a Pronounce Growth", "keywords": [{"text": "Pronounce Growth"}]}, "action": {"verb": {"text": "Witness", "tense": "future"}, "text": "to Witness", "normalized": "to Witness"}}], "concepts": [{"text": "Inflammatory bowel disease", "relevance": 0.967495, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Inflammation", "relevance": 0.687637, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Ulcerative colitis", "relevance": 0.678699, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Immune system", "relevance": 0.622288, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Gastroenterology", "relevance": 0.555219, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}], "categories": [{"score": 0.887995, "label": "/health and fitness/disease/ibs and crohn's disease"}, {"score": 0.735351, "label": "/health and fitness/therapy"}, {"score": 0.697236, "label": "/health and fitness/disease/allergies"}], "relations": [], "keywords": [{"text": "Inflammatory Bowel Disease", "sentiment": {"score": -0.944477, "label": "negative"}, "relevance": 0.99997, "count": 1}, {"text": "IBD", "sentiment": {"score": -0.944477, "label": "negative"}, "relevance": 0.826858, "count": 1}, {"text": "Treatment Market", "sentiment": {"score": -0.944477, "label": "negative"}, "relevance": 0.315268, "count": 1}, {"text": "Pronounce Growth", "sentiment": {"score": -0.944477, "label": "negative"}, "relevance": 0.085279, "count": 1}]}, "crawl_date": "2018-11-25T03:56:35Z", "url": "https://www.findmarketresearch.org/2018/06/inflammatory-bowel-disease-ibd-treatment-market-to-witness-a-pronounce-growth-during-2017-to-2025/", "host": "findmarketresearch.org", "text": "(Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-06-13T12:10:00+05:00", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": -0.563329, "label": "negative"}, "text": "IBD", "relevance": 0.864818, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"count": 5, "sentiment": {"score": -0.881353, "label": "negative"}, "text": "bowel disease", "relevance": 0.554895, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": -0.858447, "label": "negative"}, "text": "Crohn\u2019s disease", "relevance": 0.408198, "type": "HealthCondition"}, {"count": 6, "sentiment": {"score": -0.848623, "label": "negative"}, "text": "Ulcerative colitis", "relevance": 0.402252, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 5, "sentiment": {"score": -0.468517, "label": "negative"}, "text": "Drug Class", "relevance": 0.28245, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.228126, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Distribution Channel", "relevance": 0.216163, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.840657, "label": "negative"}, "text": "gastrointestinal tract", "relevance": 0.215169, "type": "Anatomy"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.201799, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia", "relevance": 0.192769, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.188492, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.795882, "label": "negative"}, "text": "Hospital Pharmacy Retail", "relevance": 0.173619, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific Latin America Brazil Mexico", "relevance": 0.16623, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America Middle East", "relevance": 0.160442, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.151663, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.144435, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.141317, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.447572, "label": "negative"}, "text": "product development", "relevance": 0.135726, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.132454, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.573549, "label": "negative"}, "text": "persistent diarrhea", "relevance": 0.129463, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.128727, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.126996, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Zealand", "relevance": 0.126087, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.846906, "label": "negative"}, "text": "abdominal cramps", "relevance": 0.123775, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.122705, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.490528, "label": "negative"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.120685, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.632995, "label": "negative"}, "text": "Shire Plc.", "relevance": 0.11658, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.116442, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Janssen Biotech", "relevance": 0.114051, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.113563, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Inc", "relevance": 0.112034, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.111646, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.228785, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited.", "relevance": 0.101129, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UCB Inc.", "relevance": 0.0984953, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie, Inc.", "relevance": 0.0976919, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20 %", "relevance": 0.0976919, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0976919, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.74934, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Inflammatory bowel disease", "keywords": [{"text": "Inflammatory bowel disease"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "sentence": " Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract.", "object": {"text": "a group of medical indication that causes chronic inflammation in the gastrointestinal tract", "keywords": [{"text": "chronic inflammation"}, {"text": "gastrointestinal tract"}, {"text": "medical indication"}, {"text": "group"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}, {"type": "Anatomy", "text": "gastrointestinal tract"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a group", "keywords": [{"text": "group"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "sentence": " Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract.", "object": {"text": "chronic inflammation", "keywords": [{"text": "chronic inflammation"}]}, "action": {"verb": {"text": "cause", "tense": "present"}, "text": "causes", "normalized": "cause"}}, {"subject": {"text": "The inflammatory bowel disease", "keywords": [{"text": "inflammatory bowel disease"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "sentence": " The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn\u2019s disease.", "object": {"text": "of Ulcerative colitis and Crohn\u2019s disease", "keywords": [{"text": "Ulcerative colitis"}, {"text": "Crohn"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprises", "normalized": "comprise"}}, {"subject": {"text": "The ulcerative colitis", "keywords": [{"text": "ulcerative colitis"}], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum.", "object": {"text": "the large intestine and anus", "keywords": [{"text": "anus"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum.", "object": {"text": "the inflammation sores in the inner lining of colon and rectum", "keywords": [{"text": "inflammation sores"}, {"text": "inner lining"}, {"text": "rectum"}, {"text": "colon"}]}, "action": {"verb": {"text": "cause", "tense": "present"}, "text": "causes", "normalized": "cause"}}, {"subject": {"text": "The Crohn\u2019s disease", "keywords": [{"text": "Crohn"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "sentence": " The Crohn\u2019s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls.", "object": {"text": "any part of gastrointestinal tract", "keywords": [{"text": "gastrointestinal tract"}], "entities": [{"type": "Anatomy", "text": "gastrointestinal tract"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " The Crohn\u2019s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls.", "object": {"text": "all the layers of gastrointestinal walls", "keywords": [{"text": "gastrointestinal walls"}, {"text": "layers"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "The ulcerative colitis", "keywords": [{"text": "ulcerative colitis"}], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " The ulcerative colitis is more prevalent than that of Crohn\u2019s disease.", "object": {"text": "more prevalent than that of Crohn\u2019s disease", "keywords": [{"text": "Crohn"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries.", "object": {"text": "equally in men and women", "keywords": [{"text": "men"}, {"text": "women"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "The IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries.", "object": {"text": "prevalence and incidence rates", "keywords": [{"text": "incidence rates"}, {"text": "prevalence"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The exact cause of inflammatory bowel disease", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "exact cause"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "sentence": " The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease.", "object": {"text": "not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease", "keywords": [{"text": "lifestyle related risks"}, {"text": "inflammatory bowel disease"}, {"text": "sedentary lifestyle"}, {"text": "genetic factors"}], "entities": [{"type": "JobTitle", "text": "product development"}, {"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding", "keywords": [{"text": "severe abdominal cramps"}, {"text": "occasional rectal bleeding"}, {"text": "persistent diarrhea"}, {"text": "pain"}], "entities": [{"type": "HealthCondition", "text": "abdominal cramps"}, {"type": "HealthCondition", "text": "persistent diarrhea"}]}, "sentence": " The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding.", "object": {"text": "The common symptoms of inflammatory bowel disease", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "common symptoms"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "The IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "Organization", "text": "IBD", "disambiguation": {"subtype": ["CauseOfDeath", "OrganizationSector"], "name": "Disease", "dbpedia_resource": "http://dbpedia.org/resource/Disease"}}]}, "sentence": " The IBD has no permanent cure and requires the lifelong disease management and treatment.", "object": {"text": "no permanent cure", "keywords": [{"text": "permanent cure"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "Organization", "text": "IBD", "disambiguation": {"subtype": ["CauseOfDeath", "OrganizationSector"], "name": "Disease", "dbpedia_resource": "http://dbpedia.org/resource/Disease"}}]}, "sentence": " The IBD has no permanent cure and requires the lifelong disease management and treatment.", "object": {"text": "the lifelong disease management and treatment", "keywords": [{"text": "lifelong disease management"}, {"text": "treatment"}]}, "action": {"verb": {"text": "require", "tense": "present"}, "text": "requires", "normalized": "require"}}, {"subject": {"text": "Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs", "keywords": [{"text": "extent antibiotic drugs"}, {"text": "biologic drugs"}, {"text": "TNF inhibitors"}, {"text": "immunomodulators"}]}, "sentence": " Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.", "object": {"text": "the symptoms of these diseases", "keywords": [{"text": "symptoms"}, {"text": "diseases"}]}, "action": {"verb": {"text": "relive", "tense": "future"}, "text": "are prescribed to relive", "normalized": "be prescribe to relive"}}, {"subject": {"text": "The global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " The global IBD treatment market is projected to be primarily driven by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD", "keywords": [{"text": "biologic drugs"}, {"text": "new product development"}, {"text": "biosimilar drugs"}, {"text": "IBD"}], "entities": [{"type": "JobTitle", "text": "product development"}, {"type": "Organization", "text": "IBD", "disambiguation": {"subtype": ["CauseOfDeath", "OrganizationSector"], "name": "Disease", "dbpedia_resource": "http://dbpedia.org/resource/Disease"}}]}, "sentence": " The global IBD treatment market is projected to be primarily driven by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD.", "object": {"text": "The global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is projected to be primarily driven", "normalized": "be project to be primarily drive"}}, {"subject": {"text": "The high prevalence and increasing incidence of Crohn\u2019s disease and Ulcerative colitis disease in developed countries", "keywords": [{"text": "Ulcerative colitis disease"}, {"text": "high prevalence"}, {"text": "Crohn\u2019s disease"}, {"text": "incidence"}], "entities": [{"type": "HealthCondition", "text": "Crohn\u2019s disease"}, {"type": "HealthCondition", "text": "Ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " The high prevalence and increasing incidence of Crohn\u2019s disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs.", "object": {"text": "the development of novel therapeutics drugs", "keywords": [{"text": "novel therapeutics"}, {"text": "drugs"}, {"text": "development"}], "entities": [{"type": "JobTitle", "text": "product development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has fueled", "normalized": "have fuel"}}, {"subject": {"text": "the development of novel therapeutics drugs", "keywords": [{"text": "novel therapeutics"}, {"text": "drugs"}, {"text": "development"}], "entities": [{"type": "JobTitle", "text": "product development"}]}, "sentence": " The high prevalence and increasing incidence of Crohn\u2019s disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs.", "object": {"text": "The high prevalence and increasing incidence of Crohn\u2019s disease and Ulcerative colitis disease in developed countries", "keywords": [{"text": "Ulcerative colitis disease"}, {"text": "high prevalence"}, {"text": "Crohn\u2019s disease"}, {"text": "incidence"}], "entities": [{"type": "HealthCondition", "text": "Crohn\u2019s disease"}, {"type": "HealthCondition", "text": "Ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "has fueled", "normalized": "have fuel"}}, {"subject": {"text": "Genetic factors", "keywords": [{"text": "Genetic factors"}]}, "sentence": " Genetic factors are found to induce the one of the forms of IBD.", "object": {"text": "the one of the forms of IBD", "keywords": [{"text": "IBD"}, {"text": "forms"}], "entities": [{"type": "Organization", "text": "IBD", "disambiguation": {"subtype": ["CauseOfDeath", "OrganizationSector"], "name": "Disease", "dbpedia_resource": "http://dbpedia.org/resource/Disease"}}]}, "action": {"verb": {"text": "induce", "tense": "future"}, "text": "are found to induce", "normalized": "be find to induce"}}, {"subject": {"text": "parents", "keywords": [{"text": "parents"}]}, "sentence": " The children of parents having IBD are more likely to develop the symptoms of IBD.", "object": {"text": "IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "The children of parents having IBD", "keywords": [{"text": "IBD"}, {"text": "children"}, {"text": "parents"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " The children of parents having IBD are more likely to develop the symptoms of IBD.", "object": {"text": "the symptoms of IBD", "keywords": [{"text": "IBD"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Studies", "keywords": [{"text": "Studies"}]}, "sentence": " Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents.", "object": {"text": "shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents", "keywords": [{"text": "IBD"}, {"text": "genes"}, {"text": "population"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"type": "Quantity", "text": "20 "}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Studies", "keywords": [{"text": "Studies"}]}, "sentence": " Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents.", "object": {"text": "that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents", "keywords": [{"text": "IBD"}, {"text": "genes"}, {"text": "population"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"type": "Quantity", "text": "20 "}]}, "action": {"verb": {"text": "show", "tense": "past"}, "text": "have shown", "normalized": "have show"}}, {"subject": {"text": "genes", "keywords": [{"text": "genes"}]}, "sentence": " Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents.", "object": {"text": "from parents", "keywords": [{"text": "parents"}]}, "action": {"verb": {"text": "inherit", "tense": "past"}, "text": "inherited", "normalized": "inherit"}}, {"subject": {"text": "The Risk of developing IBD", "keywords": [{"text": "IBD"}, {"text": "Risk"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " The Risk of developing IBD is higher when both the parents are affected with IBD.", "object": {"text": "higher"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "both the parents", "keywords": [{"text": "parents"}]}, "sentence": " The Risk of developing IBD is higher when both the parents are affected with IBD.", "object": {"text": "affected with IBD", "keywords": [{"text": "IBD"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Biopharmaceutical companies", "keywords": [{"text": "Biopharmaceutical companies"}]}, "sentence": " Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period.", "object": {"text": "made the significant investments in R&D activities", "keywords": [{"text": "significant investments"}, {"text": "R&D activities"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Biopharmaceutical companies", "keywords": [{"text": "Biopharmaceutical companies"}]}, "sentence": " Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period.", "object": {"text": "the significant investments", "keywords": [{"text": "significant investments"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "have made", "normalized": "have make"}}, {"subject": {"text": "clinical approvals", "keywords": [{"text": "clinical approvals"}]}, "sentence": " Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period.", "object": {"text": "likely to commercialize"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "clinical approvals", "keywords": [{"text": "clinical approvals"}]}, "sentence": " Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period.", "action": {"verb": {"text": "commercialize", "tense": "future"}, "text": "to commercialize", "normalized": "to commercialize"}}, {"subject": {"text": "Recent launch and approvals of new drugs in North America and Europe as well as in Japan", "keywords": [{"text": "Recent launch"}, {"text": "new drugs"}, {"text": "North America"}, {"text": "approvals"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Recent launch and approvals of new drugs in North America and Europe as well as in Japan is projected to fuel the demand for IBD treatment drugs in near future.", "object": {"text": "projected to fuel the demand for IBD treatment drugs in near future", "keywords": [{"text": "IBD treatment drugs"}, {"text": "demand"}, {"text": "future"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the demand for IBD treatment drugs in near future", "keywords": [{"text": "IBD treatment drugs"}, {"text": "demand"}, {"text": "future"}], "entities": [{"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " Recent launch and approvals of new drugs in North America and Europe as well as in Japan is projected to fuel the demand for IBD treatment drugs in near future.", "object": {"text": "Recent launch and approvals of new drugs in North America and Europe as well as in Japan", "keywords": [{"text": "Recent launch"}, {"text": "new drugs"}, {"text": "North America"}, {"text": "approvals"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is projected to fuel", "normalized": "be project to fuel"}}, {"subject": {"text": "The global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " The global IBD treatment market is broadly categorized into four segments based on drug class, disease indication, distribution channel and region.", "object": {"text": "broadly categorized into four segments based on drug class, disease indication, distribution channel and region", "keywords": [{"text": "disease indication"}, {"text": "drug class"}, {"text": "distribution channel"}, {"text": "segments"}], "entities": [{"type": "Organization", "text": "Drug Class"}, {"type": "Company", "text": "Distribution Channel"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " The global IBD treatment market is broadly categorized into four segments based on drug class, disease indication, distribution channel and region.", "object": {"text": "into four segments based on drug class, disease indication, distribution channel and region", "keywords": [{"text": "disease indication"}, {"text": "drug class"}, {"text": "distribution channel"}, {"text": "segments"}], "entities": [{"type": "Organization", "text": "Drug Class"}, {"type": "Company", "text": "Distribution Channel"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "categorized", "normalized": "categorize"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids.", "object": {"text": "segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids", "keywords": [{"text": "TNF inhibitors"}, {"text": "immunomodulators"}, {"text": "corticosteroids"}, {"text": "aminosalicyclates"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids.", "object": {"text": "into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids", "keywords": [{"text": "TNF inhibitors"}, {"text": "immunomodulators"}, {"text": "corticosteroids"}, {"text": "aminosalicyclates"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The TNF inhibitors", "keywords": [{"text": "TNF inhibitors"}]}, "sentence": " The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025.", "object": {"text": "for leading share of global IBD treatment market in 2016", "keywords": [{"text": "global IBD treatment"}, {"text": "share"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "The TNF inhibitors accounted for leading share of global IBD", "keywords": [{"text": "TNF inhibitors"}, {"text": "global IBD"}, {"text": "leading share"}], "entities": []}, "sentence": " The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025.", "object": {"text": "projected to gain its market share", "keywords": [{"text": "market share"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The TNF inhibitors accounted for leading share of global IBD", "keywords": [{"text": "TNF inhibitors"}, {"text": "global IBD"}, {"text": "leading share"}], "entities": []}, "sentence": " The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025.", "action": {"verb": {"text": "project", "tense": "past"}, "text": "is projected to gain", "normalized": "be project to gain"}}, {"subject": {"text": "its market share", "keywords": [{"text": "market share"}]}, "sentence": " The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025.", "action": {"verb": {"text": "gain", "tense": "future"}, "text": "is projected to gain", "normalized": "be project to gain"}}, {"subject": {"text": "The large share and growth of TNF inhibitors", "keywords": [{"text": "TNF inhibitors"}, {"text": "large share"}, {"text": "growth"}]}, "sentence": " The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets.", "object": {"text": "attributed to rising use of biologic drugs as second line of treatment and approvals in key markets", "keywords": [{"text": "biologic drugs"}, {"text": "key markets"}, {"text": "approvals"}, {"text": "line"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The large share and growth of TNF inhibitors", "keywords": [{"text": "TNF inhibitors"}, {"text": "large share"}, {"text": "growth"}]}, "sentence": " The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets.", "object": {"text": "to rising use of biologic drugs as second line of treatment and approvals in key markets", "keywords": [{"text": "biologic drugs"}, {"text": "key markets"}, {"text": "approvals"}, {"text": "line"}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "is attributed", "normalized": "be attribute"}}, {"subject": {"text": "Aminosalicyclates drug class", "keywords": [{"text": "drug class"}], "entities": [{"type": "Organization", "text": "Drug Class"}]}, "sentence": " Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period.", "object": {"text": "the second leading share holder of global IBD treatment market", "keywords": [{"text": "global IBD treatment"}, {"text": "share holder"}], "entities": [{"type": "Organization", "text": "Drug Class"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "holder", "keywords": [{"text": "holder"}]}, "sentence": " Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period.", "object": {"text": "share", "keywords": [{"text": "share"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "Aminosalicyclates drug class", "keywords": [{"text": "drug class"}], "entities": [{"type": "Organization", "text": "Drug Class"}]}, "sentence": " Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period.", "object": {"text": "projected to substantially lose its market share to corticosteroids and immunomodulators", "keywords": [{"text": "market share"}, {"text": "immunomodulators"}, {"text": "corticosteroids"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "its market share", "keywords": [{"text": "market share"}]}, "sentence": " Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period.", "object": {"text": "to corticosteroids and immunomodulators", "keywords": [{"text": "immunomodulators"}, {"text": "corticosteroids"}]}, "action": {"verb": {"text": "lose", "tense": "present"}, "text": "lose", "normalized": "lose"}}, {"subject": {"text": "the global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " In terms of distribution channel, the global IBD treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.", "object": {"text": "segmented into hospital pharmacy", "keywords": [{"text": "hospital pharmacy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " In terms of distribution channel, the global IBD treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.", "object": {"text": "into hospital pharmacy, retail pharmacy, and online pharmacy", "keywords": [{"text": "hospital pharmacy"}, {"text": "retail pharmacy"}, {"text": "online pharmacy"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the global IBD treatment market", "keywords": [{"text": "global IBD treatment"}], "entities": []}, "sentence": " By geography, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "object": {"text": "into North America, Europe, Asia Pacific, Latin America and Middle East & Africa", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.973503, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammatory bowel disease", "relevance": 0.789724, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Crohn's disease", "relevance": 0.648789, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Gastroenterology", "relevance": 0.515462, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Inflammation", "relevance": 0.510518, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "North America", "relevance": 0.472657, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacy", "relevance": 0.466097, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Colon", "relevance": 0.443165, "dbpedia_resource": "http://dbpedia.org/resource/Colon_(anatomy)"}, {"text": "Colitis", "relevance": 0.438136, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}, {"text": "Marketing", "relevance": 0.42848, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "United States", "relevance": 0.399639, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Colonoscopy", "relevance": 0.39293, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "Large intestine", "relevance": 0.387275, "dbpedia_resource": "http://dbpedia.org/resource/Large_intestine"}, {"text": "Helminthic therapy", "relevance": 0.371033, "dbpedia_resource": "http://dbpedia.org/resource/Helminthic_therapy"}, {"text": "Biopsy", "relevance": 0.368648, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "Small intestine", "relevance": 0.353712, "dbpedia_resource": "http://dbpedia.org/resource/Small_intestine"}, {"text": "Intestine", "relevance": 0.344654, "dbpedia_resource": "http://dbpedia.org/resource/Intestine"}, {"text": "Pharmaceutical drug", "relevance": 0.329263, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.326854, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Europe", "relevance": 0.323734, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}], "categories": [{"score": 0.986002, "label": "/health and fitness/disease"}, {"score": 0.817246, "label": "/health and fitness/therapy"}, {"score": 0.793368, "label": "/health and fitness/disorders"}], "relations": [{"type": "hasAttribute", "sentence": "Global Inflammatory Bowel Disease (IBD) Treatment Market: Overview Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract.", "score": 0.581117, "arguments": [{"text": "group", "location": [99, 104], "entities": [{"type": "Person", "text": "group"}]}, {"text": "bowel disease", "location": [80, 93], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "partOf", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.358744, "arguments": [{"text": "U.S.", "location": [5645, 5649], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Canada", "location": [5650, 5656], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.249586, "arguments": [{"text": "Germany", "location": [5664, 5671], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "U.K.", "location": [5672, 5676], "entities": [{"type": "GeopoliticalEntity", "text": "U.K.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.328597, "arguments": [{"text": "France", "location": [5677, 5683], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Italy", "location": [5684, 5689], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.931533, "arguments": [{"text": "Rest", "location": [5696, 5700], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Spain", "location": [5690, 5695], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.495226, "arguments": [{"text": "Rest", "location": [5696, 5700], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Pacific", "location": [5716, 5723], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of Middle East and Africa", "score": 0.381139, "arguments": [{"text": "Rest", "location": [5766, 5770], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Pacific", "location": [5779, 5786], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.512663, "arguments": [{"text": "India", "location": [5730, 5735], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "China", "location": [5724, 5729], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.271963, "arguments": [{"text": "India", "location": [5730, 5735], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Japan", "location": [5736, 5741], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of Middle East and Africa", "score": 0.734366, "arguments": [{"text": "Rest", "location": [5766, 5770], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "New Zealand", "location": [5754, 5765], "entities": [{"type": "GeopoliticalEntity", "text": "New Zealand", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of Middle East and Africa", "score": 0.420133, "arguments": [{"text": "Pacific", "location": [5779, 5786], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Latin America", "location": [5787, 5800], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "residesIn", "sentence": "New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of Middle East and Africa", "score": 0.428373, "arguments": [{"text": "Rest", "location": [5815, 5819], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Mexico", "location": [5808, 5814], "entities": [{"type": "GeopoliticalEntity", "text": "Mexico", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn's disease.", "score": 0.674828, "arguments": [{"text": "Crohn", "location": [265, 270], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [273, 280], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis disease"}]}]}, {"type": "hasAttribute", "sentence": "The Crohn's disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls.", "score": 0.861325, "arguments": [{"text": "Crohn", "location": [434, 439], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [442, 449], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis disease"}]}]}, {"type": "hasAttribute", "sentence": "The ulcerative colitis is more prevalent than that of Crohn's disease.", "score": 0.735465, "arguments": [{"text": "Crohn", "location": [631, 636], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [639, 646], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis disease"}]}]}, {"type": "hasAttribute", "sentence": "The high prevalence and increasing incidence of Crohn's disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs.", "score": 0.8893, "arguments": [{"text": "Crohn", "location": [1921, 1926], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [1929, 1936], "entities": [{"type": "HealthCondition", "text": "Ulcerative colitis disease"}]}]}, {"type": "residesIn", "sentence": "New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of Middle East and Africa", "score": 0.90296, "arguments": [{"text": "Rest", "location": [5815, 5819], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Latin America Middle East", "location": [5823, 5848], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America Middle East"}]}]}, {"type": "employedBy", "sentence": "Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.", "score": 0.503608, "arguments": [{"text": "inhibitors", "location": [1490, 1500], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "TNF", "location": [1486, 1489], "entities": [{"type": "Organization", "text": "TNF"}]}]}, {"type": "employedBy", "sentence": "By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids.", "score": 0.594025, "arguments": [{"text": "inhibitors", "location": [3085, 3095], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "TNF", "location": [3081, 3084], "entities": [{"type": "Organization", "text": "TNF"}]}]}, {"type": "employedBy", "sentence": "The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025.", "score": 0.413474, "arguments": [{"text": "inhibitors", "location": [3163, 3173], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "TNF", "location": [3159, 3162], "entities": [{"type": "Organization", "text": "TNF"}]}]}, {"type": "employedBy", "sentence": "The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets.", "score": 0.512588, "arguments": [{"text": "inhibitors", "location": [3337, 3347], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "TNF", "location": [3333, 3336], "entities": [{"type": "Organization", "text": "TNF"}]}]}, {"type": "locatedAt", "sentence": "By geography, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "score": 0.701766, "arguments": [{"text": "Asia", "location": [3899, 3903], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3904, 3911], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Get a free sample request @ https://www.xploremr.com/connectus/sample/258 Global Inflammatory Bowel Disease (IBD) Treatment Market: Competitive Outlook k The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market.", "score": 0.37554, "arguments": [{"text": "companies", "location": [4507, 4516], "entities": [{"type": "Organization", "text": "Biopharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "IBD", "location": [4327, 4330], "entities": [{"type": "Organization", "text": "Global Inflammatory Bowel Disease", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Get a free sample request @ https://www.xploremr.com/connectus/sample/258 Global Inflammatory Bowel Disease (IBD) Treatment Market: Competitive Outlook k The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market.", "score": 0.826613, "arguments": [{"text": "their", "location": [4530, 4535], "entities": [{"type": "Person", "text": "players"}]}, {"text": "bowel disease", "location": [4572, 4585], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.493097, "arguments": [{"text": "players", "location": [4821, 4828], "entities": [{"type": "Person", "text": "players"}]}, {"text": "bowel disease", "location": [4859, 4872], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "employedBy", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.674391, "arguments": [{"text": "Crohn", "location": [5424, 5429], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "Disease Indication\nUlcerative Colitis", "location": [5386, 5423], "entities": [{"type": "Organization", "text": "Disease Indication\nUlcerative Colitis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc. Global Inflammatory Bowel Disease Treatment Market is segmented as given below: Global Inflammatory Bowel Disease Treatment Market, by Drug Class TNF Inhibitors Aminosalicyclates Immunomodulators Corticosteroids Global Inflammatory Bowel Disease Treatment Market, by Disease Indication Ulcerative Colitis Crohn's Disease Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Global Inflammatory Bowel Disease Treatment Market, by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific China India Japan Australia &", "score": 0.54903, "arguments": [{"text": "Crohn", "location": [5424, 5429], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "Disease Global Inflammatory Bowel Disease Treatment Market", "location": [5432, 5490], "entities": [{"type": "Organization", "text": "Biogen Inc.\nGlobal Inflammatory Bowel Disease Treatment Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Global Inflammatory Bowel Disease", "sentiment": {"score": -0.974698, "label": "negative"}, "relevance": 0.805927, "count": 4}, {"text": "Treatment Market", "sentiment": {"score": -0.974698, "label": "negative"}, "relevance": 0.704705, "count": 4}, {"text": "Inflammatory bowel disease", "sentiment": {"score": -0.998522, "label": "negative"}, "relevance": 0.664337, "count": 1}, {"text": "Ulcerative colitis", "sentiment": {"score": -0.669683, "label": "negative"}, "relevance": 0.612336, "count": 1}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.669683, "label": "negative"}, "relevance": 0.611856, "count": 1}, {"text": "North America", "sentiment": {"score": -0.51464, "label": "negative"}, "relevance": 0.610576, "count": 3}, {"text": "IBD", "sentiment": {"score": -0.835716, "mixed": "1", "label": "negative"}, "relevance": 0.592516, "count": 9}, {"text": "biologic drugs", "sentiment": {"score": -0.940862, "label": "negative"}, "relevance": 0.585742, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.940862, "label": "negative"}, "relevance": 0.578473, "count": 1}, {"text": "combination of several factors", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.576019, "count": 1}, {"text": "global IBD treatment market", "sentiment": {"score": -0.975285, "label": "negative"}, "relevance": 0.569825, "count": 4}, {"text": "genetic factors", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.567597, "count": 1}, {"text": "TNF inhibitors", "sentiment": {"score": -0.659546, "mixed": "1", "label": "negative"}, "relevance": 0.561931, "count": 3}, {"text": "share of global IBD treatment market", "sentiment": {"score": -0.317951, "mixed": "1", "label": "negative"}, "relevance": 0.56019, "count": 2}, {"text": "Asia Pacific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558522, "count": 1}, {"text": "large intestine", "sentiment": {"score": -0.85163, "label": "negative"}, "relevance": 0.557129, "count": 1}, {"text": "competition matrix section", "sentiment": {"score": -0.945003, "label": "negative"}, "relevance": 0.557012, "count": 1}, {"text": "ulcerative colitis", "sentiment": {"score": -0.814989, "label": "negative"}, "relevance": 0.556895, "count": 3}, {"text": "Biopharmaceutical companies", "sentiment": {"score": 0.754172, "label": "positive"}, "relevance": 0.55387, "count": 1}, {"text": "market share", "sentiment": {"score": -0.805804, "label": "negative"}, "relevance": 0.550263, "count": 3}, {"text": "major players", "sentiment": {"score": 0.614506, "label": "positive"}, "relevance": 0.547799, "count": 1}, {"text": "autoimmune disorders", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.547604, "count": 1}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546708, "count": 1}, {"text": "exact cause of inflammatory bowel disease", "sentiment": {"score": -0.684639, "label": "negative"}, "relevance": 0.544996, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542885, "count": 1}, {"text": "Crohn\u2019s disease", "sentiment": {"score": -0.783968, "label": "negative"}, "relevance": 0.542336, "count": 3}, {"text": "development of symptoms of inflammatory bowel disease", "sentiment": {"score": -0.930045, "label": "negative"}, "relevance": 0.542061, "count": 1}, {"text": "Key Segments", "sentiment": {"score": -0.986817, "label": "negative"}, "relevance": 0.540787, "count": 1}, {"text": "significant investments", "sentiment": {"score": 0.754172, "label": "positive"}, "relevance": 0.539385, "count": 1}, {"text": "new product development", "sentiment": {"score": -0.962996, "label": "negative"}, "relevance": 0.539318, "count": 1}, {"text": "report", "sentiment": {"score": -0.945003, "label": "negative"}, "relevance": 0.537599, "count": 2}, {"text": "Europe", "sentiment": {"score": -0.51464, "label": "negative"}, "relevance": 0.537329, "count": 3}, {"text": "segments", "sentiment": {"score": -0.986817, "label": "negative"}, "relevance": 0.537311, "count": 1}, {"text": "high prevalence", "sentiment": {"score": -0.806244, "label": "negative"}, "relevance": 0.535853, "count": 1}, {"text": "gastrointestinal tract", "sentiment": {"score": -0.998522, "label": "negative"}, "relevance": 0.535258, "count": 1}, {"text": "large share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534337, "count": 1}, {"text": "Genetic factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533954, "count": 1}, {"text": "hospital pharmacy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532256, "count": 1}, {"text": "sedentary lifestyle", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.529896, "count": 1}, {"text": "SWOT analysis", "sentiment": {"score": 0.614506, "label": "positive"}, "relevance": 0.528892, "count": 1}, {"text": "Major players", "sentiment": {"score": -0.884906, "label": "negative"}, "relevance": 0.526291, "count": 1}, {"text": "players", "sentiment": {"score": -0.945003, "label": "negative"}, "relevance": 0.524594, "count": 1}, {"text": "antibiotic drugs", "sentiment": {"score": -0.940862, "label": "negative"}, "relevance": 0.522568, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522505, "count": 1}, {"text": "lifestyle", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.522305, "count": 1}, {"text": "chronic inflammation", "sentiment": {"score": -0.998522, "label": "negative"}, "relevance": 0.521618, "count": 1}, {"text": "related risks factors", "sentiment": {"score": -0.956398, "label": "negative"}, "relevance": 0.521412, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521316, "count": 2}, {"text": "approvals", "sentiment": {"score": -0.821512, "label": "negative"}, "relevance": 0.521147, "count": 2}, {"text": "Risk", "sentiment": {"score": -0.694436, "label": "negative"}, "relevance": 0.520606, "count": 1}]}, "extracted_metadata": {"sha1": "ab589d26eedd38c78b46050c952da1ff14e8ea54", "filename": "1543118195717.zip-5482cde346a824bc92b28b03473a3fe1.xml", "file_type": "json"}, "external_links": ["https://www.xploremr.com/report/258/inflammatory-bowel-disease-ibd-treatment-market", "https://www.xploremr.com/connectus/sample/258"], "title": "Inflammatory Bowel Disease (IBD) Treatment Market to Witness a Pronounce Growth During 2017 to 2025", "forum_title": "Research Insights | Find Market Research - Part 18"}, {"id": "b70s1arb32AYR8jC66Ibqs2wKavbUg_uKoG1HjPJMm7hXcsnu6tDNiSxTDEXp3zr", "result_metadata": {"score": 21.685184}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.585423, "label": "negative"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.585423, "label": "negative"}, "text": "Hanmi Pharmaceuticals Co Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.585423, "label": "negative"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9072, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.843585, "label": "/health and fitness/drugs"}, {"score": 0.813133, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.670957, "label": "/health and fitness/men's health"}], "relations": [], "keywords": [{"text": "Hanmi Pharmaceuticals Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997567, "count": 1}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.69853, "count": 1}, {"text": "Prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611781, "count": 1}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59269, "count": 1}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328596, "count": 1}]}, "crawl_date": "2018-11-25T14:15:52Z", "url": "https://www.bioportfolio.com/news/article/3826321/Hanmi-Pharmaceuticals-Co-Ltd-128940-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-Report.html", "host": "bioportfolio.com", "text": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:35 EST 25 Nov 2018 | BioPortfolio Report Blog Summary Hanmi Pharmaceuticals Co Ltd Hanmi Pharma,", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-25T12:35:00Z", "enriched_text": {"entities": [{"count": 30, "sentiment": {"score": 0.146098, "label": "positive"}, "text": "target Company", "relevance": 0.882425, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.475341, "label": "negative"}, "text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma", "relevance": 0.656107, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hanmi Pharmaceuticals Co Ltd", "relevance": 0.372089, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hanmi Science Co Ltd", "relevance": 0.297552, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.226432, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.222053, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.357081, "label": "positive"}, "text": "South Korea", "relevance": 0.215429, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "South Korea", "dbpedia_resource": "http://dbpedia.org/resource/South_Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Twitter", "relevance": 0.196048, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceutical and Healthcare News", "relevance": 0.179242, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.174334, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "developer", "relevance": 0.170402, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seoul", "relevance": 0.170227, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "OlympicHostCity", "City"], "name": "Seoul", "dbpedia_resource": "http://dbpedia.org/resource/Seoul"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alliances Profile", "relevance": 0.161382, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hwaseong", "relevance": 0.160475, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Hwaseong, Gyeonggi", "dbpedia_resource": "http://dbpedia.org/resource/Hwaseong,_Gyeonggi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.158091, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.156974, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.154224, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.150314, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.143006, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.139691, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Songpa", "relevance": 0.138105, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.138105, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 07", "relevance": 0.138105, "type": "Quantity"}], "sentiment": {"document": {"score": 0.704584, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd", "keywords": [{"text": "Hanmi Pharmaceuticals"}, {"text": "Hanmi Pharma"}, {"text": "Hanmi Science"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma"}, {"type": "Company", "text": "Hanmi Science Co Ltd"}]}, "sentence": " Hanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs.", "object": {"text": "a developer of prescription drugs and over the counter drugs", "keywords": [{"text": "prescription drugs"}, {"text": "counter drugs"}, {"text": "developer"}], "entities": [{"type": "JobTitle", "text": "developer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics", "keywords": [{"text": "liver supplements"}, {"text": "antibiotics"}, {"text": "osteoporosis"}, {"text": "antiemetics"}]}, "sentence": " The company's prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics.", "object": {"text": "The company's prescription drugs", "keywords": [{"text": "prescription drugs"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "It"}, "sentence": " It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others.", "object": {"text": "over the counter products such as vitamins, nutritional supplements and calcium supplement, among others", "keywords": [{"text": "calcium supplement"}, {"text": "nutritional supplements"}, {"text": "counter products"}, {"text": "vitamins"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Hanmi Pharma's products", "keywords": [{"text": "Hanmi Pharma"}, {"text": "products"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma"}]}, "sentence": " Hanmi Pharma's products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, antiinflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.", "object": {"text": "in the treatment of cancer, depression, dementia, dermatology, diabetes, antiinflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others", "keywords": [{"text": "osteoarthritis"}, {"text": "dementia"}, {"text": "dermatology"}, {"text": "osteoporosis"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "its manufacturing facilities", "keywords": [{"text": "manufacturing facilities"}]}, "sentence": " The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea.", "action": {"verb": {"text": "locate", "tense": "past"}, "text": "located", "normalized": "locate"}}, {"subject": {"text": "Hanmi Pharma", "keywords": [{"text": "Hanmi Pharma"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma"}]}, "sentence": " Hanmi Pharma is headquartered in Seoul, South Korea.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hanmi Pharma", "keywords": [{"text": "Hanmi Pharma"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals Co Ltd Hanmi Pharma"}]}, "sentence": " Hanmi Pharma is headquartered in Seoul, South Korea.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Hanmi Pharmaceuticals"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals Co Ltd"}, {"type": "Company", "text": "Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "target Company"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.968626, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Venture capital", "relevance": 0.904233, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Finance", "relevance": 0.869564, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Mergers and acquisitions", "relevance": 0.838032, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Over-the-counter drug", "relevance": 0.74019, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Corporate finance", "relevance": 0.722761, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Investment", "relevance": 0.697683, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Food and Drug Administration", "relevance": 0.683821, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Prescription drug", "relevance": 0.620234, "dbpedia_resource": "http://dbpedia.org/resource/Prescription_drug"}, {"text": "Corporation", "relevance": 0.618074, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}], "categories": [{"score": 0.953059, "label": "/finance/financial news"}, {"score": 0.891673, "label": "/business and industrial"}, {"score": 0.874322, "label": "/business and industrial/company"}], "relations": [{"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:35 EST 25 Nov 2018 | BioPortfolio Report Blog Summary Hanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs.", "score": 0.571995, "arguments": [{"text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals", "location": [97, 182], "entities": [{"type": "Organization", "text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals"}]}, {"text": "Report", "location": [206, 212], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2305, 2310], "entities": [{"type": "Organization", "text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals"}]}, {"text": "Region Chart", "location": [2314, 2326], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2466, 2470], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2471, 2478], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.656702, "arguments": [{"text": "Subsector Chart", "location": [2547, 2562], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2538, 2543], "entities": [{"type": "Organization", "text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2846, 2855], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2823, 2830], "entities": [{"type": "Organization", "text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [2992, 3002], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [3010, 3017], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [3115, 3127], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [3135, 3142], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [3178, 3189], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3197, 3204], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3357, 3360], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3379, 3386], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3453, 3456], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3460, 3467], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [4193, 4202], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [4150, 4157], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "subsidiaryOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:35 EST 25 Nov 2018 | BioPortfolio Report Blog Summary Hanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs.", "score": 0.513919, "arguments": [{"text": "subsidiary", "location": [355, 365], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Hanmi Science Co Ltd", "location": [369, 389], "entities": [{"type": "Organization", "text": "Hanmi Science Co Ltd"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4243, 4250], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "locations", "location": [4273, 4282], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "partOf", "sentence": "Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events.", "score": 0.396959, "arguments": [{"text": "company", "location": [4434, 4441], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Recent", "location": [4399, 4405], "entities": [{"type": "Organization", "text": "Recent"}]}]}, {"type": "ownerOf", "sentence": "The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea.", "score": 0.84261, "arguments": [{"text": "its", "location": [951, 954], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "facilities", "location": [969, 979], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea.", "score": 0.774216, "arguments": [{"text": "facilities", "location": [969, 979], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "Hwaseong", "location": [991, 999], "entities": [{"type": "GeopoliticalEntity", "text": "Hwaseong"}]}]}, {"type": "locatedAt", "sentence": "The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea.", "score": 0.993553, "arguments": [{"text": "Hwaseong", "location": [991, 999], "entities": [{"type": "GeopoliticalEntity", "text": "Hwaseong"}]}, {"text": "Songpa", "location": [1001, 1007], "entities": [{"type": "GeopoliticalEntity", "text": "Songpa"}]}]}, {"type": "basedIn", "sentence": "Hanmi Pharma is headquartered in Seoul, South Korea.", "score": 0.876905, "arguments": [{"text": "Hanmi Pharma", "location": [1038, 1050], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Seoul", "location": [1071, 1076], "entities": [{"type": "GeopoliticalEntity", "text": "Seoul"}]}]}, {"type": "locatedAt", "sentence": "Hanmi Pharma is headquartered in Seoul, South Korea.", "score": 0.985879, "arguments": [{"text": "Seoul", "location": [1071, 1076], "entities": [{"type": "GeopoliticalEntity", "text": "Seoul"}]}, {"text": "South Korea", "location": [1078, 1089], "entities": [{"type": "GeopoliticalEntity", "text": "South Korea", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "productOf", "sentence": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.86209, "arguments": [{"text": "Mergers", "location": [1250, 1257], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1240, 1247], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1867, 1874], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1831, 1838], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2130, 2140], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2121, 2126], "entities": [{"type": "Organization", "text": "BioPortfolio.com Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals"}]}]}], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.940748, "label": "positive"}, "relevance": 0.86951, "count": 2}, {"text": "com Hanmi Pharmaceuticals Co Ltd", "sentiment": {"score": 0.932027, "label": "positive"}, "relevance": 0.745993, "count": 1}, {"text": "company's prescription drugs", "sentiment": {"score": -0.305574, "label": "negative"}, "relevance": 0.734049, "count": 1}, {"text": "detailed information", "sentiment": {"score": 0.863035, "label": "positive"}, "relevance": 0.692429, "count": 3}, {"text": "company", "sentiment": {"score": 0.859752, "label": "positive"}, "relevance": 0.645632, "count": 12}, {"text": "key financial metrics", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.64151, "count": 1}, {"text": "number of deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.638948, "count": 5}, {"text": "Twitter Track topics", "sentiment": {"score": 0.932027, "label": "positive"}, "relevance": 0.617875, "count": 1}, {"text": "subsidiary of Hanmi Science Co Ltd", "sentiment": {"score": 0.932027, "label": "positive"}, "relevance": 0.61557, "count": 1}, {"text": "Alliances Profile", "sentiment": {"score": 0.940748, "label": "positive"}, "relevance": 0.612489, "count": 2}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604117, "count": 1}, {"text": "Financial Deals Analysis of the company", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.58588, "count": 1}, {"text": "Year Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584555, "count": 1}, {"text": "information", "sentiment": {"score": 0.738616, "label": "positive"}, "relevance": 0.582414, "count": 5}, {"text": "Report", "sentiment": {"score": 0.932027, "label": "positive"}, "relevance": 0.579433, "count": 1}, {"text": "report", "sentiment": {"score": 0.76333, "label": "positive"}, "relevance": 0.579433, "count": 3}, {"text": "Hanmi Pharma's products", "sentiment": {"score": -0.983381, "label": "negative"}, "relevance": 0.574967, "count": 1}, {"text": "Deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.56363, "count": 4}, {"text": "Key Recent Developments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560784, "count": 1}, {"text": "trend analysis of the company", "sentiment": {"score": 0.948968, "label": "positive"}, "relevance": 0.558181, "count": 1}, {"text": "profile presents deals", "sentiment": {"score": 0.886185, "label": "positive"}, "relevance": 0.557362, "count": 1}, {"text": "brief summary", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.556366, "count": 1}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555877, "count": 1}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551238, "count": 1}, {"text": "profile", "sentiment": {"score": 0.891799, "label": "positive"}, "relevance": 0.549763, "count": 4}, {"text": "year period", "sentiment": {"score": 0.830976, "label": "positive"}, "relevance": 0.545282, "count": 3}, {"text": "Subsidiaries", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.542231, "count": 1}, {"text": "Important Locations", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.54179, "count": 1}, {"text": "Hanmi Pharmaceuticals Co Ltd", "sentiment": {"score": 0.948968, "label": "positive"}, "relevance": 0.538897, "count": 1}, {"text": "table", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.537961, "count": 4}, {"text": "important events", "sentiment": {"score": 0.814713, "label": "positive"}, "relevance": 0.537842, "count": 1}, {"text": "value", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.537526, "count": 5}, {"text": "list of the key executives of the company", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.537435, "count": 1}, {"text": "financial deals", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.537194, "count": 1}, {"text": "Business Description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53441, "count": 1}, {"text": "major developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.533151, "count": 1}, {"text": "North America", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.531474, "count": 1}, {"text": "Detailed information", "sentiment": {"score": 0.972161, "label": "positive"}, "relevance": 0.529649, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52868, "count": 1}, {"text": "Private Equity", "sentiment": {"score": 0.766574, "label": "positive"}, "relevance": 0.527924, "count": 2}, {"text": "type", "sentiment": {"score": 0.959659, "label": "positive"}, "relevance": 0.527439, "count": 2}, {"text": "such deal", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.52703, "count": 1}, {"text": "Hanmi Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526359, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.52613, "count": 1}, {"text": "manufacturing facilities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5261, "count": 1}, {"text": "Recent developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.525426, "count": 1}, {"text": "list", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.523787, "count": 1}, {"text": "locations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523774, "count": 1}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522702, "count": 1}, {"text": "contact details of key centers of operation", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.522455, "count": 1}]}, "extracted_metadata": {"sha1": "1c74b80317b68946ae6d902b13441556721f85d7", "filename": "1543155352655.zip-1ec87f5402f31350cfcd631bcb07fed5.xml", "file_type": "json"}, "title": "Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 09112018 Prices from USD $250", "forum_title": "BioPortfolio Latest News"}, {"id": "8fazD0JvdMwgs9gZYKdbDZvTaIYS98iQbk-Md6bWv425bmejE5VHzSfWjxAdwcTa", "result_metadata": {"score": 21.595747}, "author": "Biotech365", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Pharmacology", "relevance": 0.91122, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Clinical trial", "relevance": 0.87576, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "ClinicalTrials.gov", "relevance": 0.863037, "dbpedia_resource": "http://dbpedia.org/resource/ClinicalTrials.gov"}], "categories": [{"score": 0.686606, "label": "/health and fitness/disease/cancer"}, {"score": 0.67464, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.630039, "label": "/real estate/buying and selling homes"}], "relations": [], "keywords": [{"text": "Release Drug Delivery Market Opportunity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.966714, "count": 1}, {"text": "com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605763, "count": 1}, {"text": "Clinical Trial Outlook", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592024, "count": 1}, {"text": "ResearchAndMarkets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.138846, "count": 1}]}, "crawl_date": "2018-11-24T17:19:11Z", "url": "http://biotech-365.com/global-controlled-release-drug-delivery-market-opportunity-clinical-trial-outlook-2025-researchandmarkets-com/", "host": "biotech-365.com", "text": "Pharmaceuticals International Takeda Zealand Pharma For more information about this report visit https://www.researchandmarkets.com/research/x5dmrt/global?", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T18:04:00+01:00", "enriched_text": {"entities": [{"count": 11, "sentiment": {"score": -0.200633, "label": "negative"}, "text": "Controlled Drug Delivery", "relevance": 0.936968, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.299392, "label": "negative"}, "text": "Controlled Drug Delivery Technology Approaches for Controlled Drug Delivery Global Controlled Release Drug Clinical Pipeline", "relevance": 0.916624, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": -0.393872, "label": "negative"}, "text": "Controlled Delivery", "relevance": 0.365203, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.324828, "label": "negative"}, "text": "Global Controlled Drug Delivery Market Dynamics", "relevance": 0.364583, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.575938, "label": "negative"}, "text": "Global Controlled Drug Delivery Clinical Trials", "relevance": 0.364124, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Development of Controlled Drug Delivery Technology", "relevance": 0.348984, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cataloging of Controlled Drug Delivery", "relevance": 0.342203, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Controlled Release Drug Clinical Pipeline Overview", "relevance": 0.308903, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharma Biogen Collegium Pharmaceutical Controlled Therapeutics", "relevance": 0.173936, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Drug Clinical Insight", "relevance": 0.168038, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Heron Therapeutics iCeutica Mithra Pharmaceuticals Neurim Pharmaceuticals Novartis Orexigen Therapeutics Otsuka Pharmaceutical Pfizer Purdue Pharma Syntex Pharmaceuticals International Takeda Zealand Pharma", "relevance": 0.129338, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Trial", "relevance": 0.0959124, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.436655, "label": "negative"}, "text": "Ongoing Clinical Trials", "relevance": 0.0881795, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Amylin Pharmaceuticals AstraZeneca", "relevance": 0.0791372, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Enteral Dosage Formulations", "relevance": 0.0770237, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.47322, "label": "negative"}, "text": "Ferring Pharmaceuticals", "relevance": 0.0741489, "type": "Company", "disambiguation": {"subtype": [], "name": "Ferring Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Ferring_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Competitive Landscape", "relevance": 0.0678368, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cosmo Pharmaceuticals Egalet Elan Corporation Flamel Technologies", "relevance": 0.0671178, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laura Wood", "relevance": 0.0664421, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Press Manager", "relevance": 0.0610044, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "press@researchandmarkets.com", "relevance": 0.0610044, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.2 Second", "relevance": 0.0610044, "type": "Quantity"}], "sentiment": {"document": {"score": 0.532173, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Outlook 2025\u201d report", "keywords": [{"text": "Outlook"}, {"text": "report"}]}, "sentence": " Outlook 2025\u201d report has been added to ResearchAndMarkets.com\u2019s", "object": {"text": "added to ResearchAndMarkets.com\u2019s", "keywords": [{"text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Outlook 2025\u201d report", "keywords": [{"text": "Outlook"}, {"text": "report"}]}, "sentence": " Outlook 2025\u201d report has been added to ResearchAndMarkets.com\u2019s", "object": {"text": "to ResearchAndMarkets.com\u2019s", "keywords": [{"text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "This report on the \u201cControlled Release Drug Delivery Market\u201d", "keywords": [{"text": "Controlled Release Drug"}, {"text": "Delivery Market"}, {"text": "report"}]}, "sentence": " This report on the \u201cControlled Release Drug Delivery Market\u201d is a result", "object": {"text": "a result", "keywords": [{"text": "result"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also provides key insights into the", "object": {"text": "key insights", "keywords": [{"text": "key insights"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "technology and approaches of controlled", "keywords": [{"text": "approaches"}, {"text": "technology"}]}, "sentence": " technology and approaches of controlled delivered drugs, recent", "object": {"text": "drugs", "keywords": [{"text": "drugs"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "developments and market dynamics", "keywords": [{"text": "market dynamics"}, {"text": "developments"}]}, "sentence": " developments and market dynamics that might impact its future.", "object": {"text": "its future", "keywords": [{"text": "future"}]}, "action": {"verb": {"text": "impact", "tense": "present"}, "text": "might impact", "normalized": "might impact"}}, {"subject": {"text": "report", "keywords": [{"text": "report"}]}, "sentence": " report concludes with comprehensive insight on ongoing clinical trials", "object": {"text": "with comprehensive insight on ongoing clinical trials", "keywords": [{"text": "ongoing clinical trials"}, {"text": "comprehensive insight"}]}, "action": {"verb": {"text": "conclude", "tense": "present"}, "text": "concludes", "normalized": "conclude"}}, {"subject": {"text": "Controlled drug delivery technology", "keywords": [{"text": "drug delivery technology"}]}, "sentence": " Controlled drug delivery technology is the one of the most rapidly", "object": {"text": "the one of the most rapidly"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "desired drug concentration", "keywords": [{"text": "drug concentration"}]}, "sentence": " desired drug concentration can be achieved promptly and then maintained,", "object": {"text": "achieved"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "desired drug concentration", "keywords": [{"text": "drug concentration"}]}, "sentence": " desired drug concentration can be achieved promptly and then maintained,", "action": {"verb": {"text": "maintain", "tense": "past"}, "text": "maintained", "normalized": "maintain"}}, {"subject": {"text": "all these characteristics", "keywords": [{"text": "characteristics"}]}, "sentence": " all these characteristics are provided by controlled drug delivery", "object": {"text": "provided by controlled drug delivery", "keywords": [{"text": "drug delivery"}], "entities": [{"type": "JobTitle", "text": "Controlled Drug Delivery"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by controlled drug delivery", "keywords": [{"text": "drug delivery"}], "entities": [{"type": "JobTitle", "text": "Controlled Drug Delivery"}]}, "sentence": " all these characteristics are provided by controlled drug delivery", "object": {"text": "all these characteristics", "keywords": [{"text": "characteristics"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "Controlled drug delivery systems", "keywords": [{"text": "drug delivery systems"}], "entities": []}, "sentence": " Controlled drug delivery systems provide uniform concentration of drug", "object": {"text": "uniform concentration of drug", "keywords": [{"text": "uniform concentration"}, {"text": "drug"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "controlled release", "keywords": [{"text": "release"}]}, "sentence": " controlled release has a meaning that goes beyond the scope of sustained", "object": {"text": "a meaning that goes beyond the scope of sustained", "keywords": [{"text": "meaning"}, {"text": "scope"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "controlled drug delivery market", "keywords": [{"text": "drug delivery market"}]}, "sentence": " controlled drug delivery market is the improvement and advances in the", "object": {"text": "the improvement", "keywords": [{"text": "improvement"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Polymeric controlled drug delivery", "keywords": [{"text": "Polymeric"}, {"text": "drug delivery"}], "entities": [{"type": "JobTitle", "text": "Controlled Drug Delivery"}]}, "sentence": " Polymeric controlled drug delivery is the most", "object": {"text": "the most"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "strategy", "keywords": [{"text": "strategy"}]}, "sentence": " applied strategy towards the controlled drug delivery.", "object": {"text": "towards the controlled drug delivery", "keywords": [{"text": "drug delivery"}], "entities": [{"type": "JobTitle", "text": "Controlled Drug Delivery"}]}, "action": {"verb": {"text": "apply", "tense": "past"}, "text": "applied", "normalized": "apply"}}, {"subject": {"text": "coating and in other forms", "keywords": [{"text": "coating"}, {"text": "forms"}]}, "sentence": " coating and in other forms consist of two forms synthetic and", "object": {"text": "of two forms synthetic", "keywords": [{"text": "forms"}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consist", "normalized": "consist"}}, {"subject": {"text": "medical devices", "keywords": [{"text": "medical devices"}]}, "sentence": " medical devices is expected to push the global biodegradable polymers", "object": {"text": "expected to push the global biodegradable polymers", "keywords": [{"text": "global biodegradable polymers"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "medical devices", "keywords": [{"text": "medical devices"}]}, "sentence": " medical devices is expected to push the global biodegradable polymers", "object": {"text": "the global biodegradable polymers", "keywords": [{"text": "global biodegradable polymers"}]}, "action": {"verb": {"text": "push", "tense": "future"}, "text": "is expected to push", "normalized": "be expect to push"}}, {"subject": {"text": "The future of controlled drug delivery", "keywords": [{"text": "drug delivery"}, {"text": "future"}], "entities": [{"type": "JobTitle", "text": "Controlled Drug Delivery"}]}, "sentence": " The future of controlled drug delivery is quite fertile with respect to", "object": {"text": "quite fertile"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "some"}, "sentence": " and some will be coming soon as are under clinical investigations.", "object": {"text": "coming"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "some"}, "sentence": " and some will be coming soon as are under clinical investigations.", "action": {"verb": {"text": "come", "tense": "future"}, "text": "will be coming", "normalized": "will be come"}}, {"subject": {"text": "some"}, "sentence": " and some will be coming soon as are under clinical investigations.", "object": {"text": "under clinical investigations", "keywords": [{"text": "clinical investigations"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Various depot systems", "keywords": [{"text": "Various depot systems"}]}, "sentence": " Various depot systems are under construction, along with the approaches", "object": {"text": "under construction", "keywords": [{"text": "construction"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "218 Drugs", "keywords": [{"text": "Drugs"}]}, "sentence": " Drug Class Global Controlled Release Drug Clinical Pipeline: 218 Drugs Marketed Controlled Release Drugs: 118 Drugs Majority Drugs In Phase-II & Phase-III Trials: More Than 80 Global Controlled Drug Delivery Market Future Outlook Key Topics Covered:", "object": {"text": "Controlled Release Drugs", "keywords": [{"text": "Release Drugs"}]}, "action": {"verb": {"text": "Marketed", "tense": "past"}, "text": "Marketed", "normalized": "Marketed"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.979543, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Route of administration", "relevance": 0.596975, "dbpedia_resource": "http://dbpedia.org/resource/Route_of_administration"}, {"text": "Dosage form", "relevance": 0.481021, "dbpedia_resource": "http://dbpedia.org/resource/Dosage_form"}, {"text": "Drug delivery", "relevance": 0.454328, "dbpedia_resource": "http://dbpedia.org/resource/Drug_delivery"}, {"text": "Transdermal patch", "relevance": 0.450946, "dbpedia_resource": "http://dbpedia.org/resource/Transdermal_patch"}, {"text": "Drugs", "relevance": 0.396013, "dbpedia_resource": "http://dbpedia.org/resource/Drugs"}, {"text": "Pharmaceutical drug", "relevance": 0.359403, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Clinical trial", "relevance": 0.354863, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "The Canon of Medicine", "relevance": 0.328282, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Drug", "relevance": 0.320808, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Injection", "relevance": 0.318262, "dbpedia_resource": "http://dbpedia.org/resource/Injection_(medicine)"}, {"text": "Food and Drug Administration", "relevance": 0.310905, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Pharmaceutical industry", "relevance": 0.303506, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Informed consent", "relevance": 0.300137, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}, {"text": "Medicine", "relevance": 0.299309, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.943001, "label": "/health and fitness"}, {"score": 0.855088, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.767761, "label": "/health and fitness/therapy"}], "relations": [{"type": "partOf", "sentence": "DUBLIN-(BUSINESS WIRE)-The \"Global Controlled-Release Drug Delivery Market - Opportunity & Clinical Trial Outlook 2025\" report has been added to ResearchAndMarkets.com's offering.", "score": 0.498559, "arguments": [{"text": "Opportunity & Clinical Trial\nOutlook", "location": [77, 113], "entities": [{"type": "Organization", "text": "Opportunity & Clinical Trial\nOutlook", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Release Drug Delivery Market", "location": [46, 74], "entities": [{"type": "Organization", "text": "Release Drug Delivery Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Application of Controlled Drug Delivery 9.1 Diabetes 9.2 Cancer 9.3 Cardiovascular Diseases 9.4 Neurological Disorders 9.5 Infections 10.", "score": 0.442887, "arguments": [{"text": "Delivery", "location": [4350, 4358], "entities": [{"type": "Person", "text": "Delivery\n3"}]}, {"text": "Diabetes", "location": [4363, 4371], "entities": [{"type": "HealthCondition", "text": "Diabetes"}]}]}, {"type": "hasAttribute", "sentence": "Application of Controlled Drug Delivery 9.1 Diabetes 9.2 Cancer 9.3 Cardiovascular Diseases 9.4 Neurological Disorders 9.5 Infections 10.", "score": 0.434656, "arguments": [{"text": "Neurological Disorders", "location": [4415, 4437], "entities": [{"type": "Person", "text": "Neurological Disorders"}]}, {"text": "Cancer", "location": [4376, 4382], "entities": [{"type": "HealthCondition", "text": "Cancer"}]}]}, {"type": "employedBy", "sentence": "Application of Controlled Drug Delivery 9.1 Diabetes 9.2 Cancer 9.3 Cardiovascular Diseases 9.4 Neurological Disorders 9.5 Infections 10.", "score": 0.377127, "arguments": [{"text": "Neurological Disorders", "location": [4415, 4437], "entities": [{"type": "Person", "text": "Neurological Disorders"}]}, {"text": "Cardiovascular Diseases", "location": [4387, 4410], "entities": [{"type": "Organization", "text": "Cardiovascular Diseases"}]}]}, {"type": "hasAttribute", "sentence": "Application of Controlled Drug Delivery 9.1 Diabetes 9.2 Cancer 9.3 Cardiovascular Diseases 9.4 Neurological Disorders 9.5 Infections 10.", "score": 0.616931, "arguments": [{"text": "Neurological Disorders", "location": [4415, 4437], "entities": [{"type": "Person", "text": "Neurological Disorders"}]}, {"text": "Infections", "location": [4442, 4452], "entities": [{"type": "HealthCondition", "text": "Infections"}]}]}, {"type": "employedBy", "sentence": "Drug Designing for Controlled Delivery 10.1 Enteral Dosage Formulations 10.1.1 Solid Dosage Forms 10.1.2 Liquid Dosage Forms 10.1.3 Inhalation Dosage Forms 10.2 Parenteral Dosage Forms 10.2.1 Injectable Dosage Forms 10.2.2 Implantable Device 10.3 General Mechanisms of Drug Release 11.", "score": 0.526831, "arguments": [{"text": "General Mechanisms", "location": [4704, 4722], "entities": [{"type": "Person", "text": "Injectable Dosage Forms"}]}, {"text": "Drug Release", "location": [4726, 4738], "entities": [{"type": "Organization", "text": "Controlled Drug Release"}]}]}, {"type": "locatedAt", "sentence": "Market Inclinations 11.1 Market over Routes of Administration 11.2 Market over Approaches 12.", "score": 0.656449, "arguments": [{"text": "Routes", "location": [4780, 4786], "entities": [{"type": "Facility", "text": "Routes\n7"}]}, {"text": "Market", "location": [4810, 4816], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "populationOf", "sentence": "Market Inclinations 11.1 Market over Routes of Administration 11.2 Market over Approaches 12.", "score": 0.253928, "arguments": [{"text": "11.2", "location": [4805, 4809], "entities": [{"type": "Cardinal", "text": "11.2"}]}, {"text": "Administration", "location": [4790, 4804], "entities": [{"type": "GeopoliticalEntity", "text": "Accelerative Parameters"}]}]}, {"type": "partOf", "sentence": "Global Controlled Drug Delivery Market Future Outlook 13.1 Ongoing Clinical Trials 13.2 Future Market Opportunities 14.", "score": 0.456095, "arguments": [{"text": "Future Market Opportunities", "location": [5022, 5049], "entities": [{"type": "Organization", "text": "Future Market Opportunities", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Clinical Trials", "location": [5001, 5016], "entities": [{"type": "Organization", "text": "Global Controlled Drug Delivery Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase 14.1 Unknown 14.2 Research 14.3 Preclinical 14.4 Clinical 14.5 Phase-I 14.6 Phase-I/II 14.7 Phase-II 14.8 Phase-II/III 14.9 Phase-III 14.10 Preregistration 14.11 Registered 15.", "score": 0.617291, "arguments": [{"text": "Company", "location": [5105, 5112], "entities": [{"type": "Organization", "text": "approaches"}]}, {"text": "Global Controlled Drug Delivery Clinical Trials", "location": [5054, 5101], "entities": [{"type": "Organization", "text": "Global Controlled Drug Delivery Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Marketed Controlled Release Drug Clinical Insight by Company, Indication and Phase 16.", "score": 0.798694, "arguments": [{"text": "Company", "location": [5365, 5372], "entities": [{"type": "Organization", "text": "approaches"}]}, {"text": "Marketed Controlled Release Drug Clinical Insight", "location": [5312, 5361], "entities": [{"type": "Organization", "text": "Marketed Controlled Release Drug Clinical Insight"}]}]}, {"type": "employedBy", "sentence": "Basics of Controlled Drug Delivery 4.1 Prerequisites of Controlled Delivery 4.2 Rationale for Controlled Drug Delivery 5.", "score": 0.403695, "arguments": [{"text": "Prerequisites", "location": [3608, 3621], "entities": [{"type": "Person", "text": "Prerequisites"}]}, {"text": "Controlled Delivery", "location": [3625, 3644], "entities": [{"type": "Organization", "text": "Controlled Delivery"}]}]}, {"type": "employedBy", "sentence": "Competitive Landscape Allergan Amylin Pharmaceuticals AstraZeneca BioAlliance Pharma Biogen Collegium Pharmaceutical Controlled Therapeutics (Ferring Pharmaceuticals) Cosmo Pharmaceuticals Egalet Elan Corporation Flamel Technologies GlaxoSmithKline Heron Therapeutics iCeutica Mithra Pharmaceuticals Neurim Pharmaceuticals Novartis Orexigen Therapeutics Otsuka Pharmaceutical Pfizer Purdue Pharma Syntex Pharmaceuticals International Takeda Zealand Pharma For more information about this report visit https://www.researchandmarkets.com/research/x5dmrt/global?w=4 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Delivery , Clinical Trials", "score": 0.574336, "arguments": [{"text": "ResearchAndMarkets.com\nLaura Wood", "location": [5971, 6004], "entities": [{"type": "Person", "text": "ResearchAndMarkets.com\nLaura Wood"}]}, {"text": "Contacts", "location": [5962, 5970], "entities": [{"type": "Organization", "text": "Contacts", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Competitive Landscape Allergan Amylin Pharmaceuticals AstraZeneca BioAlliance Pharma Biogen Collegium Pharmaceutical Controlled Therapeutics (Ferring Pharmaceuticals) Cosmo Pharmaceuticals Egalet Elan Corporation Flamel Technologies GlaxoSmithKline Heron Therapeutics iCeutica Mithra Pharmaceuticals Neurim Pharmaceuticals Novartis Orexigen Therapeutics Otsuka Pharmaceutical Pfizer Purdue Pharma Syntex Pharmaceuticals International Takeda Zealand Pharma For more information about this report visit https://www.researchandmarkets.com/research/x5dmrt/global?w=4 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Delivery , Clinical Trials", "score": 0.486438, "arguments": [{"text": "Delivery", "location": [6205, 6213], "entities": [{"type": "Person", "text": "Delivery\n3"}]}, {"text": "Clinical\nTrials", "location": [6216, 6231], "entities": [{"type": "Organization", "text": "Clinical\nTrials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Mechanism of Controlled Drug Release 5.1 Diffusion Controlled 5.2 Dissolution Controlled System 5.3 Water Penetration Controlled System 5.4 Erosion Controlled System 5.5 Ion-Exchange Controlled System 6.", "score": 0.761916, "arguments": [{"text": "Diffusion Controlled", "location": [3732, 3752], "entities": [{"type": "Organization", "text": "Diffusion Controlled"}]}, {"text": "5.2", "location": [3753, 3756], "entities": [{"type": "Money", "text": "5.2", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "Cataloging of Controlled Drug Delivery 6.1 Classification Based Over Delivery Systems 6.2 Classification Based Over Technicality 6.3 Classification Based Over Routes 7.", "score": 0.460916, "arguments": [{"text": "Classification", "location": [3985, 3999], "entities": [{"type": "Person", "text": "Classification"}]}, {"text": "Routes\n7", "location": [4054, 4062], "entities": [{"type": "Facility", "text": "Routes\n7"}]}]}, {"type": "locatedAt", "sentence": "Cataloging of Controlled Drug Delivery 6.1 Classification Based Over Delivery Systems 6.2 Classification Based Over Technicality 6.3 Classification Based Over Routes 7.", "score": 0.328828, "arguments": [{"text": "Classification", "location": [4028, 4042], "entities": [{"type": "Person", "text": "Classification"}]}, {"text": "Routes\n7", "location": [4054, 4062], "entities": [{"type": "Facility", "text": "Routes\n7"}]}]}, {"type": "hasAttribute", "sentence": "Cataloging of Controlled Drug Delivery 6.1 Classification Based Over Delivery Systems 6.2 Classification Based Over Technicality 6.3 Classification Based Over Routes 7.", "score": 0.735371, "arguments": [{"text": "Technicality", "location": [4011, 4023], "entities": [{"type": "Organization", "text": "Technicality"}]}, {"text": "6.3", "location": [4024, 4027], "entities": [{"type": "Money", "text": "6.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "Cataloging of Controlled Drug Delivery 6.1 Classification Based Over Delivery Systems 6.2 Classification Based Over Technicality 6.3 Classification Based Over Routes 7.", "score": 0.601385, "arguments": [{"text": "Technicality", "location": [4011, 4023], "entities": [{"type": "Organization", "text": "Technicality"}]}, {"text": "Routes\n7", "location": [4054, 4062], "entities": [{"type": "Facility", "text": "Routes\n7"}]}]}, {"type": "locatedAt", "sentence": "Approaches for Controlled Drug Delivery 7.1 Polymers 7.2 Chronopharmaceutics 7.3 Nanoparticulate Delivery System 8.", "score": 0.741911, "arguments": [{"text": "Delivery", "location": [4095, 4103], "entities": [{"type": "Person", "text": "Delivery\n3"}]}, {"text": "Polymers", "location": [4108, 4116], "entities": [{"type": "Facility", "text": "Polymers"}]}]}, {"type": "hasAttribute", "sentence": "Global Controlled Release Drug Clinical Pipeline Overview 8.1 Phase 8.2 Country/Region 8.3 Mode of Action 8.4 Drug class 8.5 Indication 9.", "score": 0.510465, "arguments": [{"text": "Global Controlled Release Drug Clinical Pipeline Overview", "location": [4180, 4237], "entities": [{"type": "Organization", "text": "Global Controlled Release Drug Clinical Pipeline Overview", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "8.3", "location": [4267, 4270], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Global Controlled Release Drug Clinical Pipeline Overview 8.1 Phase 8.2 Country/Region 8.3 Mode of Action 8.4 Drug class 8.5 Indication 9.", "score": 0.791537, "arguments": [{"text": "Mode of Action", "location": [4271, 4285], "entities": [{"type": "Organization", "text": "Mode of Action"}]}, {"text": "8.3", "location": [4267, 4270], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Release Drug Delivery Market", "sentiment": {"score": 0.299127, "mixed": "1", "label": "positive"}, "relevance": 0.830981, "count": 2}, {"text": "superiority of Controlled Drug Delivery methods", "sentiment": {"score": 0.262128, "label": "positive"}, "relevance": 0.790579, "count": 1}, {"text": "Pharmaceuticals", "sentiment": {"score": -0.366156, "label": "negative"}, "relevance": 0.642105, "count": 1}, {"text": "Controlled Therapeutics", "sentiment": {"score": -0.366156, "label": "negative"}, "relevance": 0.59122, "count": 1}, {"text": "drugs", "sentiment": {"score": 0.83199, "label": "positive"}, "relevance": 0.588687, "count": 2}, {"text": "enormous impact", "sentiment": {"score": 0.973185, "label": "positive"}, "relevance": 0.565533, "count": 1}, {"text": "medical technology", "sentiment": {"score": 0.973185, "label": "positive"}, "relevance": 0.563552, "count": 1}, {"text": "goal of any drug delivery system", "sentiment": {"score": 0.941261, "label": "positive"}, "relevance": 0.563124, "count": 1}, {"text": "ongoing clinical trials", "sentiment": {"score": 0.868855, "label": "positive"}, "relevance": 0.558216, "count": 1}, {"text": "drug delivery technology", "sentiment": {"score": 0.973185, "label": "positive"}, "relevance": 0.555827, "count": 1}, {"text": "report", "sentiment": {"score": 0.542948, "mixed": "1", "label": "positive"}, "relevance": 0.55185, "count": 5}, {"text": "drug concentration", "sentiment": {"score": 0.941261, "label": "positive"}, "relevance": 0.55069, "count": 1}, {"text": "medical devices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547769, "count": 1}, {"text": "major factors", "sentiment": {"score": 0.632295, "label": "positive"}, "relevance": 0.543568, "count": 1}, {"text": "therapeutic amount of drug", "sentiment": {"score": 0.941261, "label": "positive"}, "relevance": 0.542333, "count": 1}, {"text": "technology", "sentiment": {"score": 0.791013, "label": "positive"}, "relevance": 0.540387, "count": 1}, {"text": "various upcoming systems", "sentiment": {"score": 0.874914, "label": "positive"}, "relevance": 0.538771, "count": 1}, {"text": "transdermal patches", "sentiment": {"score": 0.765676, "label": "positive"}, "relevance": 0.538523, "count": 1}, {"text": "future market potential", "sentiment": {"score": -0.529455, "label": "negative"}, "relevance": 0.537952, "count": 1}, {"text": "biodegradable polymers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536246, "count": 1}, {"text": "intensive study of the novel segment", "sentiment": {"score": -0.529455, "label": "negative"}, "relevance": 0.533638, "count": 1}, {"text": "drug delivery", "sentiment": {"score": 0.874914, "label": "positive"}, "relevance": 0.533569, "count": 3}, {"text": "release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529938, "count": 1}, {"text": "drug delivery systems", "sentiment": {"score": 0.687215, "label": "positive"}, "relevance": 0.52823, "count": 2}, {"text": "advances", "sentiment": {"score": 0.632295, "label": "positive"}, "relevance": 0.526416, "count": 1}, {"text": "Phase", "sentiment": {"score": -0.612306, "label": "negative"}, "relevance": 0.526175, "count": 6}, {"text": "Polymers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525262, "count": 2}, {"text": "Development of Controlled Drug Delivery Technology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525193, "count": 1}, {"text": "uniform concentration of drug", "sentiment": {"score": 0.597127, "label": "positive"}, "relevance": 0.523954, "count": 1}, {"text": "E.S.T Office Hours", "sentiment": {"score": -0.510448, "label": "negative"}, "relevance": 0.523609, "count": 1}, {"text": "approaches", "sentiment": {"score": 0.791013, "label": "positive"}, "relevance": 0.523126, "count": 3}, {"text": "clinical trials", "sentiment": {"score": -0.884261, "label": "negative"}, "relevance": 0.521727, "count": 1}, {"text": "Controlled Drug Delivery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521371, "count": 4}, {"text": "Neurological Disorders", "sentiment": {"score": 0.962653, "label": "positive"}, "relevance": 0.520889, "count": 1}, {"text": "market", "sentiment": {"score": 0.868855, "label": "positive"}, "relevance": 0.520272, "count": 1}, {"text": "Global", "sentiment": {"score": 0.713993, "label": "positive"}, "relevance": 0.519785, "count": 1}, {"text": "DUBLIN", "sentiment": {"score": 0.713993, "label": "positive"}, "relevance": 0.519426, "count": 1}, {"text": "Classification", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518741, "count": 3}, {"text": "Cardiovascular Diseases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517295, "count": 1}, {"text": "extensive usage of biodegradable polymers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517046, "count": 1}, {"text": "Drug Delivery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516803, "count": 3}, {"text": "information", "sentiment": {"score": -0.366156, "label": "negative"}, "relevance": 0.516148, "count": 1}, {"text": "deliveries", "sentiment": {"score": 0.765676, "label": "positive"}, "relevance": 0.515835, "count": 1}, {"text": "Ion-Exchange Controlled System", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515601, "count": 1}, {"text": "Drugs", "sentiment": {"score": -0.884261, "label": "negative"}, "relevance": 0.515584, "count": 1}, {"text": "Basics of Controlled Drug Delivery", "sentiment": {"score": -0.500917, "label": "negative"}, "relevance": 0.515168, "count": 1}, {"text": "Second Generation", "sentiment": {"score": -0.500917, "label": "negative"}, "relevance": 0.515005, "count": 1}, {"text": "area", "sentiment": {"score": 0.973185, "label": "positive"}, "relevance": 0.514587, "count": 1}, {"text": "Mechanism", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512637, "count": 1}, {"text": "Ongoing Clinical Trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512466, "count": 1}]}, "extracted_metadata": {"sha1": "3978cea3bd512937daf211deb48fd4660194eb18", "filename": "1543079951919.zip-cb58770841231bd5475c5aadfea0ce73.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/categories.asp?cat_id=421&#038;campaign_id=x5dmrt", "https://www.researchandmarkets.com/research/x5dmrt/global?w=4", "https://www.researchandmarkets.com/categories.asp?cat_id=72&#038;campaign_id=x5dmrt"], "title": "Global Controlled-Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025 ResearchAndMarkets.com", "forum_title": "Biotech 365"}, {"id": "5wkvonDWNxlEJGoqwpE6rJg8xRmWxYzFj8ZSC9F7kFUFZE4GrUuE-DrBmybABEyj", "result_metadata": {"score": 21.470564}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zhejiang Jolly Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.717186, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9477, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical drug", "relevance": 0.6942, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}], "categories": [{"score": 0.943912, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.881065, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Zhejiang Jolly Pharmaceutical Co Ltd", "sentiment": {"score": 0.717186, "label": "positive"}, "relevance": 0.996548, "count": 1}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.717186, "label": "positive"}, "relevance": 0.614705, "count": 1}, {"text": "Prices", "sentiment": {"score": 0.717186, "label": "positive"}, "relevance": 0.605909, "count": 1}, {"text": "USD", "sentiment": {"score": 0.717186, "label": "positive"}, "relevance": 0.587772, "count": 1}, {"text": "Alliances Profile Report", "sentiment": {"score": 0.717186, "label": "positive"}, "relevance": 0.363939, "count": 1}]}, "crawl_date": "2018-11-24T19:10:04Z", "url": "https://www.bioportfolio.com/news/article/3826172/Zhejiang-Jolly-Pharmaceutical-Co-Ltd-300181-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile.html", "host": "bioportfolio.com", "text": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250 12:08 EST 24 Nov 2018 | BioPortfolio Report Blog Summary Zhejiang Jolly Pharmaceutical Co Ltd", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-24T17:08:00Z", "enriched_text": {"entities": [{"count": 31, "sentiment": {"score": 0.227503, "label": "positive"}, "text": "target Company", "relevance": 0.882293, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.471696, "label": "negative"}, "text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma", "relevance": 0.653648, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.433662, "label": "positive"}, "text": "Zhejiang Jolly Pharmaceutical Co Ltd", "relevance": 0.354285, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.219164, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.400631, "label": "positive"}, "text": "Twitter", "relevance": 0.195592, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 2, "sentiment": {"score": 0.433662, "label": "positive"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.191354, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.173864, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0.465055, "label": "positive"}, "text": "China", "relevance": 0.173685, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Huzhou", "relevance": 0.173091, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Huzhou", "dbpedia_resource": "http://dbpedia.org/resource/Huzhou"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "producer", "relevance": 0.173003, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.489215, "label": "positive"}, "text": "Hong Kong", "relevance": 0.165932, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "BodyOfWater", "Cuisine", "City"], "name": "Hong Kong", "dbpedia_resource": "http://dbpedia.org/resource/Hong_Kong"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wuling", "relevance": 0.165514, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Macao", "relevance": 0.160014, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "CityTown", "Country"], "name": "Macau", "dbpedia_resource": "http://dbpedia.org/resource/Macau"}}, {"count": 1, "sentiment": {"score": 0.466694, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.158787, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.156821, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.155789, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.153188, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.374052, "label": "negative"}, "text": "azithromycin", "relevance": 0.149472, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.149079, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Britain", "relevance": 0.148426, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.147527, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Serbia", "relevance": 0.143578, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Serbia", "dbpedia_resource": "http://dbpedia.org/resource/Serbia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Croatia", "relevance": 0.142582, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Croatia", "dbpedia_resource": "http://dbpedia.org/resource/Croatia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "clindamycin", "relevance": 0.14236, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.141814, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Malaysia", "relevance": 0.141467, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Malaysia", "dbpedia_resource": "http://dbpedia.org/resource/Malaysia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore", "relevance": 0.141224, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.138671, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.407071, "label": "positive"}, "text": "Vietnam", "relevance": 0.134026, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "doxapram", "relevance": 0.130607, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pefloxacin", "relevance": 0.13057, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.125992, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.125992, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 12", "relevance": 0.125992, "type": "Quantity"}], "sentiment": {"document": {"score": 0.740155, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma", "keywords": [{"text": "Zhejiang Jolly Pharma"}], "entities": [{"type": "Company", "text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma"}]}, "sentence": " Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma is a producer and marketer of pharmaceutical products.", "object": {"text": "a producer and marketer of pharmaceutical products", "keywords": [{"text": "marketer"}, {"text": "pharmaceutical products"}, {"text": "producer"}], "entities": [{"type": "JobTitle", "text": "producer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company offers products in the form of tablets, capsules, granules, injections, dry powders, and others.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "Wuling powder, pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule, bailing tablet, azithromycin, doxapram, pefloxacin mesylate and clindamycin phosphate", "keywords": [{"text": "pseudomonas moth powder"}, {"text": "clindamycin phosphate"}, {"text": "pefloxacin mesylate"}, {"text": "Wuling capsule"}], "entities": [{"type": "Company", "text": "Wuling"}, {"type": "Drug", "text": "azithromycin"}, {"type": "Drug", "text": "doxapram"}, {"type": "Drug", "text": "pefloxacin"}, {"type": "Drug", "text": "clindamycin"}]}, "sentence": " Its products include Wuling powder, pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule, bailing tablet, azithromycin, doxapram, pefloxacin mesylate and clindamycin phosphate.", "object": {"text": "Its products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule", "keywords": [{"text": "Wuling capsule"}, {"text": "powder"}, {"text": "cephalosporin"}, {"text": "pseudomonas"}]}, "sentence": " Its products include Wuling powder, pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule, bailing tablet, azithromycin, doxapram, pefloxacin mesylate and clindamycin phosphate.", "object": {"text": "tablet", "keywords": [{"text": "tablet"}]}, "action": {"verb": {"text": "bail", "tense": "present"}, "text": "bailing", "normalized": "bail"}}, {"subject": {"text": "Zhejiang Jolly Pharma", "keywords": [{"text": "Zhejiang Jolly Pharma"}], "entities": [{"type": "Company", "text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma"}]}, "sentence": " Zhejiang Jolly Pharma provides Linglianhua particle for menopausal syndrome treatment.", "object": {"text": "Linglianhua particle", "keywords": [{"text": "Linglianhua particle"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company also adopts medicinal fungi to produce traditional Chinese medicinal products based on biofermentation technology.", "object": {"text": "medicinal fungi", "keywords": [{"text": "medicinal fungi"}]}, "action": {"verb": {"text": "adopt", "tense": "present"}, "text": "adopts", "normalized": "adopt"}}, {"subject": {"text": "traditional Chinese medicinal products", "keywords": [{"text": "Chinese medicinal products"}]}, "sentence": " The company also adopts medicinal fungi to produce traditional Chinese medicinal products based on biofermentation technology.", "object": {"text": "on biofermentation technology", "keywords": [{"text": "biofermentation technology"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "It"}, "sentence": " It exports its products to Britain, Singapore, Japan, Malaysia, Croatia, Serbia, Vietnam, Hong Kong, Macao, the US, and other countries.", "object": {"text": "its products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "export", "tense": "present"}, "text": "exports", "normalized": "export"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company operates its subsidiaries in China.", "object": {"text": "its subsidiaries in China", "keywords": [{"text": "subsidiaries"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operates", "normalized": "operate"}}, {"subject": {"text": "Zhejiang Jolly Pharma", "keywords": [{"text": "Zhejiang Jolly Pharma"}], "entities": [{"type": "Company", "text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma"}]}, "sentence": " Zhejiang Jolly Pharma is headquartered in Huzhou, China.", "object": {"text": "headquartered in Huzhou, China", "keywords": [{"text": "Huzhou"}, {"text": "China"}], "entities": [{"type": "Location", "text": "Huzhou", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Huzhou", "dbpedia_resource": "http://dbpedia.org/resource/Huzhou"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Zhejiang Jolly Pharma", "keywords": [{"text": "Zhejiang Jolly Pharma"}], "entities": [{"type": "Company", "text": "Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma"}]}, "sentence": " Zhejiang Jolly Pharma is headquartered in Huzhou, China.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Zhejiang Jolly Pharmaceutical"}, {"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Zhejiang Jolly Pharmaceutical Co Ltd"}, {"type": "Company", "text": "Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "target Company"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Venture capital", "relevance": 0.917498, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Finance", "relevance": 0.884124, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Mergers and acquisitions", "relevance": 0.877792, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Corporate finance", "relevance": 0.732265, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Pharmaceutical drug", "relevance": 0.711197, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Investment", "relevance": 0.709851, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Pharmacology", "relevance": 0.705717, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Medicine", "relevance": 0.646575, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Corporation", "relevance": 0.633969, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}], "categories": [{"score": 0.891793, "label": "/finance/financial news"}, {"score": 0.822484, "label": "/business and industrial"}, {"score": 0.806702, "label": "/business and industrial/business operations/management/business process"}], "relations": [{"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250 12:08 EST 24 Nov 2018 | BioPortfolio Report Blog Summary Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma is a producer and marketer of pharmaceutical products.", "score": 0.906381, "arguments": [{"text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals", "location": [97, 190], "entities": [{"type": "Organization", "text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals"}]}, {"text": "Report", "location": [214, 220], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "locatedAt", "sentence": "Zhejiang Jolly Pharma is headquartered in Huzhou, China.", "score": 0.985875, "arguments": [{"text": "Huzhou", "location": [1179, 1185], "entities": [{"type": "GeopoliticalEntity", "text": "Huzhou"}]}, {"text": "China", "location": [1187, 1192], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "productOf", "sentence": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.86209, "arguments": [{"text": "Mergers", "location": [1361, 1368], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1351, 1358], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1978, 1985], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1942, 1949], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2241, 2251], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2232, 2237], "entities": [{"type": "Organization", "text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2416, 2421], "entities": [{"type": "Organization", "text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals"}]}, {"text": "Region Chart", "location": [2425, 2437], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2577, 2581], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2582, 2589], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.656702, "arguments": [{"text": "Subsector Chart", "location": [2658, 2673], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2649, 2654], "entities": [{"type": "Organization", "text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2957, 2966], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2934, 2941], "entities": [{"type": "Organization", "text": "BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [3103, 3113], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [3121, 3128], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [3289, 3300], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3308, 3315], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3468, 3471], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3490, 3497], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "employedBy", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250 12:08 EST 24 Nov 2018 | BioPortfolio Report Blog Summary Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma is a producer and marketer of pharmaceutical products.", "score": 0.509226, "arguments": [{"text": "Nov", "location": [274, 277], "entities": [{"type": "Person", "text": "Nov"}]}, {"text": "BioPortfolio Report Blog\nSummary\nZhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma", "location": [285, 376], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3564, 3567], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3571, 3578], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [4304, 4313], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [4261, 4268], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4354, 4361], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "locations", "location": [4384, 4393], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "partOf", "sentence": "Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events.", "score": 0.396959, "arguments": [{"text": "company", "location": [4545, 4552], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Recent", "location": [4510, 4516], "entities": [{"type": "Organization", "text": "Recent"}]}]}, {"type": "managerOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250 12:08 EST 24 Nov 2018 | BioPortfolio Report Blog Summary Zhejiang Jolly Pharmaceutical Co Ltd Zhejiang Jolly Pharma is a producer and marketer of pharmaceutical products.", "score": 0.655358, "arguments": [{"text": "marketer", "location": [395, 403], "entities": [{"type": "Person", "text": "marketer"}]}, {"text": "pharmaceutical products", "location": [407, 430], "entities": [{"type": "Organization", "text": "pharmaceutical products", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Its products include Wuling powder, pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule, bailing tablet, azithromycin, doxapram, pefloxacin mesylate and clindamycin phosphate.", "score": 0.308316, "arguments": [{"text": "Its", "location": [541, 544], "entities": [{"type": "Organization", "text": "Twitter Track topics"}]}, {"text": "Wuling", "location": [562, 568], "entities": [{"type": "Organization", "text": "Wuling", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It exports its products to Britain, Singapore, Japan, Malaysia, Croatia, Serbia, Vietnam, Hong Kong, Macao, the US, and other countries.", "score": 0.504522, "arguments": [{"text": "Vietnam", "location": [1033, 1040], "entities": [{"type": "GeopoliticalEntity", "text": "Vietnam", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Hong Kong", "location": [1042, 1051], "entities": [{"type": "GeopoliticalEntity", "text": "Hong Kong"}]}]}, {"type": "locatedAt", "sentence": "It exports its products to Britain, Singapore, Japan, Malaysia, Croatia, Serbia, Vietnam, Hong Kong, Macao, the US, and other countries.", "score": 0.554124, "arguments": [{"text": "Hong Kong", "location": [1042, 1051], "entities": [{"type": "GeopoliticalEntity", "text": "Hong Kong"}]}, {"text": "Macao", "location": [1053, 1058], "entities": [{"type": "GeopoliticalEntity", "text": "Macao"}]}]}, {"type": "partOf", "sentence": "The company operates its subsidiaries in China.", "score": 0.811594, "arguments": [{"text": "subsidiaries", "location": [1114, 1126], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "its", "location": [1110, 1113], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [3226, 3238], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "company", "location": [3246, 3253], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "locatedAt", "sentence": "The company operates its subsidiaries in China.", "score": 0.558472, "arguments": [{"text": "subsidiaries", "location": [1114, 1126], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "China", "location": [1130, 1135], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Zhejiang Jolly Pharma is headquartered in Huzhou, China.", "score": 0.855146, "arguments": [{"text": "Zhejiang Jolly Pharma", "location": [1137, 1158], "entities": [{"type": "Organization", "text": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Huzhou", "location": [1179, 1185], "entities": [{"type": "GeopoliticalEntity", "text": "Huzhou"}]}]}], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.997739, "label": "positive"}, "relevance": 0.863176, "count": 2}, {"text": "detailed information", "sentiment": {"score": 0.863035, "label": "positive"}, "relevance": 0.687898, "count": 3}, {"text": "company", "sentiment": {"score": 0.801606, "mixed": "1", "label": "positive"}, "relevance": 0.661348, "count": 14}, {"text": "key financial metrics", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.645206, "count": 1}, {"text": "number of deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.638271, "count": 5}, {"text": "Twitter Track topics", "sentiment": {"score": 0.999418, "label": "positive"}, "relevance": 0.621098, "count": 1}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605846, "count": 1}, {"text": "Alliances Profile", "sentiment": {"score": 0.997739, "label": "positive"}, "relevance": 0.604578, "count": 2}, {"text": "Financial Deals Analysis of the company", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.587183, "count": 1}, {"text": "Year Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582363, "count": 1}, {"text": "information", "sentiment": {"score": 0.738616, "label": "positive"}, "relevance": 0.58115, "count": 5}, {"text": "Report", "sentiment": {"score": 0.999418, "label": "positive"}, "relevance": 0.570731, "count": 1}, {"text": "report", "sentiment": {"score": 0.76333, "label": "positive"}, "relevance": 0.570731, "count": 3}, {"text": "Key Recent Developments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566573, "count": 1}, {"text": "Deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.561404, "count": 4}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560124, "count": 1}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556031, "count": 1}, {"text": "brief summary", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.555881, "count": 1}, {"text": "Zhejiang Jolly Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553411, "count": 2}, {"text": "profile presents deals", "sentiment": {"score": 0.886185, "label": "positive"}, "relevance": 0.55308, "count": 1}, {"text": "Zhejiang Jolly Pharmaceutical Co Ltd", "sentiment": {"score": 0.996047, "label": "positive"}, "relevance": 0.550056, "count": 1}, {"text": "trend analysis of the company", "sentiment": {"score": 0.996047, "label": "positive"}, "relevance": 0.548716, "count": 1}, {"text": "profile", "sentiment": {"score": 0.891799, "label": "positive"}, "relevance": 0.54592, "count": 4}, {"text": "Jolly Pharma", "sentiment": {"score": 0.999418, "label": "positive"}, "relevance": 0.544084, "count": 1}, {"text": "year period", "sentiment": {"score": 0.830976, "label": "positive"}, "relevance": 0.543535, "count": 3}, {"text": "Important Locations", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.543094, "count": 1}, {"text": "list of the key executives of the company", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.542259, "count": 1}, {"text": "financial deals", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.540431, "count": 1}, {"text": "value", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.53767, "count": 5}, {"text": "table", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.536951, "count": 4}, {"text": "important events", "sentiment": {"score": 0.814713, "label": "positive"}, "relevance": 0.536703, "count": 1}, {"text": "products", "sentiment": {"score": 0.312747, "mixed": "1", "label": "positive"}, "relevance": 0.536028, "count": 3}, {"text": "Business Description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535524, "count": 1}, {"text": "marketer of pharmaceutical products", "sentiment": {"score": 0.999418, "label": "positive"}, "relevance": 0.533839, "count": 1}, {"text": "major developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.532782, "count": 1}, {"text": "North America", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.531814, "count": 1}, {"text": "powder", "sentiment": {"score": -0.37332, "label": "negative"}, "relevance": 0.530019, "count": 2}, {"text": "Detailed information", "sentiment": {"score": 0.972161, "label": "positive"}, "relevance": 0.528604, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528162, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.527602, "count": 1}, {"text": "type", "sentiment": {"score": 0.959659, "label": "positive"}, "relevance": 0.527334, "count": 2}, {"text": "company's major financial deals", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.527251, "count": 1}, {"text": "Private Equity", "sentiment": {"score": 0.766574, "label": "positive"}, "relevance": 0.52668, "count": 2}, {"text": "contact details of key centers of operation", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.525668, "count": 1}, {"text": "Recent developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.525365, "count": 1}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524886, "count": 1}, {"text": "subsidiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52352, "count": 2}, {"text": "Subsidiaries", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.52352, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.523351, "count": 1}, {"text": "list", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.523197, "count": 1}]}, "extracted_metadata": {"sha1": "21693bfd9968f3095e7e8a2fe8f024008fe77b38", "filename": "1543086604546.zip-ee9207ce17078207b37ccf3f2912b042.xml", "file_type": "json"}, "title": "Zhejiang Jolly Pharmaceutical Co Ltd 300181 Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 08112018 Prices from USD $250", "forum_title": "BioPortfolio Latest News"}, {"id": "x6s6q97BCmAzQhei4uHv_8ZNx8LjN4-TAOXjJT8uf0XdHHexIDaRf6E--yLaWI0_", "result_metadata": {"score": 21.434517}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.463116, "label": "negative"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.463116, "label": "negative"}, "text": "Harbin Gloria Pharmaceuticals Co Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.463116, "label": "negative"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9072, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.832318, "label": "/health and fitness/drugs"}, {"score": 0.801351, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.665788, "label": "/science/weather/meteorological disaster/hurricane"}], "relations": [], "keywords": [{"text": "Harbin Gloria Pharmaceuticals Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.996548, "count": 1}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614705, "count": 1}, {"text": "Prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605909, "count": 1}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587772, "count": 1}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363939, "count": 1}]}, "crawl_date": "2018-11-25T09:50:23Z", "url": "https://www.bioportfolio.com/news/article/3826302/Harbin-Gloria-Pharmaceuticals-Co-Ltd-002437-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile.html", "host": "bioportfolio.com", "text": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250 04:12 EST 25 Reports Summary Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-25T09:12:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria", "relevance": 0.622629, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.365757, "label": "positive"}, "text": "Harbin Gloria Pharmaceuticals Co Ltd", "relevance": 0.41202, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.230883, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.365757, "label": "positive"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.220925, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harbin", "relevance": 0.218475, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Twitter", "relevance": 0.196023, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": -0.675463, "label": "negative"}, "text": "musculoskeletal disorders", "relevance": 0.185071, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Musculoskeletal disorder", "dbpedia_resource": "http://dbpedia.org/resource/Musculoskeletal_disorder"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "solid tumors", "relevance": 0.177414, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.174276, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ropivacaine", "relevance": 0.165223, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0.365757, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.16174, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.538254, "label": "negative"}, "text": "bowel syndrome", "relevance": 0.161221, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.157967, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "lubiprostone", "relevance": 0.157511, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.15683, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.154042, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0.465055, "label": "positive"}, "text": "China", "relevance": 0.151196, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.150186, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.142862, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.139507, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.139507, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 04", "relevance": 0.139507, "type": "Quantity"}], "sentiment": {"document": {"score": 0.689655, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria", "keywords": [{"text": "Harbin Gloria Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, "sentence": " Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical company that produces and markets nutritional drugs.", "object": {"text": "a pharmaceutical company that produces and markets nutritional drugs", "keywords": [{"text": "nutritional drugs"}, {"text": "pharmaceutical company"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a pharmaceutical company", "keywords": [{"text": "pharmaceutical company"}], "entities": []}, "sentence": " Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical company that produces and markets nutritional drugs.", "object": {"text": "markets nutritional drugs", "keywords": [{"text": "markets nutritional drugs"}]}, "action": {"verb": {"text": "produce", "tense": "present"}, "text": "produces", "normalized": "produce"}}, {"subject": {"text": "a pharmaceutical company", "keywords": [{"text": "pharmaceutical company"}], "entities": []}, "sentence": " Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical company that produces and markets nutritional drugs.", "object": {"text": "nutritional drugs", "keywords": [{"text": "nutritional drugs"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "produces and markets", "normalized": "produce and market"}}, {"subject": {"text": "pharmaceutical drugs for treating nutrition disorders, cancer , cardiovascular diseases, antitumor medication, respiratory medication, and musculoskeletal disorders", "keywords": [{"text": "antitumor medication"}, {"text": "respiratory medication"}, {"text": "pharmaceutical drugs"}, {"text": "cardiovascular diseases"}], "entities": [{"type": "HealthCondition", "text": "musculoskeletal disorders", "disambiguation": {"subtype": [], "name": "Musculoskeletal disorder", "dbpedia_resource": "http://dbpedia.org/resource/Musculoskeletal_disorder"}}]}, "sentence": " The company's products include pharmaceutical drugs for treating nutrition disorders, cancer , cardiovascular diseases, antitumor medication, respiratory medication, and musculoskeletal disorders.", "object": {"text": "The company's products", "keywords": [{"text": "company"}, {"text": "products"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "ropivacaine mesylate for injection; and irritable bowel syndrome with constipation in women, lubiprostone, antihistamine, vitamins and minerals, developed for chronic idiopathic constipation, opioidinduced constipation", "keywords": [{"text": "chronic idiopathic constipation"}, {"text": "irritable bowel syndrome"}, {"text": "ropivacaine mesylate"}, {"text": "antihistamine"}], "entities": [{"type": "Drug", "text": "ropivacaine"}, {"type": "HealthCondition", "text": "bowel syndrome"}, {"type": "Drug", "text": "lubiprostone"}]}, "sentence": " Its pipeline products include ropivacaine mesylate for injection; and irritable bowel syndrome with constipation in women, lubiprostone, antihistamine, vitamins and minerals, developed for chronic idiopathic constipation, opioidinduced constipation.", "object": {"text": "Its pipeline products", "keywords": [{"text": "pipeline products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Harbin Gloria", "keywords": [{"text": "Harbin Gloria"}], "entities": [{"type": "Company", "text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, "sentence": " Harbin Gloria also provides SX004 for the treatment of acute leukemias and solid tumors.", "object": {"text": "SX004 for the treatment of acute leukemias and solid tumors", "keywords": [{"text": "acute leukemias"}, {"text": "solid tumors"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The company also collaborates with hospitals and institutions to carry out its research activities.", "object": {"text": "with hospitals and institutions", "keywords": [{"text": "hospitals"}, {"text": "institutions"}]}, "action": {"verb": {"text": "collaborate", "tense": "present"}, "text": "collaborates", "normalized": "collaborate"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The company also collaborates with hospitals and institutions to carry out its research activities.", "object": {"text": "its research activities", "keywords": [{"text": "research activities"}]}, "action": {"verb": {"text": "carry", "tense": "future"}, "text": "to carry", "normalized": "to carry"}}, {"subject": {"text": "Harbin Gloria", "keywords": [{"text": "Harbin Gloria"}], "entities": [{"type": "Company", "text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, "sentence": " Harbin Gloria is headquartered in Harbin, China.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Harbin Gloria", "keywords": [{"text": "Harbin Gloria"}], "entities": [{"type": "Company", "text": "Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, "sentence": " Harbin Gloria is headquartered in Harbin, China.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Harbin Gloria Pharmaceuticals"}, {"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Harbin Gloria Pharmaceuticals Co Ltd"}, {"type": "Company", "text": "Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": []}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": []}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": []}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": []}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": []}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "pharmaceutical company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "pharmaceutical company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": []}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Irritable bowel syndrome", "relevance": 0.984227, "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}, {"text": "Pharmacology", "relevance": 0.8722, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical drug", "relevance": 0.823715, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Venture capital", "relevance": 0.768184, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Finance", "relevance": 0.738227, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Mergers and acquisitions", "relevance": 0.707693, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Constipation", "relevance": 0.671448, "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}, {"text": "Corporate finance", "relevance": 0.614044, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Investment", "relevance": 0.592278, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Pharmacy", "relevance": 0.547951, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Medicine", "relevance": 0.54352, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Corporation", "relevance": 0.524547, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}], "categories": [{"score": 0.898405, "label": "/finance/financial news"}, {"score": 0.855488, "label": "/health and fitness/disease/ibs and crohn's disease"}, {"score": 0.81359, "label": "/business and industrial"}], "relations": [{"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250 04:12 EST 25 Reports Summary Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical company that produces and markets nutritional drugs.", "score": 0.8306, "arguments": [{"text": "EST", "location": [267, 270], "entities": [{"type": "Organization", "text": "EST", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Reports", "location": [274, 281], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.441085, "arguments": [{"text": "Equity", "location": [1909, 1915], "entities": [{"type": "Organization", "text": "Private Equity", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1847, 1854], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.648284, "arguments": [{"text": "Debt Offerings", "location": [1916, 1930], "entities": [{"type": "Organization", "text": "Debt Offerings", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1847, 1854], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.618132, "arguments": [{"text": "Venture Financing", "location": [1948, 1965], "entities": [{"type": "Organization", "text": "Venture Financing", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1847, 1854], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2146, 2156], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2137, 2142], "entities": [{"type": "Organization", "text": "BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2321, 2326], "entities": [{"type": "Organization", "text": "BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals"}]}, {"text": "Region Chart", "location": [2330, 2342], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2482, 2486], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2487, 2494], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.656702, "arguments": [{"text": "Subsector Chart", "location": [2563, 2578], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2554, 2559], "entities": [{"type": "Organization", "text": "BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2862, 2871], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2839, 2846], "entities": [{"type": "Organization", "text": "BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.50864, "arguments": [{"text": "executives", "location": [3008, 3018], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [3026, 3033], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.803355, "arguments": [{"text": "subsidiaries", "location": [3131, 3143], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [3151, 3158], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250 04:12 EST 25 Reports Summary Harbin Gloria Pharmaceuticals Co Ltd Harbin Gloria is a pharmaceutical company that produces and markets nutritional drugs.", "score": 0.622416, "arguments": [{"text": "Summary\nHarbin Gloria Pharmaceuticals Co Ltd Harbin Gloria", "location": [282, 340], "entities": [{"type": "Person", "text": "Summary\nHarbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, {"text": "Reports", "location": [274, 281], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.84577, "arguments": [{"text": "competitors", "location": [3194, 3205], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3213, 3220], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.350071, "arguments": [{"text": "you", "location": [3373, 3376], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3395, 3402], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3469, 3472], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3476, 3483], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "agentOf", "sentence": "Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "score": 0.953283, "arguments": [{"text": "company", "location": [3933, 3940], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Detailed", "location": [3941, 3949], "entities": [{"type": "EventCommunication", "text": "detailed"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.368136, "arguments": [{"text": "competitors", "location": [4340, 4351], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "locations", "location": [4289, 4298], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "hasAttribute", "sentence": "Its pipeline products include ropivacaine mesylate for injection; and irritable bowel syndrome with constipation in women, lubiprostone, antihistamine, vitamins and minerals, developed for chronic idiopathic constipation, opioidinduced constipation.", "score": 0.879093, "arguments": [{"text": "women", "location": [727, 732], "entities": [{"type": "Person", "text": "women"}]}, {"text": "constipation", "location": [711, 723], "entities": [{"type": "HealthCondition", "text": "constipation"}]}]}, {"type": "bornAt", "sentence": "Harbin Gloria is headquartered in Harbin, China.", "score": 0.307641, "arguments": [{"text": "Harbin Gloria", "location": [1050, 1063], "entities": [{"type": "Person", "text": "Summary\nHarbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, {"text": "Harbin", "location": [1084, 1090], "entities": [{"type": "GeopoliticalEntity", "text": "Harbin"}]}]}, {"type": "locatedAt", "sentence": "Harbin Gloria is headquartered in Harbin, China.", "score": 0.982216, "arguments": [{"text": "Harbin", "location": [1084, 1090], "entities": [{"type": "GeopoliticalEntity", "text": "Harbin"}]}, {"text": "China", "location": [1092, 1097], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.558548, "arguments": [{"text": "Harbin Gloria", "location": [1099, 1112], "entities": [{"type": "Person", "text": "Summary\nHarbin Gloria Pharmaceuticals Co Ltd Harbin Gloria"}]}, {"text": "Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile", "location": [1113, 1197], "entities": [{"type": "Organization", "text": "Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.594271, "arguments": [{"text": "Mergers", "location": [1266, 1273], "entities": [{"type": "Organization", "text": "Mergers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1256, 1263], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "score": 0.25222, "arguments": [{"text": "company", "location": [1497, 1504], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Equity", "location": [1395, 1401], "entities": [{"type": "Organization", "text": "Private Equity", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.590828, "arguments": [{"text": "Acquisitions", "location": [1895, 1907], "entities": [{"type": "Organization", "text": "Acquisitions MAs", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1847, 1854], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.981506, "label": "positive"}, "relevance": 0.867439, "count": 2}, {"text": "pharmaceutical company", "sentiment": {"score": 0.989899, "label": "positive"}, "relevance": 0.786235, "count": 1}, {"text": "detailed information", "sentiment": {"score": 0.863035, "label": "positive"}, "relevance": 0.693403, "count": 3}, {"text": "key financial metrics", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.647413, "count": 1}, {"text": "number of deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.63831, "count": 5}, {"text": "Twitter Track topics", "sentiment": {"score": 0.989899, "label": "positive"}, "relevance": 0.637931, "count": 1}, {"text": "company's products", "sentiment": {"score": -0.947416, "label": "negative"}, "relevance": 0.62089, "count": 1}, {"text": "company", "sentiment": {"score": 0.859752, "label": "positive"}, "relevance": 0.606374, "count": 12}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606075, "count": 1}, {"text": "Alliances Profile", "sentiment": {"score": 0.981506, "label": "positive"}, "relevance": 0.601168, "count": 2}, {"text": "Year Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586034, "count": 1}, {"text": "Financial Deals Analysis of the company", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.585455, "count": 1}, {"text": "information", "sentiment": {"score": 0.738616, "label": "positive"}, "relevance": 0.583526, "count": 5}, {"text": "Harbin Gloria", "sentiment": {"score": 0.634296, "label": "positive"}, "relevance": 0.574735, "count": 2}, {"text": "Report", "sentiment": {"score": 0.989899, "label": "positive"}, "relevance": 0.570531, "count": 1}, {"text": "report", "sentiment": {"score": 0.76333, "label": "positive"}, "relevance": 0.570531, "count": 3}, {"text": "Key Recent Developments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565579, "count": 1}, {"text": "Deals", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.563084, "count": 4}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55861, "count": 1}, {"text": "brief summary", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.557635, "count": 1}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555052, "count": 1}, {"text": "profile presents deals", "sentiment": {"score": 0.886185, "label": "positive"}, "relevance": 0.553808, "count": 1}, {"text": "Harbin Gloria Pharmaceuticals Co Ltd", "sentiment": {"score": 0.972995, "label": "positive"}, "relevance": 0.54828, "count": 1}, {"text": "profile", "sentiment": {"score": 0.891799, "label": "positive"}, "relevance": 0.546406, "count": 4}, {"text": "Harbin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54632, "count": 1}, {"text": "year period", "sentiment": {"score": 0.830976, "label": "positive"}, "relevance": 0.545756, "count": 3}, {"text": "Important Locations", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.544701, "count": 1}, {"text": "irritable bowel syndrome", "sentiment": {"score": -0.887236, "label": "negative"}, "relevance": 0.543228, "count": 1}, {"text": "trend analysis of the company", "sentiment": {"score": 0.972995, "label": "positive"}, "relevance": 0.542303, "count": 1}, {"text": "list of the key executives of the company", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.54032, "count": 1}, {"text": "important events", "sentiment": {"score": 0.814713, "label": "positive"}, "relevance": 0.539353, "count": 1}, {"text": "value", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.538601, "count": 5}, {"text": "table", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.538471, "count": 4}, {"text": "financial deals", "sentiment": {"score": 0.770069, "label": "positive"}, "relevance": 0.538406, "count": 1}, {"text": "Business Description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535224, "count": 1}, {"text": "North America", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.534209, "count": 1}, {"text": "major developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.533636, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529909, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.529681, "count": 1}, {"text": "Detailed information", "sentiment": {"score": 0.972161, "label": "positive"}, "relevance": 0.529606, "count": 1}, {"text": "type", "sentiment": {"score": 0.959659, "label": "positive"}, "relevance": 0.528466, "count": 2}, {"text": "Private Equity", "sentiment": {"score": 0.766574, "label": "positive"}, "relevance": 0.528139, "count": 2}, {"text": "cardiovascular diseases", "sentiment": {"score": -0.947416, "label": "negative"}, "relevance": 0.526465, "count": 1}, {"text": "chronic idiopathic constipation", "sentiment": {"score": -0.887236, "label": "negative"}, "relevance": 0.526194, "count": 1}, {"text": "Recent developments", "sentiment": {"score": 0.883616, "label": "positive"}, "relevance": 0.526115, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.659993, "label": "positive"}, "relevance": 0.52511, "count": 1}, {"text": "company's major financial deals", "sentiment": {"score": 0.713364, "label": "positive"}, "relevance": 0.524025, "count": 1}, {"text": "contact details of key centers of operation", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.524011, "count": 1}, {"text": "list", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.52398, "count": 1}, {"text": "Subsidiaries", "sentiment": {"score": 0.77568, "label": "positive"}, "relevance": 0.523973, "count": 1}]}, "extracted_metadata": {"sha1": "636461e76f5e8e1172444793582d8124d8a24dd8", "filename": "1543139423355.zip-dd171b16dc29a00dbc337a84bf4760a3.xml", "file_type": "json"}, "title": "Harbin Gloria Pharmaceuticals Co Ltd 002437 Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23102018 Prices from USD $250", "forum_title": "BioPortfolio Kinex Pharmaceuticals Announces First Patient Dosed with Phase News"}]}